Methotrexate in the central nervous system prophylaxis of children with acute lymphoblastic leukemia by Lippens, R.J.J.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/148105
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
METHOTREXATE 
IN THE CENTRAL 
NERVOUS SYSTEM PROPHYLAXIS 
OF CHILDREN WITH ACUTE 
LYMPHOBLASTIC LEUKEMIA 
R. J. J. LIPPENS 

METHOTREXATE IN THE CENTRAL NERVOUS SYSTEM PROPHYLAXIS 
OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA 
voor 
W¡ 1ly,Marylou en Carmen 

METHOTREXATE IN THE CENTRAL NERVOUS SYSTEM PROPHYLAXIS 
OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA 
PROEFSCHRIFT 
ter verkrijging van de graad van doctor 
in de Geneeskunde aan de Katholieke 
Universiteit te Nijmegen, 
op gezag van de Rector Magnificus 
Prof.Dr.P.G.A.B. Wijdeveld volgens 
besluit van het College van Decanen 
in het openbaar te verdedigen op 
maandag ]k december I98I des namiddags 
te A .00 uur 
door 
Robert Jozef Joost Lippens 
geboren te Arnhem 
Mefar B.V. - Beetsterzwaag 

Promotor: P ro f . Dr. E.D.A.M. Sch re t l en 
C o - r e f e r e n t : Dr. E. van der K l e i j n 

Les hypothèses et les théories,même mauvaises, 
sont utiles pour conduire à des découvertes 
Claude Bernard, 
Introduction à l'étude de la 
medicine expérimentale (1865) 

Table of contents 
3 
Dankwoord k 
Abbreviations used 5 
Defi ni tions 6 
Chapter I I n t r o d u c t i o n and purpose o f the study 7 
Chapter I I M e t h o t r e x a t e and i t s metabol ism 12 
Chapter I I I C o m p l i c a t i o n s o f the p r o p h y l a c t i c t r e a t m e n t 21 
o f the CNS ( c r a n i a l i r r a d i a t i o n and MTX) 
Chapter IV O b s e r v a t i o n s in 50 c h i l d r e n w i t h ALL d u r i n g 25 
and a f t e r CNS-prophy1axis 
Chapter V The t h e r a p e u t i c c o n c e n t r a t i o n s o f MTX Ί ΐ 
Chapter VI M e t h o t r e x a t e and the c e n t r a l nervous system kG 
Chapter V I I Some aspects o f the p h a r m a c o k i n e t i c s o f 52 
drugs 
Chapter VI I I P h a r m a c o k i n e t i c s t u d i e s o f MTX in c h i l d r e n 59 
wi th ALL 
Chapter IX The p h a r m a c o k i n e t i c models o f MTX in plasma 62 
Chapter X The c o n c e n t r a t i o n p r o f i l e s o f MTX in plasma 67 
a f t e r i n t r a t h e c a l a d m i n i s t r a t i o n 
Chapter XI The c o n c e n t r a t i o n p r o f i l e o f MTX in the CSF 76 
a f t e r i n t r a t h e c a l i n j e c t i o n 
Chapter XI I The animal model i n i n t r a t h e c a l 87 
a d m i n i s t r a t i o n o f MTX 
Chapter X I I I P o s t u l a t i o n s and hypotheses o b t a i n e d from 98 
the r e s u l t s o f the p r e c e d i n g study of the 
CNS-prophy1axis in c h i l d r e n w i t h ALL 
Chapter XIV P h a r m a c o k i n e t i c s t u d i e s o f h igh-dose MTX 105 
i n t r a v e n o u s i n f u s i o n s 
Summarizing c o n c l u s i o n s 126 
Samenvatting 13^ 
References 137 
Cur r ¡cu i um v i tae 166 
k 
Dit onderzoek is slechts mogelijk geweest dank zij de inzet van velen. 
Grote dank gaat uit naar de ouders van de kinderen, die bereid waren 
hun toestemming voor dit onderzoek te geven en naar de kinderen zelf, 
die bereid waren dit onderzoek te ondergaan. 
Dank zij de nooit aflatende hulp en zorg van de verpleegkundigen en 
van de spe 1 lei dsters op de boxenafdelingen van de kinderkliniek, was 
het mogelijk dit, niet alleen voor de patientjes, erg belastende 
onderzoek vol te houden. 
De goede en prettige samenwerking met het laboratorium voor Klinische 
Pharmacie van het St. Radboudziekenhuis heeft geleid tot een bundeling 
van kennis over methotrexaat. Van bijzondere betekenis in dit onder-
zoek was het werk van mej. R. Derks en de heren E.F.S. Termond, 
M.J.M. Oosterbaan, en in een eerder stadium van J. Lankelma, bij de 
ontwikkeling van de bepalingsmethoden en bij de pharmacokinet i sehe 
bereken!ngen. 
Het proefdieronderzoek was mogelijk dank zij de hulp van de heer 
T.H.M. Arts (Centraal Dierenlaboratorium) en de heer J.H.M. Pluymen 
en de medewerkers van de afdeling Radiotherapie (hoofd: Prof. Dr. I. 
Kazem). 
Het pathologisch anatomisch onderzoek bij de geiten is verricht door 
Prof. Dr. J.L. Slooff (Pathologische Anatomie van het St. Radboud 
zi ekenhui s) . 
Lederle Nederland B.V. te Haarlem schonk voor het proefdieronderzoek 
1 g zeer zu i ver MTX. 
De tekeningen in dit proefschrift werden vervaardigd door de heer 
H.M. Berris (Medische Tekenkamer, Faculteit voor Geneeskunde). 
Het manuscript werd getypt door mej. J. Palthe en Mej. C.A.W. v/d Tempel 
De vertaling is gecorrigeerd door mevr. Drs. M.A.H, de Swart te 
Ni jmegen. 
Dit onderzoek is een onderdeel van het projekt 
"Ontwikkeling van de kwantitatieve bepaling van 
cytostatica in lichaamsvloeistoffen" 
en wordt ondersteund door subsidie van het 
Koningin Wilhelmina Fonds. 
5 
A b b r e v i a t i o n s used. 
ALL 
AUC 
C, cone. 
CF 
CNS 
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CSF 
CT 
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DAMPA 
DHFR 
e 
EEG 
f 
FH 2 ) FH4 
h , hrs 
IMFRA 
i . t . 
i . V . 
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l . p . 
m 
5-MeTHF 
MTX 
7-OH-MTX 
pat 
Rad 
SNWLK 
t , 
Ί 
a c u t e l y m p h o b l a s t i c leukemia 
area under the curve 
c o n c e n t r a t i o n 
c i t r o v o r u m f a c t o r 
c e n t r a l nervous system 
counts per second 
c e r e b r o s p i n a l f l u i d 
c o m p u t e r i z e d tomography 
dose 
d i a m i n o m e t h y 1 p t e r o i с a c i d 
d i h y d r o f o l a t e r e d u c t a s e 
= 2.7183 
electroencephalogram 
female 
reduced dérivâtes of folic acid 
hours 
i n t r a t h e c a l me tho t rexa te and f r a c t i o n a l r a d i a t i o n 
i n t ra theca1 
i ntravenous 
reciprocal time constants 
lumbar puncture 
ma 1 e 
5 - m e t h y l t e t r a h y d r o f o l a t e 
methotrexate 
7-hydroxymethot rexa te 
p a t i ent 
radiation absorbed dose 
Stichting Nederlandse Werkgroep Leukemie bij kinderen 
(Dutch Childhood Leukemia Study Group) 
time 
biological half-life time of a drug 
volume (also distribution volume of a drug) 
total body clearance of a drug 
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Défi ni t i o n s 
Some terms have c rep t i n t o the language and must be de f i ned f o r a 
good unders tand ing o f t h i s s t u d y : 
CNS-1eukemia : any, even one, leukemic c e l l , found in the CNS and the 
CSF and the meninges, causes an i nvas ion o f the c e n t r a l 
nervous system. 
CNS-prophy1axis : is the t rea tment o f the c r a n i o - s p i n a l ax i s and the 
meninges in p a t i e n t s w i t h ALL, w i t h o u t f i n d i n g leukemic c e l l s 
in the CSF sample ob ta ined a t the f i r s t lumbar puncture du r i ng 
the remiss ion i n d u c t i o n t rea tment o f the ALL. 
I n t r a t h e c a l a d m i n i s t r a t i o n : i f not i n d i c a t e d o t h e r w i s e , is the 
i n j e c t i o n o f a drug in the lumbar sac by lumbar puncture 
a t the leve l o f L З - ^ or L 4 - 5 . 
Reduced f o l a t e s : are the compounds o b t a i n e d a f t e r r e d u c t i o n o f f o l i c 
a c i d by the enzyme d i h y d r o f o l a t e - r e d u c t a s e . 
High-dose MTX a d m i n i s t r a t i o n s in t h i s s t u d y : are i n t r a v e n o u s i n f u s i o n s 
d u r i n g some t i m e , o f a s o l u t i o n c o n t a i n i n g any amount of 
m e t h o t r e x a t e and f o l l o w e d by a rescue w i t h reduced f o l a t e s . 
The c o n c e n t r a t i o n p r o f i l e of MTX: is the g r a p h i c a l r e p r e s e n t a t i o n 
o f the c o n c e n t r a t i o n of MTX versus the t i m e . 
E x s o r p t i o n : is the process o f t r a n s p o r t or uptake o f a compound from 
the CSF i n t o the b l o o d . 
Toxic r e a c t i o n s , ( t o x i с) s i d e - e f f e c t s , systemic t o x i c i t y : i n d i c a t e the 
unwanted a c t i v i t i e s o f MTX to the bone marrow and the mucosa 
o f the d i g e s t i v e t r a c t , but do not i n d i c a t e unwanted a c t i v i t i e s 
to the CNS. 
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Chapter I 
INTRODUCTION AND PURPOSE OF THE STUDY 
In a period of two years (1975-1976) 292 children under the age of 
Й have been registered as suffering from leukemia in the Netherlands; 
67 out of the 292 children died in those two years (23%). 218 (75%) 
out of 292 were suffering from acute lymphoblastic leukemia (ALL), 
of which 1% died in these two years. 
Of the patients over 14, 83 patients with ALL have been registered, 
of which 51* (65%) died (C.B.S. 1979). 
From these facts may be concluded that children under the age of 
1k with ALL have a more favorable prognosis than patients with ALL 
in the older age groups. 
Only recently, viz. after the Second World War possibilities have 
arisen to treat leukemia. The first effective treatment was given 
by Färber ОЭ^З): to children with acute leukemia the then new drug 
1
aminopterin' was given. In the following years new treatment schedu­
les were executed, prescribing cortisone and A.C.Т.Н. (Law 19^7, 
Pearson 1949), 6-mercaptopuriη (Burchenal 1953) and vincristin 
(Karon 1962), which resulted in longterm survival of children with 
ALL (Мое 1978, Pinkel 1979). 
However, this prolonged survival resulted in an increase of patients 
with CNS-leukemia: 1948: 31, 1960: 40%, 1965: 45%, 1970: 56% (Hyman 
1965, Evans 1970). 
The occurrence of an invasion of leukemic cells into the CNS and the 
meninges (overt CNS-leukemia) is a bad prognostic sign during the 
treatment of acute leukemia. The possibilities of treating this inva­
sion are relatively limited. 
The appearance of leukemic cells is evidence of the diagnosis 'CNS-
leukemia'. The absence of leukemic cells in the CNS does not deny 
the existence of small leukemic invasions in the CNS or arachnoid. 
Pathologic anatomic examinations of the brain and the meninges 
(Price І97З) show that subclinical CNS-leukemia without leukemic 
cells in the CSF is not a "micro-meningeal" or microscopic leukemia, 
but a real invasion in the meninges and occasionally the brain tis­
sues. 
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Small invasions cannot be shown during life. 
The leukemic cells in the subarachnoidal space originate in the 
marrow, and as long as the marrow contains leukemic cells, the chance 
remains that CNS-leukemia will come into existence (Mastrangelo 1970, 
Zuelzer 1978). Without a prophylactic treatment of the CNS, CNS-leu-
kemia develops in 56% of the children with ALL ('normal risk' pa-
tients), about one year or later after the diagnosis of the ALL 
(Stoppelman I967, Melhorn 1970, Evans 1970, Price 1973). It may be 
imagined that the leukemic invasion of the meninges will occur short-
ly after the origin of leukemia, when the marrow is filled up with 
leukemic cells. During the hematologic remission no new leukemic le-
sions in the CNS will occur. Zuelzer (1978) however, doubts this 
proposition: Without CNS-prophy1axis a CNS-leukemia occurs, but the 
interval between the diagnosis of ALL and CNS-leukemia varies from 
1 to 5 years. According to Zuelzer it is unlikely that leukemic cells 
remain "resting" during such a long time, given the velocity of their 
return when a CNS-leukemia has occurred. Many leukemic cells in the 
marrow must escape observation. 
It is very difficult to recognize malignant lymphoid cells in the 
marrow after a remission has been attained. The definition of the he-
matologic remission in ALL is that the bone marrow contains 5% or 
less lymphoblasts without taking into account their benign or malign 
character. Therefore the complete remission considered might be an 
1
 opt i cal i 1 1 us ¡ori'! 
If a leukemic clone has not been eradicated completely, the 
possibility of leukemic cells invading into the CNS may occur at 
any moment, even without obvious relapse of the marrow. 
CNS-prophylaxis. 
The treatment of the subclinical CNS-leukemia is called CNS-prophy-
laxis, which is an erroneous name because the treatment does not pre-
vent a disease, but treats an existing, but subclinical disease. 
As the subclinical disease occurs in 56% of the children with "nor-
mal risk" ALL, kkX of the children undergo a drast i с,burden ing and 
at longer terms even injurious treatment. But, as there is no way of 
establishing the absence of leukemic invasion in the meninges and 
the brain, this form of treatment has to be carried out with all pa-
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t i e n t s w i t h ALL. Since 1970 one or o t h e r method o f CNS-prophy lax is 
has been used w i t h n e a r l y a l l p a t i e n t s w i t h ALL. 
The s i n g l e a d m i n i s t r a t i o n of MTX i . t . ( 0 ,9 mg/kg, Melhorn 1970) has 
not shown a d i f f e r e n c e in the f requency o f CNS-leukemia; but the 
appearance o f the CNS-leukemia comes l a t e r : p a t i e n t s , t r e a t e d 
p rophy lac t i ca l 1 y w i t h MTX i . t . , develop CNS-leukemia at a s i g n i f i -
c a n t l y l a t e r t ime than p a t i e n t s w i t h o u t MTX i . t . (12 vs 7 i months) . 
Th is f i n d i n g i s con f i rmed by P o u i l l a r t ( 1972 ) , who t r e a t e d s u b c l i n i c a l 
CNS-leukemia e i t h e r w i t h c r a n i a l i r r a d i a t i o n or w i t h c y t o s t a t i c agents 
or w i t h no CNS-prophy lax is at a l l . In S t . Jude 's C h i l d r e n ' s Research 
Hosp i ta l a t Memphis the op t ima l t rea tmen t method of ALL t o t a l therapy 
are i n v e s t i g a t e d sys temet i c a l l y (Simone 1972, 1975)· The purpose is 
to reach the complete remiss ion as q u i c k l y and as e f f i c i e n t l y as 
p o s s i b l e , w i t h as l i t t l e s i d e - e f f e c t s as p o s s i b l e . The main p o i n t o f 
the t rea tment has t o be p laced a t the beg inn ing of the i n d u c t i o n 
t r ea tmen t , when the p a t i e n t has r e l a t i v e l y speaking a r a t h e r good 
c o n d i t i o n and the l a r g e s t c e l l k i l l i s wanted. The occur rence o f 
CNS-leukemia is " p r e v e n t e d " or delayed by a t rea tment e a r l y in the 
hematologic r e m i s s i o n . In the end , s u b c l i n i c a l leukemic c e l l - p o p u l a -
t i o n s are des t royed by a combinat ion o f c y t o s t a t i c agents d u r i n g 
2-3 years . In the v a r i o u s S t . Jude 's s tud ies the dose of r ad io the rapy 
( c r a n i a l i r r a d i a t i o n ) increased f rom 500 Rad and 1000 Rad (George 
I968, Aur I 9 7 I ) to 2400 Rad (Aur 1972) . This l a t t e r dose decreased the 
f requency o f o v e r t CNS-leukemia in c h i l d r e n w i t h ALL f rom 55% in 
n o n - i r r a d i a t e d p a t i e n t s t o 1% in p a t i e n t s t r e a t e d w i t h c r a n i a ! 
i r r a d i a t i o n and h% in cases t r e a t e d w i t h c r a n i o s p i n a l i r r a d i a t i o n . 
The dose of 2^00 Rad ( c r a n i a l i r r a d i a t i o n ) has been adopted in many 
cen t res t r e a t i n g c h i l d r e n w i t h ALL. However in the l a s t few years 
several r e p o r t s have been presented showing l a t e sequelae a t t r i b u t e d 
to c r a n i a l i r r a d i a t i o n : ce reb ra l a t rophy (Peylan-Ramu 1978, Ch ' i en 
I 9 8 I ) . d e c r e a s e o f the i n t e l l e c t u a l f u n c t i o n s (Levine 1978, Schuler 
I978, I 9 8 I ) , i m p a i r e d growth hormone responses (Sha le t 1976, Mor r i s 
Jones I 9 7 8 ) . 
Decrease o f the r a d i a t i o n dose (Riehm 1977) to I8OO Rad, appeared t o 
be as e f f e c t i v e as the dose of 2^00 Rad in CNS-prophylax is : in on l y 
81 o f the p a t i e n t s an o v e r t CNS-leukemia occu r red a f t e r w a r d s . 
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Freeman (1977), Zaizov (1977) and Мое (1978) obtained good results 
with patients with ALL by using high-dose MTX-infusions, combined 
with intrathecal administration of MTX, without using radiotherapy 
in this method of CNS-prophy1 axis. This method of treatment will be 
discussed later. 
An other method of CNS-prophyIaxis is recommended by Zuelzer and co­
workers (1976). Their method consists of simultaneously administering 
eranio-spinal irradiation (160 Rad) and a single i.t. injection with 
MTX. Each patient receives this therapy 15 times in 3 years. The re­
sults are similar to those of the other methods: by this IMFRA (i.t. 
MTX- Fractional Radiation) too CNS-leukemia occurs in 8% of the chil­
dren.But the toxicity of this method of treatment might be less. 
Especially infections might occur less frequently. This was confirmed 
by Mastrangelo (1978), who also claims that this method obtains good 
results in patients with high-risk leukemia: 
Out of 17 patients treated with IMFRA who had high-risk ALL during a 
follow-up period of 'ik months, only one died from a viral pneumonitis. 
None of these patients relapsed in that period. 
At the moment, the protocol of the CNS-prophylaxis advised by SNWLK 
in the Netherlands consists of cranial irradiation of 2500 Rad. 
The daily dose is 200 Rad (5 days a week). The dose on the last day 
of treatment is only 100 Rad. The whole subarachnoidal space with all 
its projections has to be taken into the radiation field. Together 
with the cranial irradiation, MTX is injected int ralumbarly. In the 
Netherlands the addition of Prednisolon intrathecaIly together with 
MTX is usual (Stoppelman 1967). During the period of CNS-prophylaxis 
the maintenance treatment is started by a daily oral administration 
of 6-mercaptopuriη. 
Duttera (1973) and Dritschllo (1976) point to the necessity of the 
hematologic remission in a patient with ALL, before the CNS-prophy-
laxis (cranial irradiation) starts. If the cranial irradiation starts 
before the hematologic remission has been reached, an overt CNS-leu­
kemia may occur the faster. The same happens in cases in which a 
hematologic relapse occurs during the first days of the CNS-prophy-
laxi s. 
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This is explained as being consequence of lesions in the endothelial 
wall of the blood vessels of the brain caused by radiation treatment. 
The circulating leukemic cells may easily pass the damaged endothelium 
and enter the subarachnoidal space. 
From the aforementioned studies it will become clear that CNS-
prophylaxis is an effective and useful treatment in antileukemic 
therapy. However, the unanimity about the method of CNS-prophylaxis 
still has to be elucidated. The purpose of this study is to evaluate 
CNS-prophylaxis according to the protocol of the Dutch Childhood 
Leukemia Study Group (SNWLK) concerning the efficacy of the treatment. 
The value of the i.t. administration of methotrexate within this 
protocol with regard to its efficacy and toxicity in children with 
ALL has been analysed by pharmacokinetic calculations and simulated 
in an animal model. Besides i.t. administration of MTX, high dosed 
intravenous infusions in children and in the animal model have been 
analysed pharmacokinetically, in order to study the possibilities of 
high-dose MTX schemes such as the CNS-prophylactic treatment procedure. 
Proposals will be made for the use of MTX in the CNS-prophylaxis to 
reduce the toxicity of the drug and to enhance its efficacy. 
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Chapter I I 
METHOTREXATE AND ITS METABOLISM 
In the investigation into synthesizing analogons of pteroy1-glutamiс 
acid (folic acid), Seeger, Smith and Hultquist (19Ί7) synthezised an 
analogon of folic acid, aminopterin, that showed antagonistic action 
against folic acid in the growth of Streptococcus faecal is R. 
This aminopterin has been used by Farber in a somewhat intuitive way 
in acute leukemia. 
Earlier (19Ί7) Farber had used another folic acid antagonist, pteroyl-
aspartate, in a patient with acute leukemia. A hypoplasia of the marrow 
caused the death of this patient. In IS'tS Färber had applied aminopterin 
in 16 children with acute leukemia. In 10 of these children this resul-
ted in an important improvement of the disease during some months. 
Shortly afterwards the aminopterin has been replaced by a-methopteri η 
(amethopteriη, methotrexate, MTX), also synthesized by Seeger e.a. 
09^9)· The advantage of MTX over aminopterin is that MTX is a more 
stable compound and can be purified better (Berlin 1963). Furthermore, 
the toxicity of MTX appears to be less than the toxicity of aminopte­
rin. However, the inhibition of the enzyme dihydrofolate-reductase 
(DHFR) is 5-10 times as high with aminopterin as with MTX (Thiersch 
ig^S, Jacobson 1954, Goldin 1955). 
After synthesis, the compound consists of yellow-orange micro-crystal­
line material and appears to be 87% pure (Seeger ÌS^S)· 
The molecular weight of MTX is kBk,5. It is fairly soluble like the 
salt in aqueous solution, but it is insoluble in lipid solvents at 
pH 7,k. 
MTX inhibits the enzyme dihydrofolate reductase in a 'stoichiometric' 
way, when d i hydrofolate is used as the substrate at pH 3 (Berlino ІЭб*», 
Werkheiser 196I). At a higher pH (7,5 or more) with dihydrofolate used 
as the substrate, the inhibition produced by MTX is not stoichiometric 
any more, but reversible. At that pH, MTX is an competitive inhibitor 
of this enzyme with regard to dihydrofolate as a substrate (Werkheiser 
1961, Bertino 196М. 
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After intravenous administration MTX passes the liver and bile and 
comes into the intestinal lumen, after which it is absorbed by the 
blood again. Part of the MTX disappears by way of the faeces. 
This enterohepatic cycle is of course important for the existence of 
the side-effects on the digestive tract. A small part of the MTX will 
be excreted by the salivary glands, but comes into the blood ag.iin 
via the digestive tract. Only a very small part of the MTX will dis­
appear by saliva (Steele 1979). 
The greater part of the MTX injected will be excreted by the kidneys. 
In Fig. 1, the pathways of MTX and its enterohepati с cycle are illu­
strated. 
ehm no: on 
e n t e r o h e p a t с 
c>cle 
F i g . 1 D i s t r i b u t i o n pathways o f MTX 
Only a few r e f e r e n c e s mention the c o n c e n t r a t i o n o f MTX in d i f f e r e n t 
organs and t i s s u e s a f t e r a s i n g l e a d m i n i s t r a t i o n (Sturm 1969, B i s c h o f 
1971, O l i v e r i o I 9 7 I ) · No r e f e r e n c e however mentions a r e l a t i o n s h i p 
between the MTX-concentrat ion in an organ and the t o x i c i t y o f MTX in 
t h a t o r g a n . Mathemat ical models o f the d i s t r i b u t i o n o f MTX in d i f f e ­
r e n t k inds o f an imals and o f d i f f e r e n t doses o f MTX have a l l o w e d t o 
c a l c u l a t e p h a r m a c o k i n e t i c parameters ( B i s c h o f 1971, O l i v e r i o 1971) 
Huffman 1973, Wan ig?'*, S t o l 1er 1975, Reich 1977, Wal lace 1978, 
Weisbrod I 9 7 8 ) . Some o f these parameters are o f importance f o r the 
i . t . a d m i n i s t r a t i o n o f MTX and w i l l be d iscussed in the f o l l o w i n g 
chapters . 
\k 
7-hydroxymethotrexate ( 7-OH-!4TX) 
After both oral and parenteral administration of MTX the drug is meta-
bolized in the liver by mixed function oxydase into 7-OH-MTX. 
In the chromatogram (HPLC-method) of plasma after the administration 
of MTX two peaks can be shown (Fig.2) 
0 
Fig. 2 H.P.L.C.-chromatogram of MTX and 7-OH-MTX (metabolite) 
of a plasma sample 
(A.U. = Angstrom Uni ts) 
The more polar peak is formed by the metabolite 7-OH-MTX (Lankelma 
I98O). The less polar peak consists of MTX. 
This metabolism takes place in a number of animals, also in man 
(Johns 1965, I967), but in goats the metabolite 7-OH-MTX could not 
be detected (own observation). 
The impurities that were the results of the manufacturing processes 
of MTX did not contain 7-OH-MTX. In several studies (Johns 1967, 
Hoffman 1973, Jacobs 1976, 1977) it is supposed that the demonstration 
of 7-OH-MTX is possible 6 hours after administering MTX. In our 
studies the concentration of 7-OH-MTX reached a maximum after 6 hrs. 
after the administration, but can be detected within 2 hours after 
administration of the drug (Lankelma 1978). 
According to Jacobs (1976) 6-12 hours after the administration of MTX 
0 001 AU 
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0.7-9.6% of the dose will be excreted as 7-OH-MTX, after ]B-2k hours 
the amount of excretion of 7-OH-MTX increases to 33? of the dose of 
MTX. 
In the kidneys of monkeys (Jacobs 1976) both MTX and 7-OH-MTX can be 
found in the lumen of the distal tubules. Only 23% is MTX however, 
and 77% consists of 7-OH-MTX. 
The enzyme DHFR is also inhibited by 7-OH-MTX, but the activity is 
1/200 to 1/1000 of the activity of MTX (Johns I967). With acid pH 
the solubility of 7-OH-MTX is even less (3-5 times) than MTX. 
After i.v. injecting 7-OH-MTX into a volunteer (2.2 mg), the plasma 
half-life time appeared to be 9 hours (Lankelma I98O). 
By adding 7-OH-MTX to a culture of KB-cells and Ehrlich ascites tumor-
cells containing H-MTX, it could be demonstrated that these cells 
contained less radioactivity than eel 1-cui tures not receiving an 
additional amount of 7-OH-MTX. This finding suggests that 7-OH-MTX 
uses the same transport mechanism into the cell as MTX (and reduced 
folates) and that the formation of 7-OH-MTX has to be considered as 
a rescue of the cell (Lankelma I98O). 
DAMPA (Diamino methyl pteroic acid) 
A second metabolite has been demonstrated by Bertino (1978). 
This metabolite, 2 ,k cHamino- N - methyl£teroiс acid (DAMPA) can 
be found in the lumen of the intestine. 
With the HPLC method Donehower (1979) showed the compound in plasma 
and urine of a patient treated with high-dose MTX infusions 
(> 50 mg/kg). The maximum concentration of DAMPA in the urine can be 
detected in Ih-kü hours after the infusion. The solubility of DAMPA 
at any pH is less than that of 7-OH-MTX. In our studies this 
metabolite has not been detected. 
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The si de-effects of MTX 
S i d e ~ e f f e c t s o f a drug can be d e f i n e d as those a c t i v i t i e s o f the drug 
t h a t do not c o n t r i b u t e t o the t h e r a p e u t i c a c t i o n wanted. C y t o s t a t i c 
agents cause many s i d e - e f f e c t s . Some o f these should be accepted in 
o r d e r t o o b t a i n an a n t i - t u m o r a c t i v i t y . Because the t i s s u e s of the 
body are not e q u a l l y s e n s i t i v e t o c y t o s t a t i c agents and one i n d i v i d u a l 
p a t i e n t may even be more s e n s i t i v e t o t h e drug than a n o t h e r , the l i m i t 
o f the d e s i r e d t h e r a p e u t i c a c t i v i t y and the acceptance o f the degree 
and number o f s i d e - e f f e c t s is d i f f i c u l t t o d e f i n e . 
To s t u d y the s i d e - e f f e c t s o f MTX the a c t i v i t i e s t h a t d i s t i n g u i s h the 
t h e r a p e u t i c a c t i v i t i e s f rom the s i d e - e f f e c t s must be d e s c r i b e d . 
For t h i s purpose the c l a s s i f i c a t i o n o f the s i d e - e f f e c t s a c c o r d i n g t o 
Condi t (1962) appears t o be u s e f u l : 
Condi t ( I962) has t r e a t e d 86 p a t i e n t s w i t h d i f f e r e n t k inds o f cancer 
w i t h h i g h dose MTX (100-2400 mg) v i a i . v . bolus i n j e c t i o n . 
The t o x i c i t y has been d i v i d e d i n t o t h r e e d e g r e e s : 
1. M i l d t o x i c i t y ( + ) : o r a l u l c e r a t i o n , nausea, v o m i t i n g and/or 
d i a r r h o e a 
2. Moderate t o x i c i t y ( + + ) : the s igns o f 1 t o g e t h e r w i t h a leukocyte 
о g 
count under 2,0 χ 10^/1 and/or p l a t e l e t count o f 50 χ 1 0 / 1 or l e s s . 
3. Severe t o x i c i t y (+++): the s i g n s o f 1 , t o g e t h e r w i t h a l e u k o c y t e 
9 9 
count under 1,0 χ 10 /1 and/or p l a t e l e t count under 25 x 1 0 / 1 . 
C o n d i t ' s s tudy i n d i c a t e s t h a t the most f r e q u e n t l y o c c u r r i n g s i d e -
e f f e c t s o f MTX concern unwanted a c t i v i t i e s o f the drug t o the marrow 
and the d i g e s t i v e t r a c t . These s i d e - e f f e c t s o f MTX w i l l be d iscussed 
in more de ta i 1 . 
Side-effeats of MIX on the intestinal mucosa. 
The mucosa o f the d i g e s t i v e t r a c t is v e r y v u l n e r a b l e t o the i n f l u e n c e 
o f MTX. This is caused by the r a p i d o r o l i f e r a t i o n o f the mucosa 
c e l l s in the c r y p t s o f the v i l l i in the i n t e s t i n a l mucosa. Ecknauer 
(1978) ment ions t h a t the whole i n t e s t i n e s produce 20 χ 10 cel 1 s / i r i n u -
I I . The p e r i o d r e q u i r e d f o r a mucosa c e l l t o reach the t o p o f the 
v i l l u s takes 48 h o u r s . At the t o p o f the v i l l u s the c e l l w i l l be 
e x f o l i a t e d in the i n t e s t i n a l lumen and d i g e s t e d . 
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About one third of the proliferating cells in the crypts should be 
in the S-phase (Trier 1962). Of course these cells are very sensitive 
to the activity of MTX. Three hours after the administration of MTX 
(orally or parenteral 1y) the number of mitoses diminishes. The length 
of the villus will decrease with an average of (>0% in the first kB 
hours after a single dose of MTX, but after 96 hours the length will 
increase again to normal within a week (Trier 1962; Taminiau 1978, 
I98O). The effect of the inhibition of the mucosa-proliferation is 
a decrease of all enzyme-activity, located in the upper part of the 
intestinal villus. The absorption of the intestinal contents 
diminishes too during the first 7 days after a single dose of MTX, 
according to the decrease of the xylose absorption (Craft 1977). 
The consequence will be a diarrhoea during the period of decreased 
absorpt ion. 
For details of the activity of the intestinal enzymes is referred to 
the literature on this matter.(Mi 11 ington 1962, Redgrave I967, Wolff 
1967, Aschord 1969, Fromm 1971, Marrone 1973, Taminiau 1978, I98O). 
The most sensitive parts of the digestive tract are the mucosa cells 
of the proximal and middle part of the ileum: within a few hours 
after a single dose of MTX, lesions of the mucosa can be observed. 
Later, the mucosa of jejunum, distal ileum, duodenum, colon and coecum 
will follow (Baskerville 1977, Jeynes 1978). 
Even a very small concentration of MTX (5 χ 10 mol/1) in the plasma 
causes an inhibition of the DNA-synthesi s of the mucosa cells in the 
digestive tract (Chabner 1973). This concentration is easily reached 
in plasma, even after the i.t. administration of MTX during the CNS-
prophylaxis, as will be shown in Chapter IX. The disturbances of the 
gastro-intestinal tract (ulcerations, diarrhoea, vomiting, loss of 
weight) during the CNS-prophylaxis may be due to the inhibiting 
action of MTX to the proliferation of the mucosa cells. 
By daily administrations of MTX (i mg/kg/dose) in rats anorexia and 
loss of weight can be observed very soon. The loss of weight in the 
animals treated is more than the loss of weight of control animals 
fed with the same amount of food eaten by the animals treated 
(Taminiau I98O). All animals treated suffered from diarrhoea. 
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After Ί days of treatment the intestinal mucosa was deprived of its 
villi, and 47% of the animals died (Mi 11ington 1962, Baskerville, 1977, 
Partridge 1979)· 
Although one may consider the way of administration of MTX to be of 
importance in the occurrence of the mucosa lesions, the time required 
for MTX after i.v. injection to reach the intestinal lumen, is however 
less than 1 hr. (Bischof 1970· This is caused by the enterohepatic 
cycle (p. 13). Because of this enterohepatic cycle the mucosa of the 
biliairy tract is damaged too ¡n the same way as the mucosa of the 
intestinal tract (Baskerville 1978). 
The influence of MTX on the hematopoiesis. 
E ry th ropo i es i s . 
The inhibition of the DNA-synthesis due to MTX, causes changes in the 
generation time of the different cell systems of the bone -narrow. After 
a single dose of MTX (6 mg/kg) the hemoglobin contents is decreased with 
0,5 - 1,7 mmol/1 in a period of 6-13 days after the administration of 
MTX (Condit I960). The daily decrease varies from 0,06 to 0,25 mmol/1. 
The number of reticulocytes drops as well. The minimum values are 
obtained from the 2nd to the 7th day after the administration of MTX. 
The number of reticulocytes will increase again after 9"19 days. 
Normally the erythrocyte precursors proliferate and mature to reticu-
locytes in 4-6 days, and these reticulocytes are resting in the marrow 
for 2-k days before entering the circulation (Linman 1975· Lord 1979). 
MTX inhibits the proliferating cells in the erythron and in these cells 
the DNA-synthesi s is inhibited during one mitotic cycle after a single 
dose. Administration of MTX over a long time causes a megaloblastic 
anemia both when administrated daily and at short intervals. After 
a dose of MTX a certain amount of megalocytes,caused by a functional 
deficiency of folic-acid dérivâtes at that time,comes into the circu-
lation. A number of normal erythrocytes will remain. A second dose of 
MTX causes a second release of megalocytes, while the number of normal 
erythrocytes is diminished by natural disappearance. Finally only 
megalocytes will remain, because the normal maturation is inhibited. 
This means the existence of a 'cumulation' not of MTX (Borrie 1966) 
but of megalocytes (Douglas 1973). 
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Long-term administration of small doses MTX with long intervals 
(once or twice a week) finally causes a megalocytosi s but not an 
anemia. 
Thrombocytopoies i s. 
After the administration of MTX (6 mg/kg) the number of thrombocytes 
shows a slight decrease between the 5th and the 12th day after the 
administration, and normalizes again between the 15th and the 27th 
day after the administration of MTX. 
The total megakaryocyt¡с maturation time is approximately 60 hours. 
In man an approximate time of 5 days has been reported (Miller 1978). 
The life-span of the platelets ranges from 9 to 12 days. This means 
that one generation of platelets is inhibited by a single dose of 
MTX. 
Leukocytes. 
Leukocytes decrease i n two phases. F i r s t the l e u k o c y t e s decrease at 
the ' t th t o 7th day a f t e r the MTX a d m i n i s t r a t i o n , and i n c r e a s e a f t e r 
t h a t f o r a s h o r t t i m e . Th is is In harmony w i t h a g e n e r a t i o n t ime o f k 
days (Linman 1975) C r o n k i t e 1979)- However, a second decrease o c c u r s 
between t h e 12th day and the 21th day a f t e r the a d m i n i s t r a t i o n . 
The t u r n o v e r t i m e o f the metamyelocytes, the band c e l l s and segmented 
c e l l s in the marrow is 159 hours ( C r o n k i t e 1979)· This may e x p l a i n 
t h a t the second decrease o f the t o t a l number o f l e u k o c y t e s a f t e r the 
MTX a d m i n i s t r a t i o n is caused by a d i s t u r b a n c e in the t r a n s i t f rom the 
p r o l i f e r a t i n g i n t o the n o n - p r o l i f e r a t i n g p o o l . A f t e r 15-29 days the 
t o t a l number o f l e u k o c y t e s in the b lood has been n o r m a l i z e d 
a g a i n . 
High-dose MTX i n f u s i o n s and the h e m a t o p o i e s i s 
A s i n g l e dose o f MTX o f 500 mg i . v . as a b o l u s - i n j e c t i o n does not cause 
a s e r i o u s decrease o f the number o f l e u k o c y t e s , b u t s p r e a d i n g the same 
dose over s e v e r a l subsequent days causes severe leukopenia and t h r o m -
bocytopen i a. 
By i n f u s i o n i n g MTX in 2b hrs t o p a t i e n t s w i t h ALL, the number o f 
lymphoblasts decreases and p r o b a b l y a l s o the normal hematopoies i s. 
W i t h i n 2k hrs a f t e r d i s c o n t i n u a t i o n o f the i n f u s i o n , a rebound w i l l 
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occur of both normal hematopoies¡s and of the lymphoblasts in the 
marrow. Increase of the lymphoblasts 24 hours after the infusion 
has been reported to range from 6% during the infusion, to 60% 
2k hours later (Ogston 1968, Kenis 1970, Shaw 1973). 
Chabner (1973) mentions the inhibition of the DNA-synthesi s on marrow 
_ Q 
c e l l s at a MTX c o n c e n t r a t i o n in the plasma o f 2 χ 10 m o l / l . 
Th is i s c o n f i r m e d by Pinedo (1977) f o r each c o n c e n t r a t i o n o f MTX 
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o f more than 10 m o l / l . The n a d i r in the marrow c e l l s is a t 30% 
o f t h e t o t a l c e l l count o f n u c l e a t e d c e l l s . A h i g h e r c o n c e n t r a t i o n 
does not i n c r e a s e the degree o f the h y p o p l a s i a , but t h e h y p o p l a s i a 
o f the marrow w i l l be reached at an e a r l i e r t i m e . 
Other side-effects of MIX 
Beside the t o x i c i t y on the d i g e s t i v e t r a c t and the hematopoies i s 
o t h e r s i d e - e f f e c t s o f MTX are known: l i ver-damage ( c i r r h o s i s ) has 
been r e p o r t e d in p a t i e n t s w i t h p s o r i a s i s (O'Rourke ідб'», Сое 1968, 
Dahl 1972, Nyfors 1976). 
Damage t o the bone t i s s u e has been mentioned by O'Regan (1973)• 
The m e t h o t r e x a t e - 1 u n g is a wel l -known c o m p l i c a t i o n , maybe t o g e t h e r 
w i t h a c o n c o m i t a n t i n f e c t i o n (Clarysse 1969, Kaplan 1978, Robbins 
1973). Acute renal impairment has been r e p o r t e d by Condi t ( 1 9 6 9 ) , 
Pitman (1975) and S t o l 1er ( 1 9 7 5 ) · The nephropathy i s caused by 
c r y s t a l l i z a t i o n o f MTX in t h e c e l l s o f the p r o x i m a l t u b u l u s 
( D a r y n k i e w i c z 1966, Pitman 1975, Jacobs 1976). 
The nephropathy can be p r e v e n t e d by a l k a l i z a t i o n o f the u r i n e w i t h 
sod i um-b îcarbonate .The u r i n a r y pH should be over 7 (Chan 1977, 
L ink 1976, Pitman 1976). A good d i u r e s i s and an adequate hyd ra t i on o f 
the p a t i e n t is o f importance in the renal e l i m i n a t i o n o f MTX. 
Dur ing and a f t e r the CNS-prophy1 ax is in c h i l d r e n w i t h ALL no o t h e r 
s ide e f f e c t s but g a s t r o i n t e s t i n a l t o x i c i t y and marrow dep ress i on , 
both due to MTX,have been observed in the p a t i e n t s o f t h i s s t udy . 
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Chapter I I I 
COMPLICATIONS IN THE PROPHYLACTIC TREATMENT OF THE CNS 
( c r a n i a l i r r a d i a t i o n and i . t . MTX). 
The known c o m p l i c a t i o n s o f the CNS-prophy1 ax is can be d i v i d e d i n t o 
two groups: 
a. systemic t o x i c r e a c t i o n s du r ing and a f t e r the CNS-prophy1axis 
b. neurological complications 
The systemic toxic reactions are termed in d i f f e r e n t ways by the 
d i f f e r e n t re fe rences (George 1968, S u l l i v a n 1969, Aur 1972, 
Zuelzer 1978) and are summarized in t a b l e 1 . 
Table 1 Systemic s i d e - e f f e c t s in CNS-prophy1axis 
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The i n f e c t i o n s mentioned by Aur (1972) and Zue lze r (1978) c o n s i s t 
o f i n t e r s t i t i a l pneumoni t is ( i n c l u d i n g pneumonias caused by 
Pneumocyst is c a r i n i i ) . v a r i c e ! l a and herpes z o s t e r ; h i s t o p l a s m o s i s , 
men ingo-encepha1 i t i s , h e p a t i t i s , sept icaemias and b a c t e r i a l m e n i n g i t i s 
have been mentioned o c c a s i o n a l l y . 
Qu i te remarkable is the h igh inc idence o f i n f e c t i o n s in the study o f 
Zue l ze r ( 1978 ) , a l t hough he c la ims t h a t t h i s IMFRA-method o f CNS-
p r o p h y l a x i s r e s u l t s in less i n f e c t i o u s pe r i ods (Zue lze r 1978). 
For the h igh inc idence o f i n f e c t i o n s in the study o f FUehm (1977) 
the complex systemic in t ravenous t rea tment can be blamed. 
The neurologia complications found du r i ng and a f t e r the CNS-prophy-
l a x i s can be a t t r i b u t e d t o d i f f e r e n t p a r t s o f the t r e a t m e n t , e i t h e r 
t o the i r r a d i a t i o n or to the i n t r a t h e c a l a d m i n i s t r a t i o n o f metho-
t r e x a t e : 
Men i ngi t i s 
Hustu (1973) mentions that with 1%% of 45 children following the 
craniospinal irradiation (without i.t. administration of MTX) a 
meningitis occurred. With 17 children that were not irradiated a 
meningitis was diagnosed in only two of them. 
Apathy-syndrome 
Due to the cranial irradiation the apathy-syndrome or somnolence 
syndrome occurs frequently. The syndrome has been described for the 
first time by Druckmann (1929): 
Children were treated for trichophythia of the head by irradiation 
of the skull. At first this treatment gave no problems, although 
sometimes a child vomited on the day after the irradiation, owing to 
radiation sickness. Epilation occurred after 14-18 days. By 
increasing the dose of irradiation, a remarkable syndrome could be 
observed: 6-8 weeks after irradiation the parents complained of the 
listlessness of their child. He/she spoke little, slowly and softly 
and showed an unbridled lethargy. He/she fell asleep when lying, 
sitting and standing and could scarcely be woken up. 
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The syndrome consisted moreover of anorexia, obstipation and a slight 
temperature. It lasted about ^-6 days, but in a few cases even 1k 
days. After reducing the dose of the radiation the syndrome did not 
occur anymore (Druckmann 1929). Freeman (1973) mentions the same 
syndrome in 79% of the children with ALL after CNS-prophy1axis ; 
Ch'ien (I98O) in 60%. The manifestations of the apathy-syndrome are 
summarized in table 6. 
It is usually concluded that the apathy-synurome is a transient cere­
bral disturbance with impairment of new myelin synthesis. 
The syndrome will probably not produce long-lived sequelae (Parker 
I978, Verzosa 1976). However, data from a study of Ch'ien (198O) 
suggest that the apathy-syndrome is an early indicator of permanent 
neurological damage, like cerebral atrophy (Crosley 1978), minerali­
zing microangiopathy and dystrophic cerebral calcifications (Price 
I978), contributing to bad short-term memory and learning disabilities 
(Schuier 1978, 1981) and to clinical apparent seizures. 
By means of computerized tomograhy (CT-scanning) brain-atrophy has 
been shown 19-67 months after the CNS-prophy1axis. This damage has 
no clinical manifestations. The CT-scanning shows an enlargement of 
the ventricles of the brain, widening of the subarachnoidal space 
and sometimes calcifications in the brain tissue. The attenuation 
coefficient of the brain tissue may be reduced (Peylan-Ramu 1978). 
Not every study mentions all these CT-scanning changes together 
(Mott 1978, Castee's-Vandaele 1978, Ludwig I98O). The IMFRA method 
also shows CT-scanning abnormalities (Mastrangelo I98O). 
Other neurologic complications 
After i.t. administration of MTX a meningeal syndrome has been des­
cribed (Baum 1971, Devivo 1977) with the signs and symptoms of a 
meningitis, but in which no bacterial or viral causes could be found 
in the CSF. 
Another form of neurotoxicity of MTX is the polyneuropathy, occurring 
shortly after the i.t. injection (б-^З hours), causing para- and 
quadriplegias (Bagshawe 1969, Weiss 1978). 
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Leukoencephalopathy (Kay 1970 is also due to the administration 
of MTX, but has been found in patients with a "damaged" brain only, 
either by invasion of leukemic cells, irradiation of the skull or by 
surgery. 
Other, very rare forms of encephalopathy have been reported by 01 iff 
(1978). In 5 patients the encephalopathy could be attributed to acute 
edema after the first dose of the cranial irradiation. Skullerud 
(1978) describes a child with encephalomyelopathy with whom the gray 
matter of the brain was damaged. This disease followed the usual 
treatment of the CNS (cranial irradiation and MTX it). 
The complications mentioned prompted us to evaluate the complications 
in our own patients with ALL during and after the CNS-prophylaxis. 
At the time of this retrospective study it was not yet possible to 
make CT-scans. In order to get informed of the changes in the brain, 
attention was given to changes in EEC's and to variations in echo-
encephalographiс data of these children as far as known. 
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Chapter IV 
OBSERVATIONS ON 50 CHILDREN WITH ALL DURING AND AFTER CNS-PROPHYLAXIS 
Treatment protocol 
Patients with untreated ALL, admitted to the pediatric department of 
the St Radboudhospita 1 Nijmegen, are treated according to the protocols 
drawn up the "Stichting Nederlandse Werkgroep Leukemie bij kinderen" 
(S.N.W.L.K.) in the Hague. This working-group coordinates the diagnosis 
and treatment of most of the children with leukemia in the Netherlands. 
The protocols have been described in detail by Van der Does - Van der 
Berg (1975, I976) and will not be described extensively here. During 
the observation period the basis of the protocols consists of a 
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remission induction treatment with vincristin (2 mg/m ) i.v. once a 
2 
week and prednison {h0 mg/m ) orally once a day both during 6 weeks. 
After attaining the hematologic remission a CNS-prophylaxis is applied, 
consisting of cranial irradiation during 17 days with a daily dose of 
200 Rad, 5 days a week (the last day 100 Rad), up to a total of 2500 
Rad; and of 5 concomitant i.t. injections of MTX and Prednisolon, 
distributed equally over the period of cranial irradiation. The dose 
2 
of MTX and Prednisolon comes to 12^ mg/m . The maximum amount of MTX 
injected per dose is 15 mg. During the CNS-prophy1axis the maintenance 
treatment starts with a continLOus first remission period of at least 
two years; after this period all treatment will be stopped. 
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The maintenance treatment consists of 6-mercaptopuri ne 50 mg/m orally 
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once a day, and after finishing the CNS-prophyIaxis, MTX 30 mg/m 
orally once a week. 
In this study 33 children received a consolidation treatment after 
every 5 weeks of maintenance treatment. The consolidation treatment 
2 
consists of prednison kO mg/m once a day during \k days, combined 
2 
w i t h v i n c r i s t i n 2 mg/m i . v . on the f i r s t and the e i g h t h day o f the 
c o n s o l i d a t i o n t rea tmen t p e r i o d . 
E s p e c i a l l y d u r i n g and s h o r t l y a f t e r the pe r i od o f CNS-prophy lax is the 
impress ion arose t h a t many t o x i c r e a c t i o n s take p lace in the c h i l d r e n . 
For t h i s reason a s tudy o f the na tu re and f requency o f the t o x i c 
r e a c t i o n s d u r i n g and a f t e r the CNS-prophy1axis was done in 50 c h i l d r e n 
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s u f f e r i n g from ALL. 
The f o l l o w - u p p e r i o d o f the 50 p a t i e n t s in t h i s s tudy ended on January 
1 s t , 1980. 
In t a b l e 2 a l l 50 p a t i e n t s have been summarized. 
· • 
1 E A 
2 І Д 
J P A 
к Е В 
5 Е В 
6 Е В 
7 J B 
9 П В 
9 N B 
10 OB 
11 « В 
12 J C 
1 3 KD 
IJ« WD 
15 « E 
16 DF 
17 MF 
1 8 KG 
1 9 S C 
2 0 D H 
2 1 H M 
Z 2 J H 
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Table 2 Survey o f the f o l l o w - u p in 50 c h i l d r e n w i t h ALL t r e a t e d 
i n t h e p e d i a t r i c department o f the S t . R a d b o u d h o s p i t a l 
Ni jmegen (June 1977-January I98O) 
This table shows that the distribution according to age is in agreement 
with the distribution according to age described by the literature 
(Table 3) . 
Age 
(years) 
0-3 
Ц-7 
8-12 
>12 
% 
36 
<t2 
20 
2 
Dritschillo 
(1976) 
31 
36 
21 
12 
M.R.C. 
(1976) 
39 
37 
16 
8 
Zuelzer 
(196Ό 
<t9 
Ίΐ 
10 
0 
Table 3 Distribution of age in 50 children with ALL compared with 
the 1 i terature 
In 2k children the complete remission continues from $Ц+ to 352+ weeks. 
In one boy the first remission ended by testicular invasion 112 weeks 
after the diagnosis ALL. 
In the other 25 children the first remission ended either by CNS-
leukemia or bone marrow relapse (Table Ц). 
Cause of relapse 
Overt CNS-leukemia 
(failure of CNS-prophylaxis/treatment ) 
Bone marrow relapse 
0 i ed 
Mean duration of first remission 
η 
13 
13 
16 
27 
26 
26 
32 
weeks + SD 
73 + 26 
119 i ΊΊ 
129 + 61 
97 + hl 
Table k Causes of relapse in 50 children with ALL 
In 8 children CNS-leukemia has not been followed by a relapse of the 
bone marrow, and in 11 children the marrow relapse has not been 
followed by CNS-leukemia. The mean duration of the remission induction 
treatment in these 50 children is 49.7 days. According to the duration 
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o f the r e m i s s i o n i n d u c t i o n t r e a t m e n t i t is p o s s i b l e t o d i v i d e the 
c h i l d r e n i n t o 3 g r o u p s : 
1. c h i l d r e n w i t h h i g h - r i s k leukemia (10 c h i l d r e n ) . 
2. c h i l d r e n hav ing a p e r i o d o f r e m i s s i o n i n d u c t i o n t r e a t m e n t of less 
than 50 days (31 c h i l d r e n ) . 
3. c h i l d r e n h a v i n g a p e r i o d o f r e m i s s i o n i n d u c t i o n t r e a t m e n t o f more 
than 50 days (9 c h i l d r e n ) . 
The f o l l o w - u p o f the c h i l d r e n in these t h r e e groups is summarized 
i η Table 5• 
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Table 5 F o l l o w - u p o f the course o f ALL in 50 c h i l d r e n a c c o r d i n g 
t o the d u r a t i o n o f the remi ss i o n - i n d u c t i on p e r i o d 
I t is very remarkable t h a t none o f the n i n e c h i l d r e n w i t h a r e m i s s i o n 
i n d u c t i o n t ime o f more than 50 days (group 111) is s t i l l in complete 
r e m i s s i o n . Two c h i l d r e n (pat 1 en 28, Table 2) w i t h h i g h - r i s k leukemia 
r e q u i r e d more than 50 days f o r the r e m i s s i o n i n d u c t i o n t r e a t m e n t . Two 
main causes f o r the long r e m i s s i o n i n d u c t i o n p e r i o d can be d i s t i n g u i s h e d : 
1. r e t a r d e d h e m a t o l o g i c r e m i s s i o n (6 c h i l d r e n ) . 
2. severe i n f e c t i o n d u r i n g the r e m i s s i o n i n d u c t i o n p e r i o d (4 c h i l d r e n ) . 
W i t h one p a t i e n t (pat 50) no reason has been found f o r the l a t e 
s t a r t o f the c r a n i a l i r r a d i a t i o n ; the r e m i s s i o n i n d u c t i o n p e r i o d 
had an u n e v e n t f u l c o u r s e . 
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The i n f e c t i o n s in 't p a t i e n t s are sep t i caemia (pat 10 and 11 ) , v a r i c e l l a 
(pat 33) and bronchopneumonia (pat 4 0 ) . Wi th these c h i l d r e n the remis -
s ion i n d u c t i o n t rea tment had to be i n t e r r u p t e d . 
Of the 26 c h i l d r e n r e l a p s i n g , 13 re lapsed in the CNS. Wi th 3 o f these 
c h i l d r e n leukemic c e l l s have been found in the CSF be fo re the prophy-
l a c t i c t rea tment s t a r t e d . Five o f the 13 be long to the group o f c h i l -
dren having a remiss ion i n d u c t i o n pe r i od o f more than 50 days. 
The p a t i e n t s w i t h ALL who had a remiss ion i n d u c t i o n p e r i o d o f normal 
d u r a t i o n ( less than 50 days) , but neve r the less re lapsed (11 c h i l d r e n ) , 
had one or more h i g h - r i s k f a c t o r s as desc r ibed by Maurer (1978) . 
The side-effects of the CJS-prophylaxris during the treatment 
The e v a l u a t i o n o f the t o x i c m a n i f e s t a t i o n s due t o the CNS-prophyIaxis 
requ i res a d i s t i n c t i o n between s i d e - e f f e c t s d u r i n g the CNS-prophy1axis 
and s i d e - e f f e c t s in the 83 days a f t e r the CNS-prophyI a x i s . 
I t has been assumed t h a t a f t e r t h i s p e r i o d (100 days a f t e r the s t a r t 
o f t he CNS-prophyI ax i s ) the o c c u r r i n g t o x i c i t y i s no longer the r e s u l t 
o f the CNS-prophyI a x i s , e x c l u d i n g the l a t e seque lae . 
Systemic s i d e - e f f e c t s 
Dur ing the CNS-prophy1axis impor tan t t o x i c r e a c t i o n s take p lace in the 
d i g e s t i v e t r a c t : 
With 9 c h i l d r e n a loss of we igh t o f at l eas t 1 kg (mean 2 .8 kg ; range 
1-15.3 k g ) , w i t h \h c h i l d r e n an o v e r t ano rex ia has been observed. One 
o f the causes o f both anorex ia and loss o f we igh t d u r i n g the CNS-prophy-
l a x i s may be cessa t i on o f the t rea tment w i t h p redn i son . 
Vomi t ing occurs f r e q u e n t l y du r i ng the CNS-prophy1axis (33 p a t i e n t s ) , 
but there is a r e l a t i o n between lumbar puncture w i t h i . t . a d m i n i s t r a -
t i o n of metho t rexa te and v o m i t i n g : o f the 250 lumbar punctures in 
these 50 c h i l d r e n , v o m i t i n g (most ly 2-h hours a f t e r the puncture) 
f o l l o w e d w i t h kb (=18%) o f the c h i l d r e n who had a lumbar punc tu re . 
Mucosa l es ions ( i r r i t a t i o n , hyperaemia, u l c e r a t i o n ) , e s p e c i a l l y o f 
the mucosa o f the mouth are we l l known in t rea tmen t procedures w i t h 
MTX. In 7 c h i l d r e n u l c e r a t i o n has occur red d u r i n g the CNS-prophy1axis. 
This s i d e - e f f e c t ir. very inconven ien t and p a i n f u l , and hampers the 
e a t i n g and d r i n k i n g . 
l)Changes in the CSF and hemato log ic s i d e - e f f e c t s are d iscussed on p.35 
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At the end o f the CNS-prophy1axis, a l l c h i l d r e n developed an a l o p e c i a , 
some o f them (11 c h i l d r e n ) however, became ba ld be fo re the CNS-prophy-
l a x i s was begun, ov/ing to the t rea tment w i t h v i n c r i s t i n . 
The i n f e c t i o n s o c c u r r i n g d u r i n g the CNS-prophy1 ax is are seldom s e r i o u s . 
In 5 c h i l d r e n i n f e c t i o n s o f the upper r e s p i r a t o r y t r a c t have been obser -
ved. One p a t i e n t s u f f e r e d f rom i n t e r s t i t i a l pneumonia. A c y s t i t i s has 
been diagnosed once. A l l these i n f e c t i o n s have been t r e a t e d w i t h a n t i -
b i o t i es . 
Asymptomatic b a c t e r i u r i a ( b a c t e r i a l counts o f more than 10 / m l , w i t h o u t 
feve r or l e u k o c y t u r i a and w i t h o u t compla in ts o f the m i c t i o n ) , have been 
observed in 7 g i r l s and 3 boys, but have not been t r e a t e d . 
We are not conv inced o f a connect ion between the CNS-prophylaxis and the 
occur rence o f i n f e c t i o n s . 
Neuro tox i c s i d e - e f f e c t s . 
The n e u r o t o x i c i t y in t h i s s tudy cons i s t ed o f p t o s i s o f one e y e l i d , be ing 
observed w i t h two c h i l d r e n . A few weeks a f t e r the CNS-prophyIaxis the 
p t o s i s d isappeared spontaneous ly . 
The side-effects due to the CNS-prophy Laxis during the 83 days after 
the treatment. 
Systemic s i d e - e f f e c t s 
In the f i r s t weeks a f t e r the CNS-prophy1 ax is a pe r i od o f i r r i t a b i l i t y 
and aggress iveness was desc r i bed o f 7 c h i l d r e n . 
Wi th two c h i l d r e n these symptoms l as ted f o r a lony t i m e . In the o the r 5 
were overcome a f t e r an unknown p e r i o d . One o f the causes o f t h i s change 
in cha rac te r may be the emot iona l d i g e s t i o n o f the pe r i od in h o s p i t a l . 
A r e s u l t o f the i r r a d i a t i o n is an increased desquamation o f the sk in o f 
the s k u l l , o c c u r r i n g w i t h a l l p a t i e n t s . This is the more s t r i k i n g be-
cause o f the t o t a l ba ldness . Rashes have been observed in 7 p a t i e n t s 
(head, neck, e x t r e m i t i e s ) . 
1) Hematologic s i d e - e f f e c t s are d iscussed on p. 35 
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The i n t e n s i t y v a r i e s . These rashes are a t t r i b u t e d to MTX. 
The d i g e s t i v e t r a c t too shows s i d e - e f f e c t s o f which the l e s i o n s o f 
the mucosa have a l ready been ment ioned. Loss o f we igh t o f more than 
1 kg . occur red in 12 o t h e r c h i l d r e n . In another 12 anorex ia has been 
no ted . Both anorex ia and loss o f we igh t form a p a r t or are the conse-
quences o f the apathy-syndrome. I n f e c t i o n s occur more f r e q u e n t l y 
a f t e r the CNS-prophy lax is : in 27 c h i l d r e n an i n f e c t i o n o f the upper 
r e s p i r a t o r y t r a c t has been observed. With 6 c h i l d r e n an i n t e r s t i t i a l 
pneumonia has been d iagnosed, 2 c h i l d r e n had to be h o s p i t a l i z e d , 
because they developed a sep t i caem ia ; one by K l e b s i e l l a ; the o t h e r , 
by Staphylococcus aureus,was f o l l o w e d by an o s t e o m y e l i t i s o f the 
t i b i a . Two c h i l d r e n developed a v a r i c e l l a i n f e c t i o n . 
Neuro tox ic s i d e - e f f e c t s . 
Neuro tox ic s i d e - e f f e c t s cons i s ted o f decreased tendon r e f l e x e s o f 
both arms and legs in ^3 c h i l d r e n . In 23 c h i l d r e n , however, the 
r e f l e x e s were subnormal be fore the s t a r t o f the CNS-prophy1axis, 
due to the remiss ion i n d u c t i o n t rea tment ( v i n c r i s t i n is cons idered 
to be the cause o f t h i s n e u r o t o x i c r e a c t i o n ) . 
This makes i t d o u b t f u l t h a t changes in tendon r e f l e x e s (Terheggen 
1378) can be cons idered to be a p a r t o f the apathy-syndrome. 
The apathy-syndrome. 
The most s t r i k i n g s i d e - e f f e c t apar t f rom the CNS-prophylax!s i s the 
apathy-syndrome ( p . 2 2 ) . Anamnest ic ly the syndrome (Table 6) can be 
suspected to e x i s t in a more or less severe degree in nea r l y a l l 
c h i l d r e n . The paren ts o f c h i l d r e n s u f f e r i n g from the apathy-syndrome 
say t h e i r c h i l d r e n are s l eepy , t i r e d , l e t h a r g i c and have l o s t t h e i r 
a p p e t i t e . Concomitant symptoms are a headache and v o m i t i n g . 
Young c h i l d r e n may not complain o f a headache but o f abdominal p a i n . 
In 39 c h i l d r e n at l e a s t one day w i t h a temperature has been observed. 
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In t h i s s tudy the syndrome s t a r t e d in 12 (24%) c h i l d r e n 2-3 months 
a f t e r f i n i s h i n g the c r a n i a l i r r a d i a t i o n . In the remain ing c h i l d r e n 
the syndrome s t a r t e d d u r i n g the f i r s t 8 weeks a f t e r i r r a d i a t i o n , 
sometimes even in the second week (2 p a t i e n t s ) . 
The m a n i f e s t a t i o n s observed in these 50 c h i l d r e n are compared w i t h 
those found in s t u d i e s o f Druckmann (1929), Freeman (1973) and 
Terheggen (1978) in Table 6 . 
number of patients 
Occurrence of the apathy syndrome 
after discontinuation of the 
cranial irradiation 
within 1 month 
after 1-2 months 
after 2-3 months 
Signs and symptoms 
sleepiness tired 
anorexia 
fever 
vomi ting 
pain (back, abdominal, head) 
diarrtooea 
obstipation 
ataxia 
disturbances of speech 
|abnormal tendon reflexes 
Study 
50 
% 
6 
22 
lb, 
62 
62 
28 
26 
i*0 
10 
2 
10 
0 
86 
Druckmann 
(1929) 
110 
X 
-
+ 
-
27 
27 
+
 i l l J 
nm 
+ 
nm 
+ 
nm 
+ 
+ 
Freeman 
(1973) 
28 
% 
25 
53 
-
78 
79 
14 
7 
17 
nm 
nm 
nm 
nm 
nm 
Terheggen 
(1978) 
33 
% 
-
70 
-
70 
70 
+ 
9 
+ 
nm 
+ 
13 
17 
U 
Table 6 The apathy-syndrome in 50 c h i l d r e n w i t h ALL compared w i t h 
the 1 i t e r a t u r e 
') nm = not mentioned 
Studies of the EEG of children with ALL before and after the 
CNS-prophy laxis 
In 20 out o f 50 c h i l d r e n admi t t ed t o the p e d i a t r i c department o f the 
S t .Radboudhosp i ta l in Nijmegen on account o f ALL, an EEG was made be-
fo re the CNS-prophy lax is . E igh t o f these c h i l d r e n acqu i red CNS-leuke-
mia l a t e r ? n . N i n e o f the c h i l d r e n showed d i s tu rbances a l ready before 
the CNS-prophylax is (Table 7 ) . 
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In 15 o f the 20 c h i l d r e n another EEG was made w i t h i n one week a f t e r 
f i n i s h i n g the CNS-prophy lax is . In 13 o f these p a t i e n t s the abnorma-
l i t i e s became more pronounced. In 8 o f the 15 c h i l d r e n a t h i r d EEG 
has been made at l eas t 2 months a f t e r f i n i s h i n g CNS-prophy1 a x i s . 
In 't c h i l d r e n an improvement o c c u r r e d , w h i l e in 3 c h i l d r e n the EEG-
a b n o r m a l i t i e s d i d not change and in 1 p a t i e n t the d i f f u s e s low ing 
became worse w i t h foca l a c t i v i t y . 
Number of patients 
No abnormal i ties 
Abnormal i ties : 
diffuse slowing 
focal activity 
i rritabi1 ity after 
photosti mul at i on 
Before CNS-
prophy 1 ax i s 
20 
11 
3 
It 
2 
1 week after 
CNS-prophylaxis 
15 
2 
9 
It 
0 
> 2 months 
after CNS-
prophylaxis 
8 
it 
3 
1 
Table 7 EEG-changes in c h i l d r e n w i t h ALL before and a f t e r CNS-
p r o p h y l a x i s 
From our i n v e s t i g a t i o n i t appears t h a t a b n o r m a l i t i e s o f the EEG can 
be found in a cons ide rab le number o f c h i l d r e n w i t h o u t ev idence o f 
an o v e r t CNS-leukemia. Whether these are due to e a r l y ( s u b c l i n i c a l ) 
leukemic invas ion as mentioned by Ko r in thenberg (1979) , cannot be 
proven. D is turbances d u e ' t o the CNS-prophylax is can a l so be suggested, 
but cannot be proved e i t h e r . 
The assessed d i s tu rbances o f the EEG are temporary (apathy-syndrome) 
in most o f the p a t i e n t s . Temporary changes in the EEG due to the CNS-
¡jrophy l ax i s as pa r t o f the apathy-syndrome, have been desc r ibed by 
Butcher (1970) , Aronson (1973) , Pamp ig l i on i (1973) and K o r i n t h e n -
t e r g (1580) and agree w i t h our f i n d i n g s . 
з^ 
The EEG a b n o r m a l i t i e s in c h i l d r e n w i t h ALL b e f o r e , d u r i n g and a f t e r 
the CNS-prophy1axis should be s t u d i e d more e x t e n s i v e l y in a proper 
f o l low-up s t u d y . 
Uitrasonic eehoencephalography Ln children with ALL. 
Echoencephalography (Α-scan) in c h i l d r e n w i t h ALL is not a p p l i e d f r e ­
q u e n t l y . Th is is very r e m a r k a b l e , because the method o f eehoencephalo­
graphy is easy and c o m p l e t e l y h a r m l e s s . I t g ives i n f o r m a t i o n about m i d ­
l i n e s t r u c t u r e s and about the s i z e o f the v e n t r i c l e s . The methods o f 
eehoencephalography have been d e s c r i b e d e x t e n s i v e l y by Kr i jgsman (1970, 
1979) and Grumme ( 1 9 7 3 ) . Between June 1976 and October 1979 eehoence­
phalography has been used w i t h 50 c h i l d r e n w i t h ALL. Not a l l the c h i l ­
dren in t h i s s tudy are mentioned in Table 2. 
The age o f these 50 c h i l d r e n is i m p o r t a n t , f o r j u s t l i k e the c r a n i a l 
c i r c u m f e r e n c e , the s i z e o f the t h i r d v e n t r i c l e depends on the c h i l d ' s 
age. In 5^% o f t h i s group o f c h i l d r e n the age was between 2 and 6 y e a r s . 
Lateral ventricles (T/D index) 
Al 1 pat i ents 
Patients which developed 
later on CNS-leukemia 
(16 patients) 
Thi rd ventricles 
Al 1 patients 
(corrected for age) 
Patients which developed 
later on CNS-leukemia 
(16 patients) 
(corrected for age) 
norma 1 
30 
8 
normal 
11 
>o.3o 
18 
8 
enl arged 
15 
5 
<0.2i* 
2 
0 
reduced 
1 
0 
abnormal {%) 
hü 
50 
abnormal {%) 
32 
31 
Table 8 Echo-encephalographi с f i n d i n g s in 50 c h i l d r e n w i t h ALL 
b e f o r e CNS-prophy1axis 
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At t h a t age the normal s i z e o f the t h i r d v e n t r i c l e v a r i e s from 2-6 mm 
(Kr i jgsman 1970). The s i z e o f the l a t e r a l v e n t r i c l e s i s expressed by 
the T/D i n d e x . Th is index is not age-dependent. The normal v a l u e l i e s 
between O.Zh and 0.30 (Kr i jgsman 1979). In a number o f c h i l d r e n the 
s i z e o f both l a t e r a l and t h i r d v e n t r i c l e is a l r e a d y abnormal (Table 8) 
b e f o r e the CNS-prophy1 a x i s . 
In 15 c h i l d r e n echoencephalography was repeated at l e a s t 3 t imes a f t e r 
the C N S - p r o p h y l a x i s , d u r i n g the p e r i o d o f o b s e r v a t i o n . With one p a t i e n t 
the t h i r d v e n t r i c l e became s m a l l e r , but w i t h another c h i l d the t h i r d 
v e n t r i c l e increased in s i z e . The l a t e r a l v e n t r i c l e s o f 3 p a t i e n t s 
d i m i n i s h e d . The r e s u l t s are too p r e l i m i n a r y t o be c o n c l u s i v e . 
I t is very r e m a r k a b l e , t h a t in c h i l d r e n w i t h ALL an e n l a r g e d v e n t r i c l e 
system may be found b e f o r e the CNS-prophylaxis has been begun. 
We are not able t o d e s c r i b e d the cause, but a r e l a t i o n w i t h the e x i s ­
tence o f leukemic invas ions in the b r a i n might be suggested. 
Laboratory findings during and after the CNS-prophylaxis 
Hematologic f i n d i n g s 
The f i r s t t h r e e months a f t e r r e a c h i n g the h e m a t o l o g i c r e m i s s i o n the 
va lues o f h e m o g l o b i n , l e u k o c y t e s and thrombocytes are h i g h l y v a r i a b l e 
owing to the c o m b i n a t i o n o f the C N S - p r o p h y l a x i s , maintenance and conso­
l i d a t i o n t r e a t m e n t s . 
Day of observation 
Hemoglobin 
(<6.5 mmol/l) 
Leukocytes 
(<3.0 χ 109/1) 
Trombocytes 
(<150 χ 109/1) 
Lymphocytes 
( <1.0 χ IO9/!) 
1 
15 
't 
7 
9 
17 
12 
8 
θ 
26 
59 
6 
it 
7 
24 
100 
11 
12 
Η 
25 
Table 9 Subnormal hematologic va lues in 50 c h i l d r e n w i t h ALL in 
r e m i s s i o n d u r i n g and a f t e r CNS-prophylaxis 
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In Table 9 the number of patients with values below normal on the 
1st, 17th, 59th, and IQOth day of the observation period have been 
mentioned, corresponding to the first and last day of the CNS-prophy-
laxis, the medium time between the first two periods of consolidation 
treatment and at the end of the observation period, two days after 
the second consolidation period. 
These values show no differences except for the lymphocytes. The 
number of lymphocytes diminishes after beginning the CNS-prophy1 axis. 
Starting the CNS-prophy1axis, many changes of the therapy protocol 
are executed: 
1. Finishing the remi ss ion-induction treatment and gradual diminish-
ing of the prednison. 
2. Start of the cranial irradiation and i.t. administration of metho-
trexate and again Prednisolon. 
3. Start of the maintenance treatment with daily 6-mercaptopur¡ne. 
All these changes may contribute to the occurrence of the lymphopenia. 
The cerebrospinal fluid (CSF) during the CNS-prophy1axis. 
During the CNS-prophy1axis 5 lumbar punctures have to be carried out, 
2 
the CSF is sampled and MTX (12^ mg/m , with a maximum per dose of 
2 
IS mg) and Prednisolon (122 mg/m ) are injected after the sampling. 
After finishing the CNS-prophy1axis, the CSF is controlled once in 
every 3 months. From the CNS-sample the total white cell count per 
mm .protein contents and the glucose concentration have been estimated, 
together with the glucose concentration in the blood. 
Every CSF-sample is examined cytologically by using the sedimentation 
method (Sayk I960, Bots 1963)· The slides are stained according to 
the May Grünwald-Giemsa method (Posthuma 1978). The pressure of the 
CSF is not measured. It has been observed that obtaining CSF during 
the CNS-prophy1axis is becoming more difficult, especially in the 
third and the fourth lumbar puncture. There is no real explanation 
for this phenomenon. 
The first sample of CSF obtained after the diagnosis ALL will be 
іакеп with the first lumbar puncture of the CNS-prophy1 axis. 
So the first lumbar puncture is the only possibility to diagnose a 
CNS-leukemi a. 
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Therefore it is important that this first lumbar puncture supplies 
a representative sample of CSF. In h children (pat. 5, 28, 31 and 
itS, Table 2) leukemic cells were found in the sedimentation prepara­
tion. In two of them the total white cell count of the CSF was normal 
(3 and k per mm ). In 5 other children the total white cell count 
was above normal (12 to 56/rmi ). In none of these 5 children the 
CSF sample contained leukemic cells, and most of the cells were 
monocytes. In none of these 5 children symptoms of infection (fever, 
meningismus) had been observed before. 
Culture of the CSF has been carried out in 2 of these children only. 
These cultures remained sterile. 
In Fig. 3 the distribution of the total white cell count of the 
5 CSF-samples during the CNS-prophylaxis is shown. An increase of 
the cell count can be observed at the second lumbar puncture, before 
the second administration of MTX and Prednisolon. 
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Fig. 3 Distribution of cell count (/ mm ) and protein contents 
(mg/1) in CSF of 50 patients with ALL during CNS-prophy1axis 
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The p r o t e i n con ten ts in the CSF cnanges du r i ng the f i v e lumbar 
punctures ( F i g . 3 ) . These changes however, are less c l e a r , a l though 
the increase o f the p r o t e i n contents was extreme (h ighes t va lue o f 
2000 mg/1) in 't p a t i e n t s . The g lucose c o n c e n t r a t i o n in the CSF 
compared w i t h the g lucose c o n c e n t r a t i o n in the b l o o d , does not change 
remarkable . Even in each i n d i v i d u a l c h i l d , the g lucose contents d i f -
f e r s very much. No r e l a t i o n can be found between the t o t a l w h i t e c e l l 
counts or p r o t e i n contents o f the CSF and the g lucose concen t ra t i on 
in the CSF. 
Discussion 
Dur ing the pe r i od o f obse rva t i on a l l the 50 c h i l d r e n remained in 
complete r em iss i on . From Table 2 i t can be concluded tha t the minimum 
d u r a t i o n o f the f i r s t remiss ion was hu weeks a f t e r the d i a g n o s i s . 
The s h o r t e s t d u r a t i o n o f the f i r s t remiss ion is to be found in the 
group o f p a t i e n t s w i t h a h i g h - r i s k leukemia (67.3 weeks) and the 
s u r v i v a l - t i m e too is s h o r t e s t in t h i s group. However, i t is s t r i k i n g 
t h a t a l l the 9 c h i l d r e n w i t h ALL w i t h o u t any o t h e r h i g h - r i s k charac-
t e r i s t i c s than the long d u r a t i o n o f the pe r i od o f remiss i o n - i n d u c t i o n 
(more than 50 d a y s ) , the f i r s t remiss ion ended and on ly 3 c h i l d r e n 
o f t h i s group are s t i l l a l i v e . From t h i s obse rva t i on may be concluded 
t h a t c h i l d r e n w i t h ALL who r e q u i r e a pro longed remiss ion i n d u c t i o n 
t r e a t m e n t , belong t o the group o f p a t i e n t s w i t h h i g h - r i s k c h a r a c t e r i s -
t i c s . The f a i l u r e t o reach a remiss ion a f t e r h weeks o f i n d u c t i o n 
t rea tmen t is now a w e l l known h i g h - r i s k s ign (Mauer 1978). However, 
i t is u n p r e d i c t a b l e at the t ime o f d i a g n o s i s . 
Accord ing t o the S t . J u d e ' s group the t rea tment has to be most 
i n t e n s i v e a t the beg inn ing o f the t r ea tmen t . At t h a t moment the leuke-
mic c e l l - l o a d is tne h i g h e s t . In t h i s s tudy aoout 50% o f the c h i l d r e n , e n -
d ing the f i r s t r e m i s s i o n , have a re lapse by CNS-leukemia. 
I t may be imagined tha t CNS-leukemia can occur a t the moment o f the 
l a r g e s t c e l l - l o a d , i n the f i r s t days o f ALL. The s u b c l i n i c a l CNS-in-
volvement must be t r e a t e d at an e a r l y s tage o f the i n d u c t i o n t rea tment 
ra the r than a f t e r a t t a i n i n g the hemato log ic r e m i s s i o n . 
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The method o f t r e a t m e n t remains a p o i n t o f d i s c u s s i o n , f o r a c c o r ­
d i n g t o the warn ings o f D u t t e r a (1973) and D r i t s c h i l o (1976) r a d i o ­
t h e r a p y cannot be a p a r t o f an e a r l y C N S - p r o p h y l a c t i с t r e a t m e n t , 
as the h e m a t o l o g i c r e m i s s i o n has not y e t been a c h i e v e d . The c r a n i a l 
I r r a d i a t i o n s h o u l d be reserved f o r t h e f i n a l CNS-prophy1axis a f t e r 
a c h i e v i n g the h e m a t o l o g i c r e m i s s i o n , or i s not grven a t a l l . 
The CNS-prophylaxis causes a number o f s i d e - e f f e c t s d u r i n g the t r e a t ­
ment and in the p o s t - t r e a t m e n t p e r i o d . Some s i d e - e f f e c t s may be due 
t o one o f the p a r t s o f the t r e a t m e n t : a l o p e c i a and the a p a t h y syndrome 
are the most s a l i e n t c o m p l i c a t i o n s o f the c r a n i a l I r r a d i a t i o n . 
The mucosa l e s i o n s and h e m a t o l o g i c d i s t u r b a n c e s can be a t t r i b u t e d t o 
th e i . t . a d m i n i s t r a t i o n o f MTX. Other s i d e - e f f e c t s , l i k e loss o f 
w e i g h t , p l e l o c y t o s e In CSF, are the r e s u l t s o f a number o f changes in 
the t r e a t m e n t d u r i n g the CNS-prophy1 a x ! s , e . g . the d isappearance o f 
P r e d n i s o n , the a d m i n i s t r a t i o n o f 6 - m e r c a p t o p u r ! n e , l . t . a d m i n i s t r a t i o n 
o f MTX and P r e d n i s o l o n . 
Both EEG and echoencephalography show changes in the b r a i n b e f o r e , 
d u r i n g and a f t e r CNS-prophy1 a x i s . A l t h o u g h our r e s u l t s are p r e l i m i ­
n a r y , these methods appear t o be an a d d i t i o n t o r e s u l t s o b t a i n e d In 
CT-scannlng. More and e x t e n s i v e e l e c t r o p h y s i o l o g i c i n v e s t i g a t i o n s t o ­
g e t h e r w i t h the EEG, echoencephalography and CT-scanning may c o n t r i ­
bute t o the d i a g n o s i s o f o v e r t CNS-leukemia and t o the u n d e r s t a n d i n g 
o f e a r l y and l a t e s i d e - e f f e c t s o f the p r e c e d i n g t r e a t m e n t on the 
b r a ! η . 
The a n a l y s i s o f t h e s i d e - e f f e c t s o f t h e CNS-prophylaxis 
r e q u i r e s a c l o s e r look at the d i f f e r e n t elements o f the CNS-prophy-
l a x i s . 
Above a l l we have t o study the d i s t r i b u t i o n o f MTX ¡η the b lood and 
t i s s u e s a f t e r the i n t r a l u m b a r a d m i n i s t r a t i o n o f I t t o p a t i e n t s d u r i n g 
th e C N S - p r o p h y l a x i s , so as t o u n d e r s t a n d the t o x i c r e a c t i o n s o f MTX 
d u r i n g t h i s t r e a t m e n t . 
E a r l y CNS-prophy1axis, b e f o r e the h e m a t o l o g i c r e m i s s i o n has been 
a c h i e v e d , may take p l a c e by I n t r a t h e c a l I n j e c t i o n o f MTX (Wol lner 
1976, Мое 1978, 1980) o r by I n t r a v e n o u s i n f u s i o n o f h igh-dose MTX 
w i t h CF-rescue (Freeman 1977, Мое 1978). The problems and p o s s i b i l i ­
t i e s o f t h e l a t t e r t r e a t m e n t w i l l be d i s c u s s e d l a t e r (Chapter XIV) 
i*0 
Some form of CNS-prophy1ax¡s is obligatory in the treatment of any 
child with ALL. This treatment may cause side-effects that should be 
accepted as being unevitable. 
Looking for ways to make the treatment easier for the patient will 
make the progress of the disease easier to cope with, without diminish-
ing the good results in the total treatment of ALL. 
i t i 
Chapter V 
THE THERAPEUTIC CONCENTRATIONS OF MTX 
The i n h i b i t i o n o f the enzyme DHFR i s the main goal o f us ing MTX 
t rea tment o f n e o p l a s t i c d i seases . By the i n h i b i t i o n o f t h i s enzyme, 
the DNA-synthesis w i l l be b l ocked . The t ime r e q u i r e d f o r i n h i b i t i o n 
o f the DNA-synthesis i s the same in both marrow and i n t e s t i n a l mucosa 
(Chabner 1973). However, the t ime requ i red f o r recovers o f the DNA-
s y n t h e s i s , d i f f e r s w i t h both t i s s u e s : a dose o f 5 mg/kg of MTX in 
mice i n h i b i t s the i n c o r p o r a t i o n o f H-UdR i n t o DNA o f marrow and 
duodenal mucosa f o r 6 hours . The marrow recovers comp le te l y in 12 
hours a f t e r the dose, but the duodenal mucosa recovers o n l y up t o 50% 
a f t e r the same pe r i od (Chabner 1973) . A t e n f o l d increase o f the dose 
of MTX i n h i b i t s the DNA-synthesis ( H-UdR- incorpora t ion ) f o r a longer 
pe r iod both in marrow {2k hours) and duodenal mucosa (36 h o u r s ) . 
A s i n g l e bolus dose of 350 mg/kg o f MTX causes an i n h i b i t i o n o f the 
marrow p r o l i f e r a t i o n p e r s i s t i n g f o r 36 hours and in the duodenal 
mucosa f o r ^8 hou rs . I n h i b i t i o n o f DNA-syn thes is , i n d i c a t e d by the 
H-UdR- incorpora t ion i n t o DNA, i s complete in most t i s s u e s when the 
-8 
c o n c e n t r a t i o n o f MTX in the plasma is more than 10 m o l / 1 . 
The DNA-synthesis in the marrow recovers 50% o r more of the l e v e l s 
before t rea tment on l y a f t e r the c o n c e n t r a t i o n o f MTX in the plasma 
-8 has become less than 10 m o l / 1 . The DNA-synthesis in the duodenal 
mucosa recovers 50% o r more of the p re t rea tmen t l e v e l s a t a plasma 
c o n c e n t r a t i o n o f less than 5 x 10 mol /1 (Chabner 1973) . B e r t i n o 
(1964) determined the minimum c o n c e n t r a t i o n of MTX in v i t r o , i n h i b i -
-8 
t i n g the enzyme DHFR c o m p l e t e l y , t o be 3 x 10 m o l / 1 . In v i t r o and 
in v i v o exper iments o f human leukemia (Hryn iuk 1969) have demonstra-
ted tha t the MTX-concent ra t ion in p lasma, requ i red f o r complete 
i n h i b i t i o n o f the DNA-synthesis is 5 x 10 m o l / 1 . Other i n v e s t i g a -
t i o n s however, accept a minimum e f f e c t i v e c o n c e n t r a t i o n o f 10 mol/1 
(Shapi ro 1975, Kimelberg 1977, 1978). 
These c o n c e n t r a t i o n s mean tha t t o x i c r e a c t i o n s in the d i g e s t i v e t r a c t 
must be accepted as being i n e v i t a b l e in the t rea tment o f acute human 
leukemia. 
k2 
By using a device for controlled drug release, implanted sub-
cutaneously in mice, Pinedo (1976) has obtained plasma plateau 
_ о _ r 
concentrations of MTX between 10 to 10 mol/1 by using infusion 
-6 -k 
rates ranging from less than 10 mg/h to more than 10 mg/h. 
He concludes that the incorporation of UdR into marrow cells of the 
mouse is completely inhibited at a MTX concentration of 2 χ 10 mol/1 
during 48 hours. The description of these experiments is beyond the 
scope of this study. For details of the methods the reports of 
Zaharko (197^), Dedrick (ig?1*), Pinedo (1976) are referred to. 
With regard to man, Djerassi (1975) demonstrates that in patients 
with 1ungcarcinoma the best antitumor effect could be obtained with 
-4 
a MTX concentration in plasma of more than 10 mol/1, showing that 
different concentrations of MTX are required in different kinds of 
tumors. 
The high concentration found by Djerassi is more in agreement with 
the results of Borsa (1969) and Chello (1977), showing that a high 
concentration (more than 10 mol/1) is required to inhibit the TMP-
synthetase activity. The use of such large doses of MTX together with 
the depletion of the reduced folate coenzyme, N N - methylenetetra-
hydrcifol ate, resulting from the DHFR- inhi bi t ion , might provide condi­
tions in which a block on the TMP-synthetase activity would result 
in increased inhibition of the DNA-synthesi s (Bertino 1977). 
In case of leukemic cells the very high concentrations may be un­
necessary. A concentration of 5 x 10 to 1 χ 10 mol/1 is sufficient 
to inhibit the leukemic cell growth and these concentrations are in 
concordance with the findings of Pinedo (1976). 
The oonoentration χ time principle. 
Not only the concentration of MTX but also the time of exposure to 
this concentration is of importance. By maintaining a certain concen­
tration during a certain period at the chosen level, the peak concen­
tration of MTX will be reduced. Six small intraventricular doseb of 
1 mq of MTX, administered every 12 hours, result in the same rate and 
the same remission time as a single large i.t. dose of 12 mg, but the 
toxicity of the repeated small dose appears to be significantly less 
(Bleyer I978). In fact, the "concentration χ time" principle is also 
the basis of an adequate use of the high-dose MTX infusions 
з^ 
influencing the occurrence of toxic reactions owing to MTX. 
A 3"hours-contact between lymphocytes (in vitro) and a MTX corcen-
tration of 1.1 χ 10 mol/1 in the culture medium is sufficient to 
depress the mitotic process of the lymphocytes. 
This inhibition can be reversed by the addition of reduced folates 
in the culture medium, but not later than 18 hours after initiating 
the culture (Rozenszajn 197Ό. 
In man, exposure to MTX exceeding bS hours, causes serious hematologic 
and gastrointestinal toxicity. This toxicity is unrelated to the dose 
of MTX. 
In Pinedo's mice-model (p.^2) the blood-concentrations have been 
reached at levels of 10 mol/1. In all animals the number of nuclea­
ted cells per femur drops to a nadir of 30% of the controls for all 
- 8 
concentrations of more than 10 mol/l. This nadir has been reached 
most rapidly at the highest concentration: within 12 hours at 
10 mol/1, within 2k hours at 2 χ 10 mol/1., within 48 hours at 
-7 -8 
2 x 1 0 mol/1 and approximately within 72 hours at 5 x 10 mol/1 
(Pinedo 1976, 1977). 
By treating patients with ALL with infusion of MTX the number of 
lymphoblasts will decrease. After ending the infusion a rebound 
phenomenon appears both in normal marrow cells (Pinedo 1976) and 
in lymphoblasts: the number of lymphoblasts that are reduced during 
the administration of MTX to about 6% of the values of before the 
infusion, may increase to GOt within 2k hours after ending the in­
fusion (Ogston 1968, Kenis 1970, Shaw 1973). The consequences of 
this rebound phenomenon is that a few days after administration of 
MTX (according to Vogler (1973) within 3 days) a second cytostatic 
agent has to be administered, in order to destroy the cells increased 
by the rebound phenomenon (Vogler 1973, Hooton 1976, Pagliardi 1976). 
In the study of Hryniuk (1969) it is concluded that a concentration 
of 5 x 10 mol/1 inhibits the DNA-synthesi s of leukemic cells. 
This value approaches the values found by Pinedo in an exposure time 
of 2k to k8 hours. If the concentration will remain the same for at 
least 2k hours, a therapeutic action (reduction of the number of 
leukemic lymphoblasts) may be expected to occur both in the marrow 
and in the CSF. 
kb 
In the following chapters the minimum therapeutic concentration of 
MTX ¡η case of leukemic cells is accepted to be 5 x 10 mol/1. 
This concentration must be maintained for at least 18 hours, although 
we know that it may cause toxic reactions in bone marrow and in the 
digestive tract. 
The dose of ИТХ in intrathecal administration. 
The dose is usually calculated according to the body-surface area. 
Pinkel (1958) suggests that the body-surface area is a better 
criterion than the body-weight, especially when a dose given in an 
animal model must be applied to man. He shows that the dose per unit 
of body-weight of a drug is higher in smaller animals than with larger 
ones, and higher with children than with adults. However, in this 
study the dose per square meter of 6-mercaptopurin and actinomycin D 
is less than with adults, while the dose of methotrexate with 
children is higher than with adults. The reasons for the use of the 
body-surface area as criterion for the dose of a drug in man, appears 
to be not so convincing as has generally been accepted. 
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Table 10 The dose of MTX in i.t. administration in children 
5^ 
Moreover, the square meters of body-surface in a child increase 
differently by age than the volume of the CSF and of the brains 
(Table 10). After the age of 12 the total volume of the CNS wi'I 
have approached the adult volume of 150 ml of CSF and 1^00 q of 
brains. Using the body-surface to calculate the dose of MTX in i.t. 
administration may cause an overdosage in the CSF. 
The dose of MTX in the CSF will always be arbitrary, because with 
the calculation of the intrathecal dose the peculiarities of the CSF 
in the spinal canal,caused by changes in the flow and pressure of the 
CSF, that are due partly to the force of the injection (Houben 1969) , 
cannot be considered. 
Instead of dose-calculation according to the body-surface, Bleyer 
(1977) proposes a dosage regimen with fixed doses according to the 
age of a child. However, the doses suggested by Bleyer up to the age 
of 6 are in accordance with or even higher than the doses calculated 
according to the body-surface with length and weight at 97% level, 
and toxicity will not be prevented. 
Considering these values it seems reasonable to suggest doses of MTX 
to be injected intrathecally with a value depending on the age of the 
child, but with a more gradual increase (Table 10). 
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Chapter VI 
METHOTREXATE AND THE CENTRAL NERVOUS SYSTEM. 
Intravenous administration of MTX 
A number of cytostatic agents will reach an active concentration in 
the CSF by an increase of the dose (Mel let 1977) after ¡.v. 
administration. MTX, with a molecular weight of hSh.S and, being 
a polar, ionised compound, can scarcely pass the blood-CSF-barrier. 
However, after an oral, intramuscular or i.v. bolus dose, a small 
concentration in the CSF will be reached too. 
The administration of MTX by i.v. infusion will cause a rather high 
concentration of MTX in the CSF depending on the dose. 
Adults have been given a dose of 500 mg MTX by an infusion with a 
duration of 2h hours by Shapiro (1975). The steady-state concentration 
of MTX in the plasma is 2 χ 10 mol/1 and during this infusion a CSF-
concentration of 6 χ 10 mol/1 has been found. Although it is a con­
centration 33 times lower in the CSF compared with the plasma, this 
concentration is near the range of therapeutic values. 
In the experiments of Kimelberg (1977) with a single i.v. injection 
of MTX in cynomolgus monkeys,only 1% of the MTX concentration in the 
plasma can be found in the CSF during the first 6 hours after the 
injection and 1% of the concentration in the plasma has been 
recovered in the CSF during the following 18 hours. So it takes some 
time to reach the maximum concentration in the CSF after i.v. acminis-
tration. However, the finding (Shapiro 1975) that the administration 
of a high dose of MTX by i.v. infusion over a period of Ik hours 
produces adequate concentrations of MTX in the CSF of the ventricles, 
provides a good method to treat malignant intracranial processes 
(Freeman 1977, Rosen 1977, Мое 1978), although most of the infused 
MTX disappears from the body without entering the CNS or the CSF. 
Intraventricular administration of MTX. 
The highest concentration of MTX in the CSF of the ventricles can be 
reached by injecting MTX by means of a drain (Ommaya 1963, Ratcheson 
1968, Spier 1978). 
hl 
The t r a n s p o r t o f MTX ¡η the CSF-space w i l l take p l a c e a c c o r d i n g t o 
physiologic CSF-flow. 
In order to administer a dose of 6.25 mg/m of MTX in this way, the 
maximum concentration of MTX in the ventricle has to amount to 
-k -5 
2 χ 10 mol/l. Four hours later a concentration of 8 χ 10 mol/1 
will be reached in the lumbar cistern. About 8 hours after the intra­
ventricular administration the maximum concentration of MTX in the 
plasma will be 1 χ 1θ"' mol/1 (Shapiro 1975). 
In the brain tissue of monkeys (Blasberg 1977, Kimelberg 1977, 1978) 
the maximum concentration of k χ 10 mol/gr tissue has been found, 
decreasing to about 9 x 1 0 mol/gr 96 hours after the injection.
r 
About 70 minutes after the injection the concentration on the corti­
cal side of the right cerebral hemisphere is 7.7 x 10 mol/gr 
tissue and at the ependym in the right lateral ventricle is 
1.2 χ 10 mol/gr tissue. The ventricular drain has been implanted 
in the left lateral ventricle. In the central part of the cerebral 
hemisphere the tissue concentration drops gradually, but 48 hours 
after the injection the differences in the concentrations have 
disappeared and the concentration in the whole of the cerebral 
tissue is about 1 χ 10 mol/gr. 
Perfusion of a solution containing I-A7 mg/kg of MTX by a drain in 
the cisterna magna or the lumbar region in monkeys causes a steady-
state concentration after 60 minutes (Sheppard 1976). Rough neuro­
toxic symptoms like convulsions, motoric disturbances and encephalo-
pathic syndromes have been observed with all concentrations. 
Extensive destructions of the white matter in all parts of the brain 
have been seen. In man the cisternal administration of MTX is unusual 
and this way of injecting MTX has not been mentioned in the used 
references. 
In dogs (Whiteside 1958) and monkeys (Sheppard 1976) some studies 
have been carried out on the distribution of MTX in the cranial sub­
arachnoidal space after cisternal administration. 
This method of administration frequently caused convulsive states. 
The intraventricular administration to man by an Ommaya reservoir is 
used more frequently (Hagbin 1977, Bleyer 1978, Goedhart 1978). 
¡t8 
Complications like menigitis and seizures seem to occur rather fre-
quently (Rubin 1966, Ratcheson 1968), but Bleyer (1978) finds sirni-
ficantly less neurotoxicity due to MTX in patients with CNS-leukemia 
by using an Ommaya-reservo ir and injecting 1 mg of MTX every 12 hours 
during 3 days. 
The concentration of MTX in the lumbar CSF ranges from 5 x 1 0 to 
2 χ 10 mol/1. Due to this method the minimum therapeutic concen­
tration is maintained in the CSF for 3 days. For reaching a CNS-
remission the total cumulative dose of MTX appears to be half of the 
dose required for attaining a CNS-remiss ion by lumbar injections with 
2 
a dose of MTX of 12 mg/m twice a week. Both methods show the same 
number of patients attaining a CNS-remiss ion and the same remission 
t ime. 
Intralwnbar administration of tlTX. 
The oldest and most frequently used way of injection MTX i.t. is 
by lumbar puncture. It was done for the first time by Sansone (195Μ 
into two children with CNS-leukemia. It has been doubtful for a long 
time whether any part of the MTX injected can reach the brain, at 
least in sufficient concentrations. However, recent studies (Shapiro 
1975, Kimelberg 1977, 1978, Bleyer 1977) show the possibilities of 
reaching even therapeutic concentrations of MTX in the ventricles 
after lumbar injection. 
Especially the combination of MTX injected i.t. during a high-dose 
MTX infusion maintains an adequate concent rat ¡on in the CSF over a 
sufficiently long time (Shapiro 1975)· According to Shapiro (1975) 
in 6 out of 7 patients a ventricular concentration of MTX from 
6 x 1 0 to even 2.2 χ 10 mol/1 was found 1-4 hours after intra-
2 
lumbar administration of 6.25 mg/m , but these concentrations are 
maintained for a short time only. 
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By using a dose of 12.5 mg/m of MTX, the concentration in the ven­
tricles is higher and remains over the maximum therapeutic concen­
trations in the CSF for at least 2k hours. The decrease of the 
concentration of MTX in the CSF follows a tripartite course (Bleyer 
1977). The first,very rapid phase, during the first 4-6 hours after 
the lumbar injection, has a biological half-life time of less than 
1 hour. 
^ 
An isotope injected intralumbarly reaches the basal cisterns 
4-6 hours after the ¡ntralumbar injection (Penning 1975)· The rapid 
decline of the concentration of MTX during the first k-β hours after 
the injection will cause a considerable loss of the drug before it 
has reached the basal cisterns. 
MTX has to be active above the site of the basal cisterns and the 
minimum therapeutic concentration of MTX is required at this site. 
The high concentrations of MTX in the spinal canal are of less 
importance in the CNS-prophy1axis in children with ALL, because 
leukemic cells are absent in the CSF of the spinal canal. 
The second part of the curve during 4 to 6 hours after the injection 
up to 36 hours after the injection has a biological half-life time 
of 4£ hours. 
The third part, occurring 48 hours after the injection, has a half-
life time of 14 hours (Bleyer 1977). 
After intralumbar injection MTX can rapidly be found in the blood: 
one hour after injecting 0.1 mg/kg i.t. of MTX, Whiteside (1958) found 
—R 
a plasma concentration of MTX of 8.8 χ 10 mol/1. The CSF-concentra­
tion at that time was 1.1 χ 10 mol/1. Bleyer (1977) mentions that 
the plasma concentration is highest between 3 and 12 hours after i.t. 
2 -7 
injection of 12 mg/m of MTX and reaches a concentration of 2 χ 10 
mol/1. The decline in the plasma concentration appears to be bi-
exponential with half-life times of 5.5 and 24 hours. The concentra­
tions and the half-life times are mean values in 76 patients with ALL. 
The ocmwrenae of neurotoxicity in relation to the concentrati ans 
of MIX in the CSF. 
In 10 out of 47 patients with ALL after undergoing a CNS-prophy1axis 
or a treatment for overt CNS-leukemia, Bleyer (1973, 1977) discovered 
severe neurotoxic syndromes. These 10 patients appear to have signi­
ficantly higher concentrations of MTX in the CSF when compared with 
the 37 patients without neurotoxic symptoms. In these 10 patients the 
elimination of MTX from the CSF appears to be significantly slower. 
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The occurrence of neurotoxicity depends on age: only 1 of the 29 
children below the age of 10 showed signs of neurotoxic reactions, 
but 3 of the 8 adolescents and 6 of the 10 adults (older than 20 
years). However, all 10 patients with neurotoxic reactions have been 
treated for overt CNS-1eukemia. 
Bleyer (1977) therefore demonstrated a significant correlation between 
age and a nigh concentration of MTX in the CSF. A significant corre­
lation between the group of patients with an overt CNS-1eukemia and 
a high concentration of MTX in the CSF has also been shown. It may be 
concluded that the brains of older patients and damaged brains are 
more vulnerable to neurotoxic actions of MTX (for example leuLoence-
phalopathy), which is probably due to a decreased elimination of MTX 
from the CSF, suggesting vascular lesions (Chapter XII). 
From the results found in the literature, it may be concluded that 
after both intralumbar and i.v. injection of MTX, sufficient MTX 
reaches the sites of the pathologic lesions in overt or subclinical 
CNS-1eukemia. However, intraventricular administration of MTX results 
in a higher concentration in the ventricles. Therefore it may be the 
method of first choice in the treatment of overt CNS-leukemia. 
In our retrospective study of 50 children with ALL (Chapter IV), 
the failure of the CNS-prophy1axis has been observed in 26% of the 
patients. According to the study of Shapiro (1975) MTX had reached 
adequate concentrations in the CSF of the ventricles. In our patients 
neither the cranial irradiation nor the intralumbar1 ν administered MTX 
have been able to destroy the leukemic cells in the intracranial 
arachnoid completely. 
In all cases the first remission was terminated by the discovery of 
leukemic cells in the CSF, the marrow still being in remission. 
This makes a reinvasion of the CNS by leukemic cells from the marrow 
unlikely. When the leukemic cells have not been influenced by MTX, 
owing to MTX-resi stance, it cannot be understood why the leukemic 
cells disappear from the CSF after the new intralumbar injection of 
MTX, as happened with our patients. 
It may be possible that some of the leukemic cells in the arachnoid 
lesions remained "sleeping" during and after the CNS-prophy1axis, 
which may be due to the very long cell cycle time of leukemic cells 
51 
in the CSF (Кію 1975)· 'η t h a t c a s e , the c r a n i a l i r r a d i a t i o n has t o 
be r e - e v a l u a t e d as w e l l . Another p o s s i b i l i t y may be t h a t MTX has not 
reached the leukemic l e s i o n s i n the i n t r a c r a n i a l p a r t o f the a r a c h ­
n o i d at a l l , o r f o r t o o s h o r t a t i m e and in t o o low c o n c e n t r a t i o n s . 
This would be c o n t r a d i c t o r y t o the f i n d i n g s o f S h a p i r o (1975) and 
B l e y e r (1973, 1977). 
In o r d e r t o s t u d y t h i s p o s s i b l e cause o f t h e f a i l u r e o f CNS-prophy-
l a x i s , the c o n c e n t r a t i o n p r o f i l e s o f MTX in b l o o d and CSF a f t e r i n t r a -
lumbar i n j e c t i o n has been s t u d i e d p h a r m a c o k i n e t i c a 1 l y in c h i l d r e n 
w i t r i ALL d u r i n g the CNS-prophy 1 axi s in the f o l l o w i n g c h a p t e r s . 
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Chapter VI I 
SOME ASPECTS OF THE PHARMACOKINETICS OF DRUGS. 
Pharmacokinetics describes the rates of changes in concentrations 
of a drug in body-fluids, tissues and organs, as a function of time 
after administration to an individual. These changes are controlled 
by the rate of absorption, distribution in the body, metabolism of 
the drug and of excretion. 
Generally these processes cannot be followed exactly in all parts of 
the body. It appears that the course of concentrations found in some 
body fluids can be described with the help of mathematical expressions 
leading to estimates of the course of the quantity of the drug in 
compartments of a fictitious volume. 
The drug is considered to be distributed homogeneously in those 
compartments. The concentrations resulting from this model undergo a 
continuous shifting due to the input of the administered drug. 
A compartment is an entity that can be described as a volume. It is 
important to realise that the compartment model is an abstract com-
plex of volumes, based on the ratio of dose and detected concentration, 
and does not have any relation to physiologic processes in or anatomi-
cal spaces of the body. A homogeneous concentration in a compartment 
is not the same as "an equal concentration in every part of the body" 
but means that the absorption and distribution of a drug in the 
compartment model does not have any influence on the elimination 
processes. 
In the following paragraphs the pharmacokinetic definitions used in 
this study, will be explained, however without describing the mathe-
matical background of the calculations. 
The volume of dtJtribution. 
The distribution of a drug in a compartment depends on both the input 
and the output of the drug in the compartment. By achieving an equili-
brium between input and output, the distribution phase in the compart-
ment has been terminated and a steady-state has been achieved. 
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The apparent volume of distribution is not an existing volume, but 
a parameter in a particular model used to fit experimental data. 
It is an abstract entity of body-fluid in which the drug is distribu-
ted homogeneously and in which the concentration is the same as that 
determined in blood. It indicates the ratio between the quantity in 
the compartment and the concentration discovered. 
The aompartment model. 
In pharmacokinetics a model is an abstract structure used to 
characterize the behaviour of a drug in biological systems and to 
describe the way of administration and the particular formulation of 
the dose. The human body actually consists of a mul timi 11¡on compart-
ment model, considering the drug concentration in different organelles 
of cells or tissues. However, simplified compartment models are used 
to fit experimental data from the blood-concentration versus time 
or urinary cumulative excretion versus time-curves. 
1. The one-compartment model (Fig.O. 
el i sink I 
I I 
Fig. h Schematic representation of the one-compartment model 
A drug is present in compartment 1. The amount of drug present at 
time zero diminishes into the sink on account of metabolism and 
ex".ret ion. 
The course of the values determined and calculated follows a hyper-
bole approaching zero when the time approaches infinity. The concen-
tration, cx, at a certain time, t (in hours), can be expressed as a 
function of the concentration at time zero, 
с . and the time according to: 
о 
с = с χ e "
k 1 2 ' t (eq 1) 
X о 
in which k:- is the reciprocal time constant of elimination, 
-1 
expressed ¡n the dimension "hours ". 
Because of the nature of this equation the terms "first order" о 
"exponential decay" is used. 
The amount of the drug can be expressed by: 
D = С χ V. 
D = dose, С = c o n c e n t r a t i o n , V = volume ( l i t e r s ) . 
The most i m p o r t a n t parameters d e t e r m i n i n g the course o f a drug a 
the dose D 
the vol urne V 
the r e c i p r o c a l t ime c o n s t a n t к 
From these parameters the f o l l o w i n g f a c t o r s can be c a l c u l a t e d : 
1. The c l e a r a n c e o f the d r u g , 
Clearance = k-. χ V ( 1/hr) 
2. The b i o l o g i c a l h a l f - l i f e t ime ( t , ) o f a d r u g , b e i n g the t ime 
hours r e q u i r e d t o reduce t h e c o n c e n t r a t i o n o f the drug t o one 
h a l f a f t e r the e q u i l i b r i u m has been reached: 
0.693 
t, = 
3
 к 12 
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2. The two-compartment model. 
The drug is distributed in the central compartment and the 
concentration reaches an equi 1 ibri um w¡th a peripheral compart 
ment (Fi g.5). 
1 
кІЗ 
к12 
к21 
2 
Fig. 5 Schematic representation of the two-compartment model 
Many substances follow this model after ¡.v. bolus injection and 
also after the i.v. bolus injection of MTX. In this model the 
reciprocal time constants are distinguished by the directions of 
the constants: k.. means that the reciprocal time constant is direc-
ted from the central compartment (1) to the peripheral compartment 
(2), k-. from the peripheral compartment (2) to the central compart-
ment (1). The reciprocal time constant of elimination is expressed 
by к . 
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3. F i r s t o r d e r k i n e t i c s . 
In the case o f i . t . a d m i n i s t r a t i o n o f MTX a s l i g h t d i f f e r e n c e 
i n the two-compartment model can be o b s e r v e d . The drug is put 
i n t o a r e s e r v o i r , compartment 0, out o f which the c e n t r a l 
compartment is g r a d u a l l y r e p l e n i s h e d ( F i g . 6 ) . 
k13 
Fig. 6 Schematic representation of the two-compartment model with 
f i rst order kine t i cs 
It will be clear thft in case of a very large к . the situation of 
the usual two-compnriment model with the i.v. bolus injection (Fig.5) 
has been reached again. In this particular two-compartment model 
with first order kinetics, the compartment 0 is the compartment of 
administration and k.. is the reciprocal time constant indicating 
the passing of the drug into the central compartment (1). 
This model can be described als follows: 
С ^
А ^ е - ^ . e " " "
1
 + А 2 . е - ^ ( e q 2 ) . 
in w h i c h Ap. A1 and A2 are r e l a t e d by An = - ( A + A.) ( m o l / l ) . 
C. = the c o n c e n t r a t i o n in plasma in t ime t ( m o l / l ) . 
к 
. . = f i r s t - o r d e r r a t e c o n s t a n t o f d r u g - d i s a p p e a r a n c e from 
compartment 0 ( h ) . 
a and β are o b t a i n e d from the s lopes o f the plasma-disappearance 
c u r v e and are d e f i n e d by: 
α . β = k 2 1 . k 1 3 
a + β =k 12+k 2 1+k 1, 
a and β are expressed by the dimension "hours " (h ). 
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By keeping all parameters in the mathematical model of the two-
compartments with first order input at a fixed value, and by 
varying only the k... , a spectrum of concentration profiles for the 
central compartment can be constructed (Fig.7; Lankelma I98O) 
concen l rohon 
m o l / l 
IHE PHARMACOKINETICS OF 
MEÏH0TREXA1E 
af ter m l r o l h e c a l m jec l ions 
28 hours 
F i g . 7 C a l c u l a t i o n o f the c o n c e n t r a t i o n p r o f i l e s o f the two-compart -
ment model w i t h f i r s t o rde r k i n e t i c s w i t h v a r i a b l e kg^ 
The h a l f - l i f e t ime o f a drug i n j e c t e d i n t o the CSF can be c a l c u l a t e d 
by 
0.693 
01 
(eq 3) 
in which к is the reciprocal time constant indicating the velocity 
of transport of the drug from the CSF into the central compartment. 
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The area ипдет the curve (AUC). 
The AUC of the concentration in the plasma of a drug is a value 
related to the quantity of the drug in the body. It can be 
calculated easily by the trapezoidal rule and is model-independent. 
From time zero to the last point for determination of the concentra­
tion in the plasma the AUC is composed of trapezoids only, except 
for the value of time zero to the first value of detection of the 
drug. 
The AUC is expressed as follows: 
c. χ t1 f с + с Ί ( с + с 
AUC is expressed by the dimension "mol.h/l" (eq k) 
Assuming that the time required for a drug to come into the large 
cisterns after i.t. administration is about 6 hours, the loss of 
the drug from the CSF into the blood during these 6 hours can be 
calculated with the help of the AUC. The remaining amount of the 
drug in the CSF will come into the cisterns and will be distributed 
in the subarachnoidal space of the skull. In the case of MTX this 
remaining concentration has to be over 5 x 10 mol/1 over a period 
of at least 18 hours, in order to expect a sufficient antileukemic 
action of the drug (p. kh) . 
In one of the following chapters will be calculated that only some 
of the i.t. doses of MTX approximate these values. 
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Chapter VI I I. 
PHARMACOKINETIC STUDIES OF MTX IN CHILDREN WITH ALL. 
Description of the patients used in the pharmacokinetic 
studies of MIX after intrathecal administration. 
The purpose of this study is to relate the toxic reactions in 
children with ALL during the CNS-prophylaxis on MTX to the 
pharmacokinetic activities after the five subsequent intrathecal 
administrations of MTX. 
It has been possible to study l'i children with ALL admitted to the 
pediatric department of the St. Radboudhospital in Nijmegen in 1977. 
All the children have reached a hematologic remission at the be­
ginning of the CNS-prophylaxis and they have remained in remission 
during the CNS-prophylaxis. All 14 children have been treated 
according to the protocol outlined on p. 25 
Table 11 gives a survey of the dose of MTX and the intervals of 
administrating the doses to the 14 children. None of the 14 
children received MTX before the CNS-prophylaxis. 
P a t i e n t 
1 .RvH 
2 RJ 
3 JvC 
I t . L N 
5.HH 
6 RH 
7 RE 
8 IM 
9 PR 
1 0 . RW 
Π .MD 
12 DV 
13.ΜΗ 
l i t DF 
Sex 
т / Г 
m 
m 
η
1 
m 
m 
m 
m 
F 
m 
m 
m 
m 
π 
m 
A l l c h i I d r e n 
Age 
Y 
2 . 5 
3 . 2 
3 . 6 
2 8 
3 . 0 
3 8 
6 1 
5 . 6 
5 8 
7 6 
7 . 9 
8 k 
8 9 
юл 
r c c i e 
Dose оГ MTX a n d 
p r e d n ι s o l ó n 
ι t . (mg) 
8 25 
8 . 7 5 
8 . 0 0 
7 00 
7 . 0 0 
9 00 
9 . 0 0 
10 00 
10 00 
1 0 . 0 0 
1 3 . 5 0 
12 50 
12 50 
13 50 
•jeà c r a n ι a l ι r r a d ι 
I n t e r v a l b e t w e e n d o s e s ( d a y s 
, l - l I 
5 
^ 
3 
k 
3 
II 
5 
3 
3 
h 
h 
3 
h 
3 
1 l - l 1 I 
3 
3 
h 
3 
h 
it 
3 
k 
h 
3 
3 
5 
3 
k 
1 1 1 - IV IV-V 
3 
3 
h 
Ί 
h 
3 
3 
li 
Ц 
Ή 
7 
? 
i, 
a t i o n ( 2 5 0 0 Rad ι π 13 T r a c i or 
_ 
s ) 
Table 11 Survey of 14 children with ALL during CNS-prophylaxis 
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The prognos is o f these ^^^ c h i l d r e n is no t o f the same o rde r as t ha t 
which cou ld be expected in an unse lec ted group o f c h i l d r e n w i t h ALL. 
In t a b l e 12 the data a t the t ime o f d iagnos is of ALL and the events 
d a r i n g the two years o f maintenance t rea tment are ment ioned. 
The age o f the c h i l d r e n v a r i e d between 2¿ and 10i y e a r s . Only one 
o f the c h i l d r e n is a g i r l . The leukocy te count a t d iagnos i s o f ALL 
v a r i e d between 2,2 χ 1 0 / 1 and kk,0 χ 1 0 / 1 in 13 c h i l d r e n . 
One boy ( p a t . 3) had a i n i t i a l l e u k o c y t e count of Й ^ . О χ 10 / 1 ; 
t h i s boy, c l a s s i f i e d in the h i g h - r i s k group of ALL, a l s o s u f f e r e d 
f rom Down's syndrome. Two o t h e r c h i l d r e n ( p a t . 6 and 11) have a l s o 
been c l a s s i f i e d in the h i g h - r i s k group o f ALL, on account o f the 
d i s c o v e r y o f leukemic c e l l s in the CSF sample o f the f i r s t lumbar 
p u n c t u r e ( = f i r s t lumbar p u n c t u r e o f the C N S - p r o p h y l a x i s ) . 
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Table 12 Survey o f the i terns at d i a g n o s i s and d u r i n g the f o l l o w - u p 
o f ]k chi 1 dren wi t h ALL 
A l t h o u g h in p a t i e n t 8 the CSF c o n t a i n e d 56 w h i t e c e l l s / m m , the 
s e d i m e n t a t i o n p r e p a r a t i o n d i d not show any leukemic c e l l s . 
Only 5 c h i l d r e n have remained in complete r e m i s s i o n f o r more than 
2 y e a r s ( t h e date o f f i n i s h i n g the f o l l o w - u p study i s 1-1-1980) and 
i t has been p o s s i b l e t o stop the m a i n t e n a n c e - t r e a t m e n t o f these 
5 c h i l d r e n . However, one c h i l d ( p a t . 8) developed a bone marrov,' 
r e l a p s e 3 months a f t e r the c e s s a t i o n o f the maintenance t h e r a p y . 
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The complete remiss ion in 9 p a t i e n t s has been t e r m i n a t e d by 
CNS-leukemia in 't and by bone marrow re lapse in 5 c h i l d r e n . Of these 
9 c h i I d r e n 8 d i e d . 
Toxic reactions during and shortly after CNS-prophylaxis. 
The t o x i c i t y o f CNS-prophylax is is g iven in Table 13· 
Pat l e n t 
SYMPTOMS 
A p a t h y syndrome 
We igh t l o s s ^ 1 kg 
U l c e r a t i o n s o f t h e mucosa 
o f t h e m o u t h 
L e u k o p e n i a « 2 . 0 x 1 0 9 / l ) 
T h r o m b o c y t o p e n i a K l O O x l C r / 1 ) 
Anemia (^6 l* m m o l / 1 ) 
I n f e c t i o n s 
D i a r r h o e a 
Rash 
Headache 
Fever ( £ 3 8 ° ) 
Grade o f t o x i с І t y 
1 
+ 
5 . Ί 
+ 
-
-
-
-
+ 
+ 
+ 
2 3 ^ 5 6 7 3 9 10 1 1 1 2 13 
+ +• + 
2 5 - -
+ -
+ + -
+ -
- + -
+ + -
+ -
+ ++ -
- + + + + + + •*- + 
- - 1 2.5 - 2 - - 3 1 
- - - + - - + - -
- - - + - - + - -
- - - + - - + - -
- - - + - - • - -
- - - + - - + - -
- - - + - + + - + 
- - - +++ - + +++ - + 
\k 
+ 
1.7 
+ 
-
-
-
-
+ 
+ 
Table 13 Survey o f the s i d e - e f f e c t s d u r i n g and a f t e r CNS-prophylaxis 
in l'i chi Idren w i t h ALL 
The apathy-syndrome, a f t e r C N S - p r o p h y l a x i s , can be c o n s i d e r e d t o be 
an e f f e c t of the c r a n i a l i r r a d i a t i o n and has been observed in 13 
ch i 1 dren . 
The i . t . a d m i n i s t r a t i o n o f MTX may cause l e u k o p e n i c p e r i o d s . 
Dur ing these p e r i o d s i n f e c t i o n s may o c c u r . D u r i n g our r e s e a r c h o n l y 
i n f e c t i o n s o f the r e s p i r a t o r y t r a c t have been observed i n f o u r 
p a t i e n t s . When b e g i n n i n g the C N S - p r o p h y l a x i s , none o f t he c h i l d r e n 
showed a b n o r m a l i t i e s o f hemoglobin c o n t e n t , number o f l e u k o c y t e s o r 
p l a t e l e t s . The mucosa o f the d i g e s t i v e t r a c t d i d n o t show u l c e r a t i v e 
l e s i o n s . I t may be concluded t h a t the s i d e - e f f e c t s and t he i n f e c t i o n s 
d u r i n g the CNS-prophylax is are due t o the t r e a t m e n t w i t h c y t o s t a t i c 
agents d u r i n g the p e r i o d of C N S - p r o p h y l a x i s . 
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Chapter IX. 
THE PHARMACOKINETIC MODELS OF MTX IN PLASMA. 
Colleating the samples for detection of MTX. 
Of all patients blood samples have been collected. The volume of 
the samples is 3 ml. The blood has been collected in heparinized 
tubes and well mixed. With the I1* children the times of sampling 
were: shortly before the i.t. injection of MTX (time zero) and 
i, 1 , 2 , 6, 12, 2k and 48 hours after the i.t. injection of MTX. 
CSF samples have been collected prior to the i.t. administration 
of MTX at the second, third, fourth and fifth lumbar puncture. 
Of these samples the MTX concentration (= the trough concentration 
of the preceding injection) has been measured. 
It has not been possible to acquire a sufficient quantity of CSF 
with all lumbar punctures. In order to make it possible to follow the 
MTX-concentrations in the CSF more accurately, CSF of 10 other children 
with ALL during the usual CNS-prophy1axis have been collected and 
added to the samples of the \k children described before. 
Detection of MTX. 
We de tec ted c o n c e n t r a t i o n s of MTX in CSF and b lood d u r i n g our 
i n v e s t i g a t i o n s by us ing h igh -p ressu re 1¡qu id-chromatography (HPLC) 
acco rd ing t o the method o f Lankelma (1978) . 
The l i m i t o f d e t e c t i o n o f t h i s method is a t a MTX-concent ra t ion o f 
2 χ 1 0 " 8 m o l / 1 . 
In the CNS-prophylax is the small doses o f MTX r e s u l t in c o n c e n t r a ­
t i o n s t h a t are too small t o be d e t e c t e d by t he HPLC method. These 
small c o n c e n t r a t i o n s can o n l y be d e t e c t e d w i t h t he enzymat ic 
i n h i b i t i o n method of B e r t i n o ( 1 9 6 Ό , which has a lower l i m i t o f 
-g 
d e t e c t i o n of 3 x 10 m o l / 1 . 
The l a t t e r method has been a d j u s t e d t o the HPLC-method o f d e t e c t i o n . 
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Pharmacokinetio observations on a ahild after -i.t. administration 
of MTX. 
In a previous study (Lankelma I98O) we showed that the 
pharmacokinetic values of distribution and elimination of MTX are 
reproducible in subsequent intravenous methods of administration. 
It was also demonstrated that particularly the last two i.t. 
injections of MTX during the CNS-prophylaxis of children with ALL 
showed a course identical to the i.v. administrations. 
However, the first two i.t. doses showed a different course. The 
phenomenon is caused by a change in transfer-rate. This is 
illustrated by the concentration profiles of MTX in plasma after 
i.t. injection in a boy (pat. Ί Table 11) with ALL. 
This child is considered to be representative of the majority of 
the children in this study. The concentration profiles of MTX in 
plasma have been followed after the 5 subsequent intrathecal 
injections (Fig. 8 ) . It is evident that the decrease in the 
concentrations of MTX in the plasma of the first 2 doses of 7 mg 
i.t. are slower than the 3 last ones. The maximum concentrations of 
the first 2 doses are 2.6 and 4.0 χ 10 mol/1 respectively, 2 hours 
after the injection. 
NTFUTH INJECTION 
7 m g MTX 
F i g . 8 C o n c e n t r a t i o n p r o f i l e s o f MTX in plasma in a p a t . w i t h ALL 
a f t e r the 5 i . t . i n j e c t i o n s o f MTX d u r i n g CNS-prophylaxis 
6k 
The 3 last doses show maximum concentrations of 6.1 χ 10 mol/1 
after 1 hour (dose 3), l'i χ 10 mol/1 after 30 minutes (dose A) and 
9.2 χ 10 mol/1 also after 30 minutes (dose 5). It may be possible 
that the maximum concentration after the 5th dose will be higher and 
will be reached earlier, because of the small plateau at the top of 
the 5th curve, but in this patient we did not take samples earlier 
than 30 minutes after the injection. In the first 2 profiles the 
concentration in the plasma at 2b hours after the injection is 
relatively high (9 and 8 χ 10 mol/1). But the concentration in the 
plasma 2b hours after the third, fourth and fifth injection is far 
less (1.6, 1.0 and 1.0 χ lu"9 mol/1). 
This is in accordance with the mathematical profile of a two-
compartment model with first-order kinetics (p.56 ). 
Because of the early appearance and the high maximum concentrations 
of MTX in the plasma it can be wondered whether the concentrations of 
MTX in the CSF at the level of the cisterns with the last 3 i.t. 
injections is sufficient to reach the minimum therapeutic concentra­
tion for a period of time sufficiently long. 
The concentration of MTX in the plasma is too small to pass the 
blood-brain barrier and to resupply the CSF. 
The two types of elimination of MTX from the plasma 
after repeated intrathecal injection of MTX. 
In the preceding paragraph it has been suggested that the first two 
i.t. injections cause a slower decline of the MTX-concentrat ion in 
the plasma than the last 3 injections. In 10 adult patients 
suffering from ALL (Lankelma 1980) the concentration profiles after 
the 5 i.t. administrations during the CNS-prophy1axis have been 
plotted against time and put together in one graph (Fig. 9). 
Although according to the calculation of the two-compartment model 
with first-order kinetics it might be expected (Fig. 7) that a wide 
scale of curves would be found, actually only two groups of curves 
have been found in these patients: 
1. The upper group with elimination curves of a slow type and 
2. the lower group with elimination curves of a fast type. 
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The elimination curves of MTX of children with ALL during the 
administration of MTX in the CNS-prophylaxis have been added 
separately in Fig. 9, which shows that in children too two groups 
can be distinguished, but that both the slow and the fast group are 
steeper with children than with adults. 
According to the description of the two-compartment model with first 
order kinetics, the occurrence of these two types is caused by the 
change of the к . in the subsequent doses of MTX during the 
CNS-prophylaxis. 
methotrexate concentration η Dlasma ( m o l / ) 
distribution of methotrexate e immatlon curves 
aller ntrathecal п|есІіол m οβυ ts ana cm dren 
t. I s l ° w 'i"» a 0 u l 1 5 
К lost type oöults 
F i g . 9 Two types o f e l i m i n a t i o n o f MTX from plasma a f t e r i . t . i n j e c -
t i o n o f MTX du r i ng CNS-prophylaxis in a d u l t s and c h i l d r e n 
w i t h ALL. I = 3.0 x 10 " 8 m o l / l . ( p . 6 6 ) / , ' * ' = it.O χ l o A i o l / l ( p . S O 
A l though i t has t o be concluded from F i g . 7 t h a t , owing t o an 
i n f i n i t e number of changes o f k... , the d i f f e r e n c e s between the slow 
and the f a s t type d i s a p p e a r , f o r p r a c t i c a l use b o t h types o f 
c o n c e n t r â t i o n - v e r s u s - t i me curves can be d e f i n e d : a curve w i t h a slow 
type of e l i m i n a t i o n in the plasma a f t e r i . t . i n j e c t i o n o f MTX can be 
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defined as having a concentration of MTX in the plasma of more than 
-8 
3.0 χ 10 mol/1 Zh hours after injection. 
A curve with a fast type of elimination is defined as a concentration 
-8 
of MTX in the plasma of less than 3.0 χ 10 mol/l 2h hours after 
the injection. 
In Fig. 9 this value is indicated by I 
A slow type curve means a slow transport of MTX from the CSF into 
the blood (exsorpt ¡on), consequently a small k..., and a long half-
life time (t,) of MTX in the CSF (eq. 3). 
A fast type curve indicates a fast transport of MTX from the CSF into 
the plasma, consequently a large knl and a short half-life time of 
MTX in the CSF. 
-8 
In the fast type a concentration of less than 3.0 χ 10 mol/l is 
maintained for less than 2k hours after injection. In this type the 
concentration of MTX in plasma is higher during the first hours 
following the injection, than in the slow type curve. In our 
investigation we observed that toxic reactions during the CNS-
prophylaxis owing to MTX occur more often after the third, fourth 
and fifth i.t. dose of MTX (table 21). 
Especially these last 3 doses have a shorter time of exposure to MTX 
on account of the high concentrations in plasma, than the first 2 
doses. Obviously the concentration of MTX in plasma requires a 
threshold for causing side-effects, regardless of the duration of 
the exposure. This may indicate a cumulative effect in subsequent 
administrations of MTX at short intervals (Fig. 10). 
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Chapter Χ 
THE CONCENTRATION PROFILES OF MTX IN PLASMA AFTER INTRATHECAL 
ADMINISTRATION. 
Description of the concentration profiles and the phajcmacoTcinetic 
parameters in the plasma of 14 children with ALL after intrathecal 
administration of MTX during the CNS-prophylaxis. 
In a p r e v i o u s c h a p t e r (Chapter IX) was d e s c r i b e d t h a t the c o n c e n t r a ­
t i o n p r o f i l e s a f t e r each o f the 5 i . t . doses d u r i n g the CNS-
p r o h y l a x i s in c h i l d r e n w i t h ALL are not i d e n t i c a l . The e l i m i n a t i o n 
o f Í1TX a f t e r the l a s t 3 doses is more rap id than a f t e r the f i r s t 2 . 
MTX mo l / 
F i g . 10 Concen t ra t i on p r o f i l e s o f MTX in plasma a f t e r i . t . i n j e c t i o n s 
d u r i n g CNS-prophylaxis in a pa t . w i t h ALL and the f i t t i n g 
model caI cui a t ion 
NOTE the changes in the shape o f the curves 
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This phenomenon ¡s caused by an increase of the k... (reciprocal 
value of the t, of MTX in the CSF). In 9 of the ]k children studied 
2 
this type of elimination can be confirmed. Fig. 10 shows a typical 
example of this type of concentration profile. In this group of 
children the first 2 doses are followed by a slow type, the last 
3 doses are followed by a fast type of curve. 
This sequence of curves has not been observed in all children. 
In 2 children only a slow type existed (Fig.11). 
MTX mo l / l 
6 16 2i 32 ¿0 ¿8 
hours 
F i g . 11 Concen t ra t i on p r o f i l e s o f MTX in plasma a f t e r i . t . i n j e c t i o n s 
d u r i n g CNS-prophy1axis in a pa t . w i t h ALL and the f i t t i n g 
model c a l c u l a t i o n . 
NOTE the s i m i l a r shapes o f the curves in t h i s pa t . 
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In 3 other patients a fast type of elimination was found in all 5 
curves, although the maximum concentration of MTX in the plasma was 
not equally high. The maximum concentration was reached at later 
stages in the first curve than in the 2 last ones. However, the 
decline of the concentration profile following the maximum concen­
tration showed a steeper course than in the first curves. 
Of our Й patients 64 concentration profiles have been made. 
The slow type of elimination has been found in 28 curves (kk%). 
The fast type of elimination has been found in 38 curves (53%)· 
In 23 (92%) of the slow type curves the concentration of MTX in 
plasma remains over 10 mol/1 for a period of 12 hours or more after 
the i.t. injection. In 35 (90%) of the fast type curves the concentra­
tion of MTX in plasma remains over 10 mol/1 for a period of less than 
12 hours after injection. The period of exposure to a certain concen­
tration does not appear to be determinative, but the level of the 
concentration in plasma is rather more important for the occurrence 
of toxic side-effects. 
In 27 of all concentration profiles (42%) the exposure time to a 
concentration of 10 mol/1 in plasma was more than 12 hours; 
15 (56%) were followed by side-effects. In 37 of the concentration 
profiles (58%) the exposure time was less than 12 hours and 12 (32%) 
of these were followed by toxic reactions owing to MTX. 
On the basis of these data, it may be concluded in general that during 
the CNS-prophy1axis the first two concentration profiles in plasma 
after i.t. injection of MTX follow an elimination according to the 
slow type, and the last 3 according to the fast type. The fast type 
of elimination of MTX from the CSF into the blood and an exposure 
time in plasma to MTX in a concentration of more than 10 mol/1 are 
the causes for the toxic reactions owing to MTX during the 
CNS-prophy1 axis. These toxic reactions may be expected especially 
after the third i.t. injection. 
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The pharmacokinetic parameters (Table 14) have been obtained from the 
5th i.t. dose. These values have been calculated as described ¡n 
Chapter VII. The parameters vary strongly and may depend on unknown 
individual factors. 
PhA'MACOKINETIC PARAMETERS OF MTX AFTER 
THE 5ti ι t INJECTION DURING CNS PROPHYLAXIS 
P a t i e n t 
1 
2 
3 
Ί 
5 
6 
7 
f» 
9 
ID 
1 1 
12 
13 
1 ^ 
HvH 
HJ 
Jv*. 
LN 
HH 
RH 
RE 
IM 
PR 
RW 
hD 
OV 
MH 
DF 
", 
. , Ο -
1 1 
n o l / l 
S- 1 
85 
5 1 
1 10 
77 
21. 
153 
127 
1 3 ' 
-
" Ό ^ 
152 
"J 
»2 
~ " , o 5 
ml/I 
100 
0 08 
0 55 
" 
93 
0 1 
Ь2 
5 2 
3 
3-
2 
'S 
·, 9 
53 
ОС 
„-' 
0 79 
0 23 
0 ' 6 
1 l b 
о з 
0 З11 
' 25 
0 79 
С 5 ' 
а »б 
0 Ь5 
3 I t-
о ς«. 
о t e 
fi 
h 
0 26 
0 0 3 1 
0 ,5 χ О " 6 
0 2 li 
0 =1 . ι " J 
0 62 д I O " 2 
0 Ib 
0 0 5 3 
0 0 " 3 
с 
0 091. 
С 
3 0 5 7 
С 5 
к 1 2 
h " ' 
0 08 
0 006 
u 160 
0 31S 
0 0 2 « 
0 139 
С 2 2 8 
0 06 
ι. 381 
з oog 
106 
0 10 
1 4 3 
k 2 l 
h " 
0 60 
0 032 
о оеоз 
0 1.1. 
3 M 
0 0 0 6 8 
о βι 
0 0 7 8 
3 055 
3 19 
0 12 
0 20 
3 373 
3 1.0 
к
. з 
h " 1 
0 3^2 
0 223 
0 0 0 0 1 
0 6 2 ? 
0 Н О 
0 2 -
0 3 3 7 
0 Ί 2 2 
С 8 5 ' 
с 315 
2 P I . 
0 - 3 
3 1Θ8 
, 
1 
и зе 
22 Í 5 
12 66 
10 6 1 
20 62 
25 7h 
28 62 
1 , Π 
" 92 
I t 1(5 
25 04 
> 85 
17 ' I 
39 55 
"г I 
j 
1 
2 04 
4 38 
> 5 0 0 
7 71 
--
i l l 29 
I I 6 9 
(,1 75 
І 4 1-8 
7 02 
20 6 6 
2 1 29 
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Table I1» Pharmacokinetic parameters obtained from the 5th i.t. 
injection of MTX in CNS-prophy1axis of children with ALL 
It is not possible to relate the toxic reactions to the pharmaco­
kinetic parameters. This may be due to the small number of patients, 
but also to the great variations in the different pharmacokinetic 
values. The differences in the course of the elimination curves in 
plasma are caused by changes in the k
n l after i.t. injection. 
These changes are reflections of changes in the transport of MTX from 
the CSF into the blood (Table 15). 
The half-life times of MTX in the CSF have been calculated according 
to eq. 3 (Table 16). 
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D o s e 
P a t l e n t 
1 RvH 
2 RJ 
3 J v C 
h LN 
5 HH 
6 RH 
7 RE 
8 IH 
9 PR 
10 RW 
11 MD 
12 DM 
13 MH 
Ι Ί DF 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
23 
15 
18 
19 
20 
20 
18 
08 
07 
11 
12 
08 
18 
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I I 
0 12 
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0 25 
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Dose 
Pat lent 
1 RvH 
2 RJ 
3 JvC 
4 LN 
5 HH 
6 RH 
7 RE 
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9 PR 
10 RW 
11 MD 
12 DV 
13 ΜΗ 
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1 
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Ί 
3 
3 
3 
3 
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8 
9 
6 
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β 
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0 50 
--
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0 21 
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0 48 
0 20 
I 1 1 
1 22 
3 85 
--
0 60 
0 18 
5 78 
4 62 
6 30 
0 15 
0 38 
0 07 
0 89 
0 29 
0 14 
IV 
1 34 
--
4 08 
0 17 
--
0 28 
3 65 
0 37 
0 13 
--
1 08 
0 62 
0 09 
0 16 
V 
0 89 
0 001 
0 96 
0 24 
0 31 
--
3 65 
0 83 
0 09 
2 17 
1 05 
0 23 
0 10 
0 55 
Table 16 
Table 15 
-1, Table 15 Changes of kgi (h ) of MTX after i.t. injection during 
CNS-prophy1 axis in lU children with ALL 
Table 16 Changes of tx (h) of MTX in CSF after i.t. injection during 
CNS-prophy1 axis in 1^ children with ALL 
The more rapid transport from the CSF into the blood caused an earlier 
maximum concentration in the blood and also a more rapid elimination 
of MTX. 
In all children, except pat.7, the к increases (the t, becomes 
shorter), comparing the k.- of the first dose to the k
n
. of the last 
dose. It is remarkable that the k
n l of the first dose varies very little 
in all children, compared with the doses following. From this particular 
observation may be concluded that after a single dose the concentration 
profile of MTX in plasma shows a nearly identical course in different 
patients. The differences between the average values of к . in patients 
with and those without toxic reactions are consirable (Table 17). The 
number of patients however, is too small to conclude that these diffe­
rences are statistically significant. 
In our research the calculation of the concentration profile of MTX 
after intrathecal administration has been based on the similarity of 
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the concentration profile of MTX in plasma after the 5th i.t. 
injection and the concentration profile in plasma after an i.v. 
bolus injection. 
The assumption has been made that the calculations of the i.v. bolus 
injection can be applied in the same way to the concentration profile 
after the 5th i.t. injection. It has to be kept in mind that this 
fitting procedure forms an approach to the discovered concentration 
profile. In a number of cases the differences between the calculated 
and the measured prof:les are considerable. 
Dose 
Number oF 
patients 
samoled 
Pat ιents with 
s de effects 
Pat ιents withoi t 
si de effects 
Al 1 pat ents 
1 
1Ί 
"•ean
 K01 
0 21 
1 15 
о in 
n 
3 
t 
1Ί 
1 1 
13 
mean k,,, 
1 66 
0 30 
1 00 
η 
7 
6 
13 
1 1 1 
13 
mean k 0 1 
5 83 
1 76 
2 З1· 
η 
7 
6 
'3 
I ' 
12 
mean k,,, 
2 52 
2 66 
2 63 
η 
6 
6 
12 
J 
13 
mean k,,, 
0 77 
3 20 
2 26 
η 
8 
5 
13 
Table 17 The differences of the average values of kg, (h ) of MTX 
of toxic and non-toxic children with ALL during CNS-prophy-
1 axi s 
This difference may influence the pharmacokinetic parameters. 
In the Gk detected concentration profiles of the 1^ children, 
only 23 (45%) show a similarity with the calculated profiles. 
The pharmacokinetics of a drug in a patient is described by a 
ph irmacoki neti с model and approaches the concentration in a patient 
but depends on the conscientiousness when sampling plasma in patients. 
In 2 patients (pat.10 and 12) samples have been taken every 5 minutes. 
Fifteen minutes after the injection a higher concentration has been 
found in both patients, compared to the value obtained 30 minutes 
after the injection. 
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Beside the importance o f the sampl ing o f b l o o d , the m e t a b o l i s m o f MTX 
w i l l a l s o i n f l u e n c e the p h a r m a c o k i n e t i c p a r a m e t e r s . 
The aonoentration profile of 7-OH-MTX in plasma after intrathecal 
infection of MTX. 
The occu rrence o f 7"0H-MTX is due t o metabol ism by mixed f u n c t i o n 
oxydase o f MTX in t h e l i v e r ( p . l ' t ) . From r e s u l t s o b t a i n e d from pa­
t i e n t s w i t h c h o r i o c a r c i n o m a , t r e a t e d w i t h very l o n g - t e r m c o n t i n u o u s 
i . v . a d m i n i s t r a t i o n o f MTX (Lankelma 1978), i t is known t h a t a gradual 
increase o f 7-OH-MTX appears in subsequent t r e a t m e n t p e r i o d s . The same 
has been shown w i t h p a t i e n t s w i t h head-and-neck cancer (Lankelma I98O). 
M TX mol / I 1 
π 1 ' 1 ^ 1 1 1 1 ^ ^ 1 
8 16 2¿ 32 ¿,0 48 8 16 2L 32 40 48 
hours 
F i g . 12 Concen t ra t ion p r o f i l e s o f MTX in plasma a f t e r i . t . i n j e c t i o n s 
du r i ng CNS-prophy1axis in a pa t . w i t h ALL and the f i t t i n g 
model c a l c u l a t i o n . 
NOTE the changes in d e t e c t a b i 1 i t y o f 7-OH-MTX 
In children a gradual increase in the concentration of 7-OH-MTX 
is shown too during the CNS-prophy1axis (Table 18), together with 
an earlier appearance of 7-OH-MTX after the subsequent injections 
of the treatment (Fig.12). 
The time during which 7-OH-MTX can be detected is about the same in 
all doses, varying between 15 and 18 hours. 
In 3 children 7-OH-MTX has not been found because the method of 
detection by HPLC had not been developed at that time in our 
institution. With the enzymatic method of detection of MTX used, 
7-OH-MTX cannot be detected. In one other patient 7-OH-MTX could 
not be demonstrated by the HPLC-method either. Obviously this patient 
could not metabolize MTX into 7-OH-MTX at such a rate that it could 
be detected. The liver function tests of this boy were completely 
normal before and after the CNS-prophylaxis. 
In k other patients, 7-OH-MTX appears very late and for a short time 
only in the CNS-prophy1axis and disappears again quickly. 
Dose 
Number of pat ents 
Mean time (h) after injection 
of detection of 7-OH-MTX 
Mean maximal concentration 
(peak) of 7-OH-MTX 
( χ 10" 8 mol/1) 
' 
11 
8 
't 7 
1 1 
10 
6 
8 i. 
Ill 
10 
1| 
3 Ί 
IV 
9 
5 
8 6 
V 
10 
3 
io 9 
Table 18 Occurrence of 7-OH-MTX in plasma after i.t. injection of 
MTX 
The occurrence of 7-OH-MTX is a form of rescue. Lankelma(I98O) 
demonstrated a decrease of the intracellular radioactivity of 
H-MTX by adding 7-OH-MTX to the culture medium of Ehrlich ascites 
cells the same way as adding reduced folates to the medium. This 
means a competitive action of 7-OH-MTX for the transport systet.i of 
MTX. Increase of the concentration of 7-OH-MTX during the CNS-
prophylaxis in subsequent doses could mean that a detoxification 
effort is made by the liver. 
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According to this logic it may be considered that MTX might become 
less effective as antitumor agent, owing to its own metabolism. 
Although some studies (Johns 1965, 1967) indicate that 7-OH-MTX 
also inhibits the enzyme dihydrofolate reductase, there is too 
little action to be of clinical importance in the treatment of ALL 
and in the dose-levels of MTX used. 
Moreover, a decrease of the antileukemic action of MTX due to the 
presence of 7-OH-MTX could not be confirmed in our patients. 
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Chapter X I . 
THE CONCENTRATION PROFILE OF MTX IN THE CSF AFTER 
INTRATHECAL INJECTION. 
I t is not p o s s i b l e to sample the CSF as f r e q u e n t l y as the b l ood . 
In t h i s s tudy the CSF-samples have been taken j u s t be fore the next 
¡n t ra lumbar dose of MTX du r i ng the CNS-prophy lax is . The pharmacoki -
n e t i c model p e r m i t s the c a l c u l a t i o n o f the amount of MTX remaining 
in the CSF f o r a c e r t a i n t ime a f t e r the i . t . a d m i n i s t r a t i n g , 
acco rd ing t o 
Qt = Q0 .e ^ 5 ) 
Q = the concentration requested of MTX in the CSF. 
Q = concentration of MTX in the CSF at the time of injection (t ) . 
о ·' о 
In the boy described before (Fig. 8 ) , a dose of 7 mg of MTX has been 
injected intra1umbarly. Following the first i.t. dose a k
n l has been 
found of 0.19 h (Table 15). The concentration of MTX in the CSF 
following this first i.t. injection decreases from 7.7 x 10 mol/1 
directly after the injection on the place of injection to 8.1 χ 10 
mol/1 2Α hours after the injection. This concentration in the CSF is 
considered to be sufficient to maintain the therapeutic concentration. 
However, a k.. of 2.93 h .following the 5th i.t. injection,results 
in a decrease of the concentration of MTX in the CSF during the first 
24 hours after the injection to nearly zero. We conclude that in the 
fast type of elimination practically all the MTX disappears from the 
CSF within 2k hours. Most of the MTX will be exsorbed in the first 
six hours after the injection and these 6 hours are required for the 
MTX to pass the spinal canal and to enter the cisterns. 
The aonaentration aourse of Ta intratheaalty injected, 
simultaneously with MTX. 
In a girl with ALL Tc has been administered together with MTX 
during the CNS-prophylaxis. Our studies have taken place with the 
77 
consent of her parents. For this study the first dose (slow type of 
elimination of MTX) and the fourth dose (fast type of elimination of 
MTX) have been chosen. Although it cannot be proved, we assume that 
the behavior of MTX in the CSF after intralumbar injection is the 
same as the behavior of Tc , because the distribution and the 
transport of a drug injected in the CSF depends for a great deal on 
the properties of the flow of the CSF. 
Fig. 13 Concomitant i.t. administration of MTX and Te in a pat. 
wi th ALL. 
Measurement of radioactivity: source 1 at L IV, source 2 at 
Tn XII, source 3 at Th II, source 't at С II. 
Time of measurement: 10, 60, 120, and 270 min.after i.t. injec-
t ion. 
After intralumbar injection of this MTX-Tc a bolus of radio­
activity is formed in the lumbar sac. At this place the radio­
activity decreases gradually, because a part of the drug is trans­
ported upwards with the flow of the CSF. However, at none of the 
next points of measurement the same high radioactivity compared 
to the place of injection, has been found. This indicates that an 
amount of the drug injected, disappears from the CSF or is retained 
at lower points in the spinal canal. 
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At the place of the large cisterns ( point of measurement IV) a 
rather constant, but low value of radioactivity can be measured 
during the 270 minutes of the experiment. The amount of radio­
activity recovered at this place is 5% of the radioactivity at the 
place of injection. The rest of the isotope has remained in the 
lower parts of the spinal canal or has been exsorbed into the blood. 
The distribution of the isotope over the spinal column is illustrated 
in Fig. 13. The upper part of this chart shows the distribution of 
the radioactivity over the spinal column after the first i.t. 
injection of MTX during the CNS-prophylaxis. The concentration profile 
of MTX in plasma appears to be of the slow type (concentration of 
-8 
MTX in plasma 2k hours after the i.t. injection = 5.3 x 10 mol/1 
(Fig. 9). On the absciss, the points of measurement show the 
distribution of the isotope along the spinal column. 
The lower part of the chart shows the distribution of radioactivity 
over the spinal column after the fourth i.t. injection of the CNS-
prophylaxis (on day ^k). The concentration profile of MTX in plasma 
after this i.t. injection appears to be of the fast type (concen­
tration of MTX in plasma 2k hours after the i.t. injection = 
_Q 
3.6 χ 10 mol/l (Fig. 9). At the place of injection (L IV) the 
radioactivity is after 10 minutes higher than after the first dose. 
This confirms that more radioactivity can be found earlier in the 
blood after the fourth injection and it may also be concluded that 
the exsorption of the drug from the CSF into the blood increases in 
subsequent injection with a short interval. 
The anatomical and physiologic factors influencing the exsorption 
of a drug from the CSF are unknown. Exsorption from the spinal canal 
takes place predominantly from the CSF into the venous plexus. 
However, 270 minutes after the injection the radioactivity at the 
place of injection is almost equally high in both inject ioni (20*» vs 
290 cps). In the cisterns ( point IV) too the radioactivity is 
about as high after both injections. Considering that the transport 
upwards is probably the same in both injections, it may be 
concluded from this observation that most of the exsorption of the 
isotope takes place in the lower parts of the spinal canal and that 
the exsorption is higher after injections with a fast type of 
e 1 i mi nat¡on in pi asma. 
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This ¡s confirmed by Table 19. The concentration of the isotope in 
plasma is determined as percentage of the radioactivity of a standard 
solution of Tc (3.5 mCi) at different times after the i.t. 
inject ion. 
This confirms that more radioactivity can be found earlier in the 
blood after the fourth injection and it may also be concluded that 
the exsorption of the drug from the CSF into the blood increases in 
subsequent injections with a short interval. 
The anatomical and physiologic factors influencing the exsorption 
of a drug from the CSF are unknown. Exsorption from the spinal canal 
takes place predominantly from the CSF into the venous plexus of the 
spinal canal directly. 
Time of 
collectinq 
blood sample 
(hours after i.t. injection) 
5 
2І 
5* 
percentage oi" 
radioactivity in the 
sample compared to 
the standard solution 
dose 1 
9 
22 
18 
dose IV 
31 
26 
IS 
Table 19 The exsorption of Tc -MTX from CSF into blood 
Increased exsorption after repeated i.t. injection of MTX may be 
supposed to be caused by vascular damage owing to direct local action 
of MTX. The influence of the concomitant i.t. administration of 
Prednisolon and of the cranial irradiation on the process of exsorp­
tion has not become clear from studying patients. 
MTX aoncentration in CSF in 24 ehildren with ALL during 
the CNS-prophylaxis. 
Prior to each i.t. administration of MTX, a CSF-sample has been 
collected from all l^ children that have been studied. 
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However, i t has not been p o s s i b l e t o c o l l e c t a r e p r e s e n t a t i v e sample 
o f CSF f r o m a l l the c h i l d r e n s t u d i e d , e s p e c i a l l y b e f o r e the t h i r d and 
the f o u r t h dose. In o r d e r t o be a b l e t o d i s p o s e o f as many CSF-
samples as p o s s i b l e , CSF-samples have been taken in the same way from 
10 o t h e r c h i l d r e n w i t h ALL d u r i n g t h e i r C N S - p r o p h y l a x i s . 
In a l l 68 samples o f CSF the r e m a i n i n g c o n c e n t r a t i o n o f the MTX of the 
p r e c e d i n g dose has been e s t i m a t e d . The i n t e r v a l between two doses 
v a r i e s f rom 2 t o 7 days. In Table 20 the mean c o n c e n t r a t i o n s o f MTX 
in t h e CSF have been m e n t i o n e d . 
A sudden decrease o f the c o n c e n t r a t i o n o f MTX in the lumbar CSF is 
noted the t h i r d day a f t e r the i n j e c t i o n . 
Days a f t e r 
i . t . i n j e c t ion 
2 
3 
it 
5 
7 
Number o f 
pat i e n t s 
3 
30 
2k 
В 
3 
Mean HTX-conc3ntrat ion 
χ 1 0 " 8 n o l / 1 (ranqe) 
25.3 (11."-37) 
3.2 ( 0 . 1 3 - 7 . i t ) 
1.6 (0-7.7) 
0.6 (0-2.3) 
0.3 (0-0.5) 
Table 20 C o n c e n t r a t i o n o f MTX in CSF 2-7 days a f t e r i . t . i n j e c t i o n 
in 68 doses 
B l e y e r (1977) d e t e c t e d a h a l f - l i f e t ime o f MTX in the CSF of Ц 
2 
h o u r s . A f t e r the a d m i n i s t r a t i o n o f an i n t r a t h e c a l dose o f 12 mg/m 
he d i s c o v e r e d t h a t the mi η i murr t h e r a p e u t i c c o n c e n t r a t i o n was t o be 
m a i n t a i n e d over 24 h. However, in our research the same h a l f - l i f e 
t ime has been found as in the study o f B l e y e r , but o n l y a f t e r the 
f i r s t dose. The f o u r t h dose in our study shows a h a l f - l i f e t ime of 
about 1 hour ( F i g . 1 4 ) . 
Fig. Й Concentrations of MTX in CSF 72 and 96 hrs after the first 
i.t. injection in children with ALL during CNS-prophyI axis 
and comparison with the decline in concentration discovered 
by Bleyer (1977). The interrupted line shows the decline in 
concentration we have observed after the fourth i.t. injec­
tion in these children. 
Although it has not been mentioned by Bleyer, the results of his 
study may be derived either from the concentration-decline of the 
first dose of the CNS-prophylaxis or may be the resultant of the 
mean decline of all doses together. 
In the scattergram (Fig. 15) the decrease of the half-life time of 
the subsequent i.t. doses of MTX in our children is shown again. The 
small cross lines indicate the mean half-life time for each dose. 
The first dose has a half-life time of 4 hours, the second one of 
2.8, the third 1.2, the fourth 0.5 and the fifth 0.9 hours. 
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Fig. 15 Half-life times (h) of MTX in CSF after i.t. injections in 
children with ALL during CNS-prophylaxis. 
The concentration profile in the CSF can be calculated by a 
pharmacokinetic model. For this purpose the way of transport of MTX 
in the spinal canal has to be considered first: after intralumbar 
injection MTX is transported as a bolus (wave-phenomenon) into the 
direction of the brain. During this transport a certain amount of 
MTX is eliminated from the CSF into the blood ( k
n l ) . This k n l is the 
reciprocal time constant of elimination (kj,) of the CSF. By another 
reciprocal time constant (k 1 7) MTX is transported from the place of 
injection to the base of the brain. During this transport ai 
elimination of MTX from the CSF into the blood takes place (k...). 
By simulating the pharmacokinetic events of MTX in the CSF some 
99m 
assumptions have to be made. From the study of T c ^ , the half-life 
time at the place of injection is known to be about 70 minutes. 
This is in accordance with a k 1 2 of 0.59 h . Because the flow of the 
CSF may be considered constant, the transport of Tc and of MTX 
must be identical. Thus, the к _ of MTX in the CSF is 0.59 h" as 
well. Extrapolating the concentration of MTX in the CSF at the place 
and the tι те of adninistration of 10 mg of MTX i . t. , the 
concentration of MTX in the CSF at time zero is 5 x 10 mol/1. 
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(Fig. 17). This value results ¡π a volume of distribution of the first 
compartment of Q.kk 1. It has been assumed that the volume of distri­
bution of compartment one is the same as the volume of distribution of 
compartment two. 
Taking into account the changes of the kg 1 according to the mean values 
for k
n l in the subsequent i.t. injections in the children. 
(Table 17). the concentrations can be calculated. The concentration 
profiles of the second compartment (i.e the large cisterns) can be 
calculated (Fig.l6) according to the two-compartment with one metabo-
1 i te mode 1 : 
С . e 
о 
•
( к 12 Л і ' · 1 
F i g . 
20 2t 
Time Ihrs) 
16 Calculation of the concentration profiles of MTX in CSF after 
i.t. injections with increasing exsorption. 
The peak concentration in the second compartment is equally high as 
in the first compartment. Of course this is not in agreement with 
our findings of Fig. 13. 
This simplified model-cai cui at¡on shows that only the first injection 
causes a considerable concentration of MTX in the upper cervical region 
of the spine (base of the brain), which remains for a sufficiently long 
period (18 hours) higher than the minimum therapeutic concentration 
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(5 χ 10 mol/1). The h other doses cause a concentration higher than 
the minimum therapeutic concentration, but the period in which this 
concentration is maintained is too short (second dose 6 hours, the last 
3 doses only 2 hours). 
This is too short to produce any therapeutic effect in the leukemic cells 
cells in the subarachnoidal space of the skull. The concentration of 
MTX at the place of injection diminishes according to an exponential 
elimination as in the one-compartment model. This is illustrated by 
the left part of Fig.16. 
We iiius t realize that the model described in Fig. 16 is a very simplified 
one and only describes the pharmacokinetics of a drug in a tube, 
It does neither consider the different transport velocities of a drug 
in the CSF, nor the subsequent differences in volume of the CSF space 
the drug has to pass from the lumbar sac into the large cisterns. 
To maintain the minimum therapeutic concentration in the CSF at a level 
of 5 x 10 mol/1 during at least 18 hrs, the maximum k
n 1 from the CSF 
into the blood can be calculated and appears to be 0.95 h (t, in the 
CSF = 0.73 h). The concentration of MTX in plasma 18 hours after the 
i.t. injection - which belongs to the value of к . of 0.95 according 
_ Q 
to eq 2 - is 3.9 x 10 mol/. This is in agreement with the lowest 
value of the slow elimination type (Fig.9) 18 hours after the i.t, 
i nject ion (F ig.9 • ) · 
-8 
The discovery of a concentration of MTX in the plasma of 4 χ 10 
mol/1 18 hours after the i.t. injection indicates that the concen­
tration in the CSF is less than 5 χ 10 mol/1. 
In that case the conclusion has to be that minimum therapeutic 
concentration in the CSF cannot be maintained for more than 18 hours 
and that the next i.t. dose had rather be postponed until the 
transport system of the meninges has recovered again. From Table 15 
it may be concluded that in the first i.t. dose of MTX the k
n l is 
-1 
less than 0.95 h with all children. In the next doses the value 
of the k.. varies but may also be less than 0.95 h 
In these 14 patients the first uose of MTX i.t. has reached an ade­
quate concentration of MTX in the CSF during 18 hours or more 
in accordino with the value of the к .. 
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Determination of the MTX-concentrat ion in the plasma will give an 
indication of the value of the last A i.t. doses. 
Determining the k
n l after every i.t. injection of MTX, however, is 
difficult in practice. It is much easier to measure the concentration 
of MTX in plasma 18-20 hours after the i.t. administration of MTX. 
-8 
A concentration of MTX in plasma of more than k χ 10 mol/1 at that 
time, is considered to be in agreement with a k... in the CSF of 
0.Э5 h or less. That injection results in an effective concentration 
of MTX in the CSF. A concentration of MTX in plasma less than 
-8 
4 x 1 0 mol/1 is considered to be in agreement with a k,,., in the CSF 
of more than 0.95 h . In that case the injection did not result in 
an effective concentration of MTX in the CSF and therefore a different 
method of administrating MTX into the CSF is recommended. 
We have applied these assumptions to the 14 children studied: 
in Table 21 the concentrations of MTX in plasma of the 14 children 
studied are given. 
The signs > and < indicate the concentrations of MTX in plasma after 
-8 
i.t. injection of more (>) or less (<) than 4 χ 10 mol/1 18 hours 
after the injection. After the first dose 11 children had a concentra-
-8 
tion of MTX in plasma of more than 4 χ 10 mol/1, 18 hours after the 
injection. These 11 children have maintained a concentration level in 
the CSF of more than 5 x 10 mol/1 during 18 hours. In 3 children, 
however, the concentration of MTX in plasma after the first intra-
-8 
thecal dose was less than 4 χ 10 mol/1. Consequently, the concentra­
tion of MTX in the CSF did not reach the minimum therapeutic concen­
tration ( 5 x '0 mol/1) for a sufficiently long period (18 hours). 
In only 3 children all i.t. doses resulted in adequate concentrations 
of MTX. In the other patients none or only some of the doses reached 
this concentration χ time-level. Consequently, we may assume that the 
administration of MTX has been effective in only 3 children during 
the complete CNS-prophy1axis. 
A few of the doses - usually the first (8 children) and the second 
(3 children) and sometimes the third (pat.8) - are also effective. 
All other doses should be considered as being ineffective in des­
troying leukemic cells in the subarachnoidal space of the skull. 
We could not ascertain any relationship between the findings in 
Table 21 and the occurrence of hematologic or gastrointestinal side-
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e f f e c t s . I t would be o f i n t e r e s t t o study the r e a l c o n c e n t r a t i o n 
p r o f i l e o f MTX in the CSF, but in c h i l d r e n f r e q u e n t sampl ing of the 
CSF is i m p o s s i b l e . 
Table 21 C o n c e n t r a t i o n o f MTX in plasma at 4 χ 10 m o l / 1 , a f t e r 
i . t . i n j e c t i o n s o f MTX, 18 hrs a f t e r i n j e c t i o n , in 14 c h i l d r e n 
w i t h ALL d u r i n g CNS-prophylaxis and the r e l a t i o n s h i p w i t h 
t o x i c s i d e - e f f e c t s 
-8 
< = c o n c e n t r a t i o n in plasma < k χ 10 mol/1 18 h a f t e r i . t . i n j e c t i o n 
-8 
> = c o n c e n t r a t i o n in plasma > k χ 10 mol/1 18 h a f t e r i . t . i n j e c t i o n 
0 = no v a l u e a v a i l a b l e o f the c o n c e n t r a t i o n in plasma 
Beside the d e s i r e d c o n c e n t r a t i o n p r o f i l e o f MTX, i t may be o f i n t e r e s t 
t o study the i n f l u e n c e s o f e i t h e r c r a n i a l i r r a d i a t i o n o r P r e d n i s o l o n 
or o f both on the c o n c e n t r a t i o n p r o f i l e o f MTX in CSF and plasma. To 
o b t a i n an impression o f these d i f f e r e n t a s p e c t s , the CNS-prophy1 ax is 
has been s i m u l a t e d in an animal model . 
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Chapter XI I 
THE ANIMAL MODEL IN THE INTRATHECAL ADMINISTRATION OF MTX. 
Introduation. 
Surveying the concentration profiles of MTX in the CSF in an 
individual patient is impossible. Only the relative course of the 
concentration of MTX in the CSF can be calculated from the concentra 
tion profile in plasma.The influence of the different parts of the 
CNS-prophylaxis (radiotherapy, i.t. MTX or Prednisolon) on the 
concentration profiles of MTX ¡η the CSF are also difficult to study 
separately. Tied to the rigid trial-protocols of the SNWLK we are 
not able to compare variations in the CNS-prophylaxis of children 
with standard-risk ALL. Moreover it is not very inviting to change 
a protocol, obtaining good results in a very dangerous condition 
like ALL, without having the guarantee that the results will be as 
good as with the traditional protocol. 
To this purpose, the concentration profile of MTX in the CSF and the 
interaction of MTX, Prednisolon and cranial irradiation has been 
studied in an animal model. The animals chosen are female midget 
goats of about 8 months to 1 year old. The average weight of the 
goats is 10 kg. Goats have been chosen for practical reasons: 
goats are rather clean, which is important for radiotherapy, because 
the animals are using the facilities of human patients. The sub­
cutaneous fat layer of goats is thin, so it was assumed that the 
execution of lumbar punctures would be easy. The small weight of the 
animals (about 10 kg) allows rather easy manipulation. The goats are 
large enough to obtain sufficient CSF and blood samples. The last 
but not the least important motif is that goats are cheap to acquire 
and support. 
Methods. 
The animals have been accomodated in the C e n t r a a l P r o e f d i e r e n 
L a b o r a t o r i u m o f the C a t h o l i c U n i v e r s i t y o f N i jmegen. 
( D i r e c t o r D r . W . J . I . v . d . G u l d e n ) . The an imals have been fed the usual 
g o a t - f o o d d u r i n g the p e r i o d o f s t u d y . 
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Under general anaesthesia (Pentotal i mg/kg ¡.v.) a drain was put 
into the jugular vein. 
A second drain was put into the lumbar part of the spinal canal: 
A cánula with the opening in the lateral side, in stead of at the 
point, was brought into the spinal canal in the intravertebral area 
of L3"!-1* or Lk-L5, ascertaining the area of the opening of the cánula 
in the spinal canal by collecting a sample of CSF. An arterial drain 
was pushed carefully through the cánula along a distance of 15"20 cm 
and fixed to the skin. The mandrin was removed and a dull cánula was 
fixed at the end of the drain to allow the collection of CSF with a 
disposable syringe. Both drains are closed with a sterile cap be-
tween the subsequent sample takings. After placing the drains, a 
depot penicilline (Pendural D/F) is injected intramuscularly. 
In order to be able to irradiate the skull of the animal, without 
anaesthesi zing some provisions were made: the goat was placed in a 
narrow box in which a broad sling had been fastened under its belly, 
preventing the animal to lay down. The head-and-neck region stuck 
out of the box through an opening in one of the sides. 
During the irradiation the head was fastened by letting the mandible 
rest on a shelf and by strapping the front part of the head. Both 
horns were set tight in two holes, that fitted for each goat. 
In the goats the CNS-prophylaxis was simulated, but each goat 
underwent a treatment slightly different from the others: 
goat a. Cranial irradiation only (2500 Rad). 
goat b. I.t. administration of MTX (0.5 mg/kg) two times a week 
Zì weeks (corresponding to 5 doses). 
goat c. Cranial irradiation together with MTX (0.5 mg/kg) and Pred-
nisolon (12¿ mg each dose) both i.t. and two times a week 
during 2i weeks. 
goat d. Cranial irradiation together with MTX i.t. (0.5 mg/kg) two 
times a week during 2ì weeks. 
Blood and CSF-samples have been collected in b, с and d at 0:15 and 
30 minutes and 1, 3, 6, 12, 2k, 36, hS, 72 and 96 hours after injec­
tion. MTX and 7-OH-MTX have been detected by HPLC-method as mentioned 
before (p. 62 ) . 
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After the last blood and CSF sample the goats were killed by an over­
dose of Pentotal i.v. The CNS with the meninges were isolated and 
collected for pathologic anatomical examination. 
The cranial irradiation has taken place according to the data given in 
Table 22. 
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Every qoat receives 2 opposite lateral Fields a day durinn 13 days 
Table 22 Data of cranial irradiation during simulation of CNS-prophy-
laxis in goats (Apparatus Stabilipan) 
Results 
The sampling of the CNS according to the aforementioned scheme appear­
ed to be not a simple one. During the whole period of the experiment 
the drains had to be changed frequently. This caused loss of CSF and a 
delay in the sampling times. 
Side-effects too have been present in the goats: The appetite of the 
animals diminished. The goats receiving MTX i.t. showed an increase 
of salvation. None of the animals showed any loss of hair of the skull 
during the irradiation. 7-OH-MTX did not occur in any of the goats, 
neither in plasma nor in the CSF. 
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The concentration of MIX in the plasma of the goats. 
In Table 23 the most important data of the concentration profiles 
have been given, arranged according to the dose and the kind of 
simulation treatment. After adding Prednisolon to the treatment a 
gradual increase of the maximum concentration of MTX in plasma 
occurred. However, the period in which to obtain this maximum concen­
tration is reached.increases in the subsequent doses. In goats, the 
maximum concentration in plasma is obtained later in the subsequent 
doses in the animals receiving cranial irradiation too, whereas no 
difference in time is observed in the animal receiving MTX i.t. only. 
This phenomenon is contradictory to the observation on children. 
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Table 23 Maximum concentrations of MTX in plasma after i.t. injection 
during simulations of CNS-prophy1axis in goats 
The concentration of MIX in the CSF of the goats. 
In Table 2^ the main data about the decrease of the concentration of 
MTX in the CSF have been given. A very high concentration has been 
found 30 minutes after the injection. This concentration declined 
rapidly and 6 hours after the injection a decline of a factor of 
120-200 could be observed. However, by adding Prednisolon to the 
treatment the decline 6 hours after the injection is less, only a 
factor 25 lower compared with the schedules without Prednisolon. 
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Adding P r e d n i s o l o n t o the t r e a t m e n t a l s o causes a h i g h e r v a l u e o f 
the AUC (eq 4) o f the f i r s t 2k h o u r s . T h i s means t h a t the e x s o r p t i o n 
o f MTX f rom the CSF due t o P r e d n i s o l o n in the f i r s t 2k hours a f t e r 
the i n j e c t i o n is s m a l l e r than in both o t h e r schedules w i t h o u t p r e d n i 
s o l o n . 
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Table 2k C o n c e n t r a t i o n s o f MTX in CSF a f t e r i . t . i n j e c t i o n d u r i n g 
s i m u l a t i o n s o f CNS-prophyI a x i s in goats 
F i g . 17 shows a remarkable d i f f e r e n c e in the a r e a s - u n d e r - t h e - c u r v e 
o f the 3 d i f f e r e n t t r e a t m e n t s c h e d u l e s . 
These d i f f e r e n c e s cannot be understood and may be caused by a l a r g e 
numbers o f d i f f e r e n t f a c t o r s . 
When comparing the AUC of b lood t o the AUC o f CSF, i t might be sugges­
t e d t h a t a decrease o f the AUC in the CSF i s f o l l o w e d by an increase 
o f the AUC in b l o o d , b o t h in schedule I I and I I I . Both animals 
r e c e i v e d r a d i o t h e r a p y a p a r t from the MTX i . t . 
The animal t r e a t e d w i t h o u t r a d i o t h e r a p y ( l ) showed a c o n s t a n t p a t t e r n 
o f the AUC b o t h in plasma and in CSF. The a c t i v i t y o f P r e d n i s o l o n 
( I I ) is s u r p r i s i n g . The AUC increases very q u i c k l y f o l l o w i n g the 
second dose, but then d e c r e a s e s , f o l l o w i n g the subsequent t h r e e 
doses. The number o f d a t a , however, is t o o small t o draw c o n c l u s i o n s 
on the i n f l u e n c e s o f the t h r e e s e p a r a t e models o f t h e r a p y -which 
d i f f e r in one p a r t o f the C N S - p r o p h y l a x i s - on the c o n c e n t r a t i o n 
p r o f i l e s o f MTX in the CSF or the b l o o d . 
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'.Γ9ί!?Αίΐ?Χ°Ρχ * radiotherapy 
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intralumbar dose 
F i g . 17 Area Under the Curve in b lood ( lower p a r t ) and CSF (upper 
p a r t ) in goats in 3 d i f f e r e n t s i m u l a t i o n s o f CNS-prophy1 a x i s , 
(values in b lood χ 1 0 " ° m o 1 . h / l , values in CSF χ 1 0 " 3 m o l . h / 1 ) . 
In F i g u r e 18 we compare the c o n c e n t r a t i o n p r o f i l e o f MTX in the CSF 
in the g o a t , w i t h the c o n c e n t r a t i o n p r o f i l e in plasma in the animal 
t r e a t e d w i t h MTX i . t . o n l y . 
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360 hours 
Fig. 18 Concentration profiles of MTX in blood and CSF in a goat 
during simulation of CNS-prophy1axis with MTX i.t. (10 mg) 
only. 
A great difference can be observed between the concentration of MTX 
in the CSF and in plasma. MTX also disappears very rapidly from the 
plasma, while the concentration in the CSF shows a more extensive 
course. Remarkable is the course of the concentration of MTX in 
plasma after the 5th dose. These results are exactly the ooposite of 
the results in children and may be due to the difference in the 
administration of MTX. 
^ 
The use of a drain in the spinal canal makes the way MTX has to go 
shorter and it passes over the lower parts of the spinal canal. 
It remains difficult to draw conclusions that are applicable to 
human situations from this animal model. 
Discussion. 
The simulation of the CNS-prophy1 axis in goats invites more questions 
than can be answered. According to Fig. 17 (II and III) it looks as 
if the cranial irradiation causes some increase of the elimination 
of MTX from the CSF according to the AUC in plasma. This may be 
explained by the reduction of the CSF-product¡on in the choroid 
plexus owing to the cranial irradiation, and a concomitantly 
increased exsorption of the CSF through the venous plexus of the 
spinal canal owing to the decreased flow of the CSF. 
With regard to the influence of prednisolon on the exsorption of MTX 
an obvious explanation is impossible. Comparing the AUC of schemes 
I and III with scheme II, the elimination of MTX from the CSF seems 
to be less in scheme II. Moreover, the increase of AUC in plasma 
shown in scheme II and III suggests a cumulation of MTX in plasma 
after i.t. injections with short intervals caused by cranial irra-
diation. 
Local administration of corticosteroids will not only cause a change 
in the permiability of membranes, but a vasoconstriction as well. 
(Zweifach 1953, Wyman ISS1*. Sutton 1971). The administration of 
prednisolon i.t. may be considered as being a local application for 
the blood vessels in the spinal canal and causes a vasoconstriction 
of these vessels. If this is the explanation, the venous plexus of 
the spinal cord may be passed less easily by MTX and the drug may 
diffuse into the blood at a smaller rate. This mechanism might ex-
plain the less easy exsorption of MTX into the blood compared with 
both other schedules. 
The vasoconstrictive activity of prednisolon will also cause a 
decrease of the CSF pressure (Houben 1969). 
Comparison of the goat model with the human situation is only possi-
ble to a small extent. The CSF-space in the lumbar sac of the goats 
is smaller than in human beings and the spinal canal has a horizon-
tal position, while with man the spinal canal will be in a vertical 
95 
p o s i t i o n again some hours a f t e r t h e i n j e c t i o n . The i n f l u e n c e o f t h i s 
change in p o s i t i o n on a l t e r a t i o n o f the CSF-flow i s , a c c o r d i n g t o 
the study o f Houben ( І 9 б 9 ) і very s t r i k i n g . 
Moreover, the use o f a d r a i n in the s p i n a l canal in o r d e r t o i n j e c t 
the d r u g s , causes a pass-over o f the lower p a r t o f the s p i n a l c a n a l . 
The v a r i a t i o n o f CNS-pressure, r a d i o t h e r a p y and the p o s s i b l e 
o c c u r r e n c e o f an a r a c h n o i d i t i s , u s u a l l y deducted from the i n c r e a s e 
o f the number o f c e l l s in the CSF, cause a severe damage t o the CNS. 
H a l l ( I978) shows t h a t the a d m i n i s t r a t i o n o f g l u c o c o r t i c o i d s reduces 
the damage o f the trauma t o the s p i n a l c o r d by r e s t o r i n g damaged 
s y n a p t i c f u n c t i o n s . Moreover, the a d m i n i s t r a t i o n o f P r e d n i s o l o n may 
prevent adhesions due t o chemical a r a c h n o i d i t i s caused by MTX. 
C o n s i d e r i n g these d a t a , the a d d i t i o n o f P r e d n i s o l o n t o the i . t . 
i n j e c t i o n s d u r i n g the CNS-prophy1 a x i s i s l i k e l y t o have a f a v o u r a b l e 
e f f e c t in t h i s t r e a t m e n t . 
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PATHOLOGICAL A. ATOMICAL EXAMINATION 0Γ Thh CENTRAL NERVOUS SYSTEM 
AFTER SIMULATION OF THE CNS-PRO^hYLAXIb IN 5 GOATS. 
Macroscoptc fbnáingb. 
A f t e r t a k i n g the l a s t b lood and CSF „amples f o r the d e t e c t i o n o f MTX, 
the animals were k i l l e d by an overdose o f p e n t o t a l . The CNS has been 
i s o l a t e d f rom the backs ide o f the an ima l . 
A f t e r opening the s p i n a l canal a g rea t number o f adhesions o f the 
meninges have been observed in a l l the an ima ls , e s p e c i a l l y some 
cen t ime te rs c r a n i a l o f the d r a m t i p . No adhesion in the s k u l l cou ld 
be observed. There is no r e l a t i o n between the macroscopica l adhesions 
and the method o f CNS-prophy1axis. 
Мгсгозоорго findinga 
Five goats underwent a s i m u l a t i o n o f the CNS-prophy1axis a c c o r d i n g 
t o one o f the f o l l o w i n g methods 
a. С a n i a l i r r a d i a t i o n (2500 Rad). 
b. MTX ι . t . ( 0 . 5 mg/kg) o n l y . 
с C r a n i a l i r r a d i a t i o n (2500 Rad) + MTX ι . t . (0.5 mg/kg) 
+ P r e d n i s o l o n ι . t . (12г mg). 
d. C r a n i a l i r r a d i a t i o n (2500 Rad) + MTX ι . t . ( 0 . 5 mg/kg) 
e. MTX ι . ν . (1000 mg) by i n t r a v e n o u s i n f u s i o n d u r i n g Zk hours 
(goat I I Ι ρ 108) . 
Two animals did not receive cranial irradiation. Four goats received 
MTX The goats receiving MTX (b, c, d and e) showed slight vascular 
changes in the form of hyalin thickening of the walls m the meninges 
and brain. These changes have been found diffusely in the CNS and not 
only in sites of inflammatory reactions due to the drain. The 
vascular changes are considered to be a characteristic action of MTX 
into the vascular walls 
In the irradiated goats, moreover, the myelme in the pons and 
medulla oblongata showed a thin and edematous aspect 
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The meninges of the spine showed an inflammatory reaction in all 
goats, except for the goat treated according to (a). In goat (e) 
the inflammatory reaction consisted of an exudation containing poly-
nuclear cells. The goats (b) , (c) and (d) showed a more chronic 
inflammatory reaction consisting of lymphocytes, plasma cells and 
only a few polynuclear cells. 
The goat treated by the scheme Prednisolon (с) showed a thickened 
arachnoid and an increase in the size of the perivascular spaces. 
In the spinal cord changes have been observed like edema and degene­
ration of some cells in the anterior horn. 
The chronic inflammatory changes in the meninges of the spinal cord 
are caused by the ¡ntralumbar cánula and by the "trauma" of the 
repeated injections of the drugs. In goat (e) treated with MTX i.v. 
only, the drain remained just for a relatively short period (55 h) 
only in the spinal canal. It caused an acute inflammatory reaction 
with exudation and polynuclear cells. 
Our findings suggest that vascular changes in the meninges and the 
CNS directly after the CNS-prophylaxis are caused by the i.t. adminis-
tration of MTX (both i.t.and i.v.) and not by cranial irradiation. 
The late changes after radiotherapy, resulting in the so-called late 
radionecrosi s of the brain, are caused by vascular degeneration 
cwing to the preceding radiation treatment, occurring later. 
The symptoms and signs during the post-CNS-prophy1 act i с period, 
together causing the apathy-syndrome, are likely to be caused by 
disturbances in the equilibrium of de- and remyeli η i sat ion owing 
to the cranial irradiation. From this study of goats, it may be 
concluded with caution, that the onset of the changes in myelinisation 
can be found already at once after the cranial irradiation. 
It has to be kept in mind, however, that all changes in the CNS 
directly following the treatment, which have been found in these 
goats, are very small. 
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Chapter XI I I 
POSTULATIONS AND HYPOTHESES OBTAINED FROM THE RESULTS OF THE 
PRECEDING STUDY OF THE CNS-PROPHYLAXIS IN CHILDREN 
SUFFERING FROM ALL. 
The good results of the "total therapy" of the "standard-risk" ALL, 
obtained until now, are without any doubt the result of an effective 
hematologic remission induction treatment and the diminution of the 
incidence of overt CNS-leukemia» This diminution is obtained by either 
cranial irradiation and i.t. administration of MTX or by one of them. 
Without the prophylactic treatment of the CNS, the probability of 
occurrence of overt CNS-leukemia accounts for 56%, according to the 
findings at necropsies (Price 1973). Owing to the CNS-prophy1axis the 
frequency of overt CNS-leukemia has decreased to about 10% of the 
chi 1 dren wi th ALL. 
However, in our study we have found a fai 1 ure-i neidence of still 26% 
in group of children with ALL chosen at random. In our group, 8 of the 
children had high-risk ALL, without overt CNS-leukemia at the time of 
diagnosis. In 2 of them a relapse occurred in the CNS. This means that 
the patients with high-risk ALL have not especially contributed to the 
high incidence of failure of the CNS-prophy1axis. The CNS-prophy1axis 
failed in 5 out of 9 children with standard-risk ALL, having a 
remission induction period of more than 50 days, and in 6 out of the 
31 children with ALL (19%), also without any evidence of high-risk 
factors and an unremarkable remission induction period of less than 
50 days. This leads to the assumption that several other factors may 
contribute to the failure of the CNS-prophylaxis. One of these factors 
appears to be the low resultant concentration of MTX in the 
intracranial subarachnoidal space after intralumbar administration. 
In the usual treatment of ALL and especially in the protocol for CNS-
prophylaxis in the Netherlands, it is inevitable that side-effects of 
the treatment will occur. The most common side-effects during and 
after the CNS-prophyIaxis are the apathy-syndrome, occurring a few 
weeks after the treatment by cranial irradiation. The depression of 
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the marrow and damage to the mucosa of the digestive tract are 
important side-effects, due to the i.t. injected MTX. 
From the literature (Riehm 1977, Nesbit 1981) it is known that 
reduction of the dose of radiation to 1800 Rad is as effective as the 
use of 2400 (or 2500) Rad in the CNS-prophylaxis. One may wonder 
whether in standard-risk ALL the total radiation dose must be given in 
one continuous treatment or intermittently (Zuelzer 1976, Mastrangelo 
I978) or whether the cranial irradiation must be given at all (Мое 
1978, 1980, 1981). 
It has been known for more than 50 years now that cranial irradiation 
with a high dose of radiation causes the apathy-(somnolenee) syndrome, 
and that reduction of the dose reduces the incidence and the severity 
of this syndrome (Druckmann 1929). A recent study (Ch'ien I98O, I98I) 
shows a connection between the severity of the apathy-syndrome and the 
occurrence of late sequelae, like reduction of intelligence, cerebral 
atrophy and too early dementia. As the prognosis of ALL in children 
improves to such a degree that curation of the disease in many 
children may be spoken of, the side-effects of the cranial irradiation 
mentioned above may be considered to be intolerable. These side-
effects may be avoided by reducing the dose of the radiation; even if 
this change of the protocol might have a negative influence the 
value or results of clinical trials, this should be executed as soon 
as possible. 
The narrow therapeutic action of MTX results in a number of side-
effects, of which some are inevitable. In particular the lesions in 
the mucosa of the digestive tract occur in very small concentrations 
of MTX. However, the condition of children with ALL in remission 
during the CNS-prophy1axis, will improve considerably by reducing the 
possibilities of the occurrence of side-effects caused by MTX. In 
that case the therapeutic value of MTX should remain the same. 
Because we are bound to the trial protocols of the SNWLK, we have not 
been able to study such other methods. 
The physiologic and pharmacologic processes occurring after i.t. 
injection of MTX and Prednisolon can be summarized as follows: 
After injection of MTX and Prednisolon by lumbar puncture, the 
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drugs will spread very quickly over the CNS into the terminal cistern. 
The increase in the volume of the fluid in the lumbar sac will cause 
a considerable increase of the pressure in this space (Houben 1969). 
This increased pressure causes compression of the blood vessels in 
the lower part of the spinal canal« 
The effect of this compression will be augmented by the local 
vasoconstrictive activity of Prednisolon ( ρ . 9 Ό . The result of these 
actions is an increase of the space in the lower part of the spinal 
canal and by this mechanism the increased pressure in the spinal 
canal is partially and gradually reduced. The change of the pressure 
and the movement of fluid by the force of injection cause an 
undulatory movement of the CSF, that contains MTX and Prednisolon, 
in the spinal canal. The duration of this undulatory movement after 
injection of 5 nil of saline is 5 minutes, according to the study of 
Houben (1969). Upwards in the very narrow space of the spinal canal, 
the pressure of the undulatory movement will be subdued and a more 
gradual movement, together with a more physiologic flow of the CSF, 
can be observed. The level in the spinal canal at which this more 
gradual movement occurs, is not known and may depend on the force 
and the volume of the injection. It may also be influenced by the 
vasoconstrictive properties of Prednisolon. 
On account of the vasoconstriction the exsorption of MTX will be 
slow, and MTX will be transported into the intracranial 
subarachnoidal space without considerable loss. However, just as 
in other tissues,MTX will at the same time have a toxic activity 
into the walls of the blood-vessels of the spinal canal. The exact 
damage of each dose is unknown. However, from the animal model it 
appears that owing to the repeated i.t. injection of MTX hyalin 
changes in the wall of the blood vessels can be observed. Owing 
to these changes the functions of the blood vessels will not be 
optimal and MTX will pass into the plasma more easily through these 
damaged vascular walls. The study of the i.t. injection of Tc -MTX 
shows that this damage may especially occur in the lower part of the 
spinal canal. 
Most of the MTX injected will disappear from the CSF after the last 2 
or 3 doses of the CNS-prophy1axis in the lower part of the spinal 
canal and an insufficient amount of MTX will be available for 
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anti-leukemiс action in the intracranial part of the subarachnoidal 
space, the expected site of the highest load of leukemic cells in the 
CNS. Another consequence of the quick disappearance of MTX from the 
CSF as a result of the damage to the vascular walls is, that a high 
concentration of MTX appears in the plasma over a rather long period 
of time,causing undesired actions of MTX, like mucosa lesions In the 
digestive tract and depression of the marrow. In this case the side-
effects are Inacceptable, because MTX does not contribute to the 
wanted antileukemic activity In the subarachnoidal space. 
Inefficacious administration of MTX î.t. can be prevented by 
determination of the concentration of MTX in the plasma 18-20 hours 
after every i„t. injection. We discovered that a concentration of 
-8 
MTX of more than k χ 10 mol/1 in plasma at that t¡me,indicates that 
the exsorptlon of MTX from the CSF Into the blood is slow, 
Sufficient MTX will be available in the intracranial subarachnoidal 
space to obtain a concentration of MTX in the CSF of at least 
5 χ 10 mol/1 during at least 18 hours. This slow type of exsorption 
does not cause high peak concentrations in plasma. The chance of 
side-effects is small therefore. 
-8 
A concentration In plasma of less than k χ 10 mol/1 18-20 hours 
after the injection indicates that the concentration of MTX in plasma 
has been high. In that case toxic side-effects may occur. The rapid 
exsorption of a large amount of MTX In a short period after the l.t. 
injection from the CSF results in the Inability to achieve the 
minimum therapeutic concentration (5 χ 10 mol/1) in the intra­
cranial subarachnoidal space during a sufficiently long period 
(l8 hrs). This dose has been without therapeutic use in the CNS-
prophylaxi s. 
In the study of our patients it appears that 18 hours after the 
first i.t. injection 80% of the children had a concentration of MTX 
-8 
in plasma of more than 't χ 10 mol/1. After the second dose this 
concentration was observed in 50% and after the third, fourth and 
fifth in only 25% of the children (Table 21). It may be concluded 
that only the first i.t. dose of MTX and in 50% of the children also 
the second dose have had a therapeutic value in the CNS-prophy1axls. 
The determination of the concentration of MTX in plasma 18 hours 
after the i.t. administration, makes it possible to judge the 
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efficacy of the i.t. dose of MTX in the CSF. From studies of Ogston 
(1968), Kenis (I97O) and Shaw (1973) it is known that the rebound 
phenomenon of 1ymphoblasts requires repeated doses of MTX (Vogler 
1973). 
To obtain the minimum therapeutic concentration (5 x 10 mol/1) in 
the intracranial subarachnoidal space in subsequent administrations 
of MTX (i.t., i.V.) during 18 hrs we propose 3 ways of 
admi η i strat ion : 
1. Direct administration of MTX in the ventricles of the brains by 
a subcutaneous Ommaya reservoir, connected with the ventricles by 
a drain (Ommaya 19бЗі Ratcheson I968, Goedhart 1978). This method 
has been applied by Bleyer (1978), with very good results. The 
concentration of MTX in the ventricle, and also in the 
subarachnoidal space of the brains is very high and in the spinal 
canal adequate concentrations have been detected. The studies of 
brain scans (Penning 1975) indicate that a drug injected in this 
way, is detectable over the convexity of the brains during at 
least 2k hours. We have as yet little experience with intra­
ventricular administration of MTX and only in a number of children 
suffering from overt CNS-1eukemia. From two of those patients we 
obtained high concentrations of MTX in the ventricles and 
in the lumbar sac after intraventricular injection of 12i mg MTX. 
In plasma MTX has also been detected after the intraventricular 
injection, but only 2 hours after the injection for the first time. 
In our opinion (until now) the use of this method is restricted to 
children with overt CNS-leukemia. 
2. Extension of the interval between two injections may give the 
opportunity to heal the damaged wall of the blood vessels in the 
spinal canal. The length of this interval is unknown, but some 
indications have been given in a number of studies: The IMFRA-
method of CNS-prophy1axis (Zuelzer 1976) causes little side-
effects. In this method the interval between two injections is 
2-3 months. 
Our own experience - in children with overt CNS-leukemia - show 
that i.t. administration of MTX every 4-6 weeks is tolerated 
without side-effects, but we have not studied the concentration 
profiles of MTX in these cases. 
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From studies with high-dose ¡„v. infusions with MTX, we learned 
that an Interval of one week between two infusions may result in 
severe toxic reactions, but an interval of three weeks resulted in 
a good tolerance (Chapter XIV). 
Continuation of the CNS-prophylaxis with intralumbar injections of 
MTX, after finding a concentration of MTX of less than 
-8 k χ 10 mol/1 in plasma 18 hrs after the i.t, injection, may be 
possible, but the next i.t. dose should be postponed for at least 
3 weeks. In such cases high-dose MTX i.v. infusions may be 
preferred for the continuation of the CNS-prophy1axis (3). 
3. Especially In case of a fast elimination type of MTX from the CSF 
after the first i.t. injection of the CNS-prophylaxis 
(concentration of MTX in plasma 18 hrs after the first injection 
-8 is already less than k χ 10 mol/1), further i.t. administration 
of MTX appears to be without therapeutic value. 
I.v. Infusion of MTX followed by a rescue with reduced folates 
appears to be an effective and hardly burdening way to obtain an 
optimal concentration of MTX in the CSF. MTX passes the blood-brain-
barrier slowly. To obtain the minimum therapeutic concentration 
of MTX ( 5 x 1 0 mol/1) in the CSF during an 18-hours period, a 
high concentration level in plasma is necessary. A high dose-rate 
of MTX by i.v. infusion is required to maintain that particular 
concentrât ion. 
When acquiring an adequate and homogeneously distributed concen-
tration of MTX the function of the choroid plexus is very 
important. The choroid plexus produces about 25 ml of CSF per hour. 
In adults, with an amount of 150 ml of CSF, the CSF will be 
replaced every 6 hours. The influence of the cranial irradiation 
on the function of the choroid plexus is not known. To obtain a 
homogeneously distributed concentration of MTX in the CSF, the i.v. 
infusion has to be continued for 6 hours. Only at that time one 
may conclude that steady-state concentration of MTX in the CSF has 
started. In order to obtain a maximum inhibition of lymphoblasts 
the minimum therapeutic concentration of MTX must be maintained 
over a period of at least 18 hours, the continuation of the high-
dose MTX infusion has to be 2k hours. In the following chapter, 
the method of high-dose MTX infusions will be described. 
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The results of this method of CNS-prophylaxis will be developed 
further, taking into consideration the literature and our own 
studies of the animal model and of children with ALL. 
C h a p t e r X I V 
PHARMACOKINETIC STUDIES OF HIGH-DOSE MTX INTRAVENOUS INFUSIONS 
Introduction 
The cont inuous i .V . i n f u s i o n o f a s o l u t i o n w i t h MTX in ALL has been 
c a r r i e d out f o r the f i r s t t ime by D je rass ie (1967) ; n 1 0 p a t i e n t s w i t h 
f requent re lapses o f ALL. These f i r s t i n v e s t i g a t i o n s have been done 
w i t h o u t any form o f rescue w i t h reduced f o l a t e s and w i t h o u t a l k a l i z a -
t i o n of the u r i n e in these p a t i e n t s . In a l l p a t i e n t s a remiss ion had 
been a t t a i n e d , but the t rea tment was compl ica ted by severe s i d e - e f f e c t s 
l i k e e . g . haemorrhages. 
In a study o f mice bear ing L-1210 leukemia, Gold in (1955) showed t h a t 
the a d m i n i s t r a t i o n o f reduced f o l a t e s , a t an a p p r o p r i a t e i n t e r v a l f o l i o 
wing the MTX i n f u s i o n , caused a h ighe r c u r e - r a t e and an improvement o f 
the t h e r a p e u t i c index o f MTX in h i gh -doses . 
This obse rva t i on has been e f f e c t i v e l y a p p l i e d in c l i n i c a l s t u d i e s w i t h 
h igh-dose MTX, as ad juvant t rea tment o f osteosarcoma ( J a f f ë 1973, 
1977; Rosen 1975) and o f b ra i n - t umors (Rosen 1977, D je rass i 1977). 
R e l i a b l y documented exper iences w i t h h igh-dose MTX i . v . i n f u s i o n s in 
p a t i e n t s w i t h ALL are scarce : Wang (1976) , Freeman (1977) and Мое 
(1978) a d m i n i s t e r e d h igh-dose i n f u s i o n s , f o l l o w e d by CF-rescue in t he 
CNS-prophy1axis o f p a t i e n t s w i t h ALL a f t e r the complete r e m i s s i o n . 
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In these p r o t o c o l s the t o t a l dose o f MTX was 500 mg/m . 
The i n f u s i o n t ime was Ih h. Dur ing the i n f u s i o n o f MTX the drug was 
a l s o i n j e c t e d i n t r a t h e c a l l y ¿-2 hours a f t e r the s t a r t o f the i n f u s i o n . 
This combinat ion o f a d m i n i s t r a t i o n s by Freeman and by Мое seems t o be 
supported by p r e v i o u s s t u d i e s o f O l d e n d o r f ( 1 9 6 7 ) , who used C-sucrose 
in r a b b i t s and o f Bourke ( 1 9 7 3 ) , u s i n g C - f 1 u o r o u r a c i 1 in monkeys, 
r e p o r t i n g t h a t the c o n c o m i t a n t use o f i . t . t o g e t h e r w i t h i . v . i n j e c ­
t i o n s caused h i g h e r l e v e l s o f the drugs in the CSF and a more equal 
d i s t r i b u t i o n t h r o u g h o u t the CNS, than w i t h e i t h e r method s e p a r a t e l y . 
However, in our o p i n i o n the d i f f e r e n c e between the m o l e c u l a r 
w e i g h t o f f l u o r o u r a c i l and MTX (131 vs 45^) and sucrose and MTX 
(3^2 vs 45^) causes a more easy passage o f f l u o r o u r a c i l and sucrose 
over the b l o o d - b r a i n b a r r i e r than MTX. 
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Freeman (1977) r e p o r t s in h i s f i r s t study t h a t the c o n c e n t r a t i o n o f 
MTX in the CSF o f the lumbar sac is more than 10 mol w i t h i n 10 minu­
tes a f t e r s t a r t i n g the i . v . i n f u s i o n , p r i o r t o the i . t . a d m i n i s t r a t i o n 
2 
o f MTX. In these schedules MTX has been g iven i . t . (12 mg/m ) as w e l l 
a t the s t a r t o f the i n f u s i o n . The r e s u l t i n g c o n c e n t r a t i o n o f MTX in 
t h e CSF is 5 x 10 mol and at the end o f the i n f u s i o n s t i l l more than 
10 m o l . A d m i n i s t r a t i o n o f MTX i . t . o n l y , r e s u l t s in a c o n c e n t r a t i o n 
o f MTX in the CSF t h a t is 5 t imes lower. 
Having used t h i s method o f t r e a t m e n t , Freeman (1979) r e p o r t e d on 52 
p a t i e n t w i t h ALL ( i n c l u d i n g 13 p a t i e n t s w i t h a h i g h - r i s k type o f ALL). 
D u r i n g the f o l l o w - u p o f 22-68 months 15 c h i l d r e n (29%) r e l a p s e d , o f 
w h i c h 8 (151) in the CNS. 
In a s t u d y oy Green (1980), 3 t r e a t m e n t schedules have been compared: 
1. Three i . v . i n f u s i o n s o f h igh-dose MTX w i t h i . t . a d m i n i s t r a t i o n 
o f MTX d u r i n g the i n f u s i o n ( i n t e r v a l 3 weeks). 
2. C r a n i a l i r r a d i a t i o n o f 2400 Rad in 12 f r a c t i o n s t o g e t h e r w i t h 
5 i . t . i n j e c t i o n s o f MTX d u r i n g the i r r a d i a t i o n . 
3. S i x i . t . i n j e c t i o n s d u r i n g 3 weeks. 
In s t a n d a r d - r i s k ALL the d i s e a s e - f r e e s u r v i v a l appeared t o be h i g h e r 
in the group t r e a t e d a c c o r d i n g t o 1. 
However, c r a n i a l i r r a d i a t i o n t o g e t h e r w i t h i . t . MTX (2) in p a t i e n t s 
w i t h CNS-relapse and in p a t i e n t s w i t h h i g h - r i s k ALL.appeared to be 
b e t t e r than both o t h e r methods (1 and 3 ) . 
In the s t u d i e s o f Мое (1978, 1980, 1981), u s i n g the same CNS-prophy-
l a x i s as Freeman, w i t h h i g h - d o s e MTX i . v . i n f u s i o n s and i . t . MTX, the 
r e l a p s e s o f c h i l d r e n w i t h ALL due t o CNS-leukemia are very few: o n l y 
3 o u t o f a group o f 66 c h i l d r e n s u f f e r i n g from ALL r e l a p s e d on account 
o f an i n v a s i o n o f leukemic c e l l s i n t o the CNS (Мое 1980, 1981). 
These w o n d e r f u l r e s u l t s are in c o n t r a s t w i t h those o f Freeman (1979) 
and Green ( 1 9 8 0 ) , and a l s o w i t h o u r own r e s u l t s (Chapter I V ) . 
An i m p o r t a n t d i f f e r e n c e in the t r e a t m e n t p r o t o c o l o f Мое, compared 
w i t h the o t h e r t r e a t m e n t p r o t o c o l s , is the use o f k i . t . i n j e c t i o n s 
2 
o f MTX (12 mg/m ) d u r i n g the f i r s t f o u r weeks o f the r e m i s s i o n induc­
t i o n t r e a t m e n t . The c o n c e n t r a t i o n s o f MTX in the CSF o b t a i n e d by the 
Norv.-egian study group ( B r a t l i d 1978) appear t o be in agreement w i t h 
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the c o n c e n t r a t i o n s o b t a i n e d by Freeman ( 1 9 7 7 ) : the mean c o n c e n t r a ­
t i o n in plasma was 2.3 x 10 m o l / ] , a n d in the CSF at the t ime o f 
d i s c o n t i n u a t i o n o f the i n f u s i o n 2.0 χ 10 m o l / l . 
The d i f f e r e n c e in p r o g n o s i s o f the method o f CNS-prophy1 a x i s o f Мое 
and t h a t o f Freeman, r e q u i r e s p h a r m a c o k i n e t i c study o f the ways o f 
h igh-dose MTX i n f u s i o n s as a method o f CNS-prophy lax is . 
Because i t is i m p o s s i b l e t o study the d i f f e r e n c e s in the c o n c e n t r a t i o n 
p r o f i l e s o f MTX in plasma and CSF a c c u r a t e l y in c h i l d r e n d u r i n g the 
i . v . i n f u s i o n w i t h MTX, we decided t o analyse the c o n n e c t i o n w i t h the 
concomitant c o n c e n t r a t i o n p r o f i l e s in the animal-model f i r s t . 
Studies of the phavmaookinctios of high-dose MTX in plasma and CSF 
in goats 
In 3 f u l l y grown goats (mean w e i g h t 3^ kg) b lood and CSF-samples have 
been c o l l e c t e d a c c o r d i n g t o the methods d e s c r i b e d b e f o r e t o measure 
the MTX-concentrat i o n . 
MTX has been a d m i n i s t e r e d by i .V. i n f u s i o n s . The i n f u s i o n t imes have 
been 3, 6 and 24 hours w i t h a dose o f 300, 500 and 1000 mg. The dose 
r a t e s (mg/kg/h) were 2 . 7 8 , 2.5 and 1.25. In Table 25 the f i n d i n g s o f 
MTX c o n c e n t r a t i o n in these 3 animals have been summarized. 
Animal 
Dose (mg) 
Duration of Che infusion (h) 
Dose rate (mg/kg/h) 
Mean maximum concentration in plasna 
( χ IO" 6 mol/l) 
Mean maximum concentration in lumbar CSF 
( χ ID" 6 mol/l) 
Ratio of MTX concentration plasma/CSF 
Time of reaching maximum concentration 
In the CSF (h) 
Half life time in plasma (h) 
Hal f li fe time in CSF (h) 
1 
300 
3 
2 78 
15 
ι о 
Hl 
3 
3 
li 
2 
500 
6 
2 5 
12 
2 Ц 
5 
Ц 
5 1 
5 ι 
3 
1000 
2Ί 
1 25 
3 7 
0 16 
25 
8 
6 6 
6 1 
Table 25 F i n d i n g s d u r i n g and a f t e r i . v . i n f u s i o n s o f MTX in plasma 
and CSF in g o a t s . In none o f the 3 animals 7-OH-MTX has 
been d e t e c t e d 
In Fig. 19 the concentration profiles of MTX in plasma and CSF of 
the goat receiving 1000 mg of MTX in 2^ hrs are calculated: 
mol / 
io P. ... ·-
10'-
^ Й С И 
F tting crt Ihe cone prof e il 
. detected cone π ρ 
о detected cone η CSF 
Dose 1000mg / 24 noues 
Fig. 19 Concentration profile of MTX in plasma and CSF in a goat 
treated by high-dose MTX infusion (1000 mg in 2A hrs) and 
the fitting model calculation. 
However, this compartment model does not fit the detected concentra­
tion profiles entirely. More complicated calculations seem to be re­
quired to fit the profiles of MTX in plasma and CSF completely. 
Up to now we have not been able to find the exactly fitting model of 
high-dose MTX i.v. infusions in the CSF. 
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The parameters c a l c u l a t e d from t h i s model are 
k 1 2 = 0.20 h "
1 
k 2 1 = 0.13 h "
1 
к = 0.004 h " 1 
к = 0.17 h " 1 
к ^ = 4.95 h " 1 
V1 = 3.86 ι 
From these f i g u r e s i t may be concluded t h a t a l l r e c i p r o c a l t i m e - c o n ­
s t a n t s have about t h e same v a l u e , but the r e c i p r o c a l t i m e c o n s t a n t k.... 
is very s m a l l . Th is va lue r e p r e s e n t s the t r a n s p o r t o f MTX from the 
b l o o d i n t o the CSF and d e s c r i b e s the n a t u r e o f the b l o o d - b r a i n (CSF)-
Ь а т і е г . Another remarkable v a l u e is the small volume o f d i s t r i b u t i o n 
o f MTX in the c e n t r a l compartment o f the g o a t . 
I t may be concluded ( a t l e a s t f o r the animal-model) t h a t a f t e r a 24-
hours i . v . i n f u s i o n o f MTX an e q u i l i b r i u m is o b t a i n e d between the 
c o n c e n t r a t i o n o f MTX in the CSF and the c o n c e n t r a t i o n o f MTX in p l a s ­
ma. I t is not a l l o w e d however, t o put t h a t a " s t e a d y - s t a t e " c o n c e n t r a ­
t i o n has been reached. T h e o r e t i c a l l y a s t e a d y - s t a t e c o n c e n t r a t i o n can 
be o b t a i n e d o n l y a f t e r an i n f u s i o n p e r i o d o f 4 t imes the h a l f - l i f e 
t ime o f a d r u g . The h a l f - l i f e t ime o f MTX in plasma in o u r e x p e r i m e n t s 
is 6 . 6 . h. 
The maximum c o n c e n t r a t i o n o f MTX in the CSF i s reached l a t e r than in 
plasma. The d i f f e r e n c e in t ime o f these two maxima is 6-8 hours 
( F i g . 1 9 ) . 
In c h a p t e r V we have assumed t h a t in the case o f ALL, t h e t h e r a p e u t i c 
c o n c e n t r a t i o n o f MTX (5 x 10 mol/1) should be m a i n t a i n e d d u r i n g at 
l e a s t 18 hours in o r d e r t o o b t a i n an i r r e v e r s i b l e i n h i b i t i o n o f the 
DNA-synthesi s in l y m p h o b l a s t s . From our o b s e r v a t i o n s on t h e b e h a v i o r 
o f MTX in the CSF d u r i n g i . v . i n f u s i o n , we may conclude t h a t the d u r a ­
t i o n o f an i n f u s i o n w i t h MTX,in o r d e r t o o b t a i n t h e minimum t h e r a p e u ­
t i c c o n c e n t r a t i o n in the CSF w i l l have t o be 18 + 6 = 24 h o u r s . 
110 
High-dose MTX ъп ohildren suffering from osteosarcoma 
In two boys with an osteosarcoma of the right femur high-dose MTX i.v. 
infusions have been administered as adjuvant treatment. 
In patient 1, the treatment consisted of 3 i-v. infusions of each 
3000 mg of MTX, followed by CF-rescue. Each infusion time was 6 hours. 
The maximum concentrations of the three infusions showed only small 
variations. In all samples the metabolite, 7"0H-MTX, has been detected 
(Table 26). 
In patient 2, two i.v. infusions of MTX have been administered. The 
infusion time was again 6 hours. The doses of the 2 infusions diffe­
red: the first infusion had a dose of 5700 mg, the second one of 
7500 mg. In Table 26 the most important data on both patients are 
g i ven. 
Pat lent 
Inrubion no 
Day of treatment 
Duration of the infusion (h) 
Dose (mg) 
Dose rate (mg/kg/h) 
METHOTREXATE 
Maxi mum concentratior 
( χ 10" 6 mol/l) 
7-OH-MTX 
Maximum concentration 
( χ l(f6 mol/l) 
Time of reaching maximum 
concentration (h) 
1 
1 
! 
6 
3000 
16 0 
200 
2 1 
e 
2 
3 
6 
3000 
16 0 
Ί50 
2 6 
7 
3 
12 
6 
3000 
16 0 
300 
2 6 
3 
2 
1 
1 
6 
5700 
31 7 
ΊΟΟ 
9 5 
9 
2 
III 
6 
7500 
hi 7 
3800 
9 8 
8 
Table 26 High-dose MTX infusions in 2 pat. with osteosarcoma 
It is remarkable that an 1.3 times increase of the dose rate results 
in a tenfold increase of the concentration of MTX in plasma, even 
after an interval of 14 days between the two subsequent infusions. 
The metabolite, 7-0H-MTX has been detected in all infusions. With the 
first infusion (Table 26) the increase of the concentration of the 
metabolite is rather slow. 
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Wi th l a t e r i n f u s i o n s i n t o the same p a t i e n t the increase is more 
r a p i d l y and reaches a maximum va lue as q u i c k l y as MTX i t s e l f . 
A f t e r d i s c o n t i n u a t i o n o f the i n f u s i o n the c o n c e n t r a t i o n o f 7"0H-MTX 
may increase d u r i n g a few hours and the e l i m i n a t i o n appears to be 
somewhat s lower than tha t o f MTX. 
The use o f h igh-dose MTX- in fus ions r equ i r es a number o f p recau t i ons 
to prevent se r i ous t o x i c r e a c t i o n s . These c recau t i ons are e x t e n s i v e l y 
desc r ibed by Chan (1977) and Bleyer (1978) , and we s h a l l r e f e r to 
these s t u d i e s . 
High-dose MTX infusions in children with ALL and the concentration 
of MTX in the CSF. 
The f requen t t o x i c i t y o f the usual p ro toco l o f CNS-prophy1axis in 
c h i l d r e n w i t h ALL (2500 Rad c r a n i a l i r r a d i a t i o n and 5 subsequent i . t . 
i n j e c t i o n s o f MTX) and the occur rence o f the l a t e sequelae mentioned 
in the l i t e r a t u r e , l i k e ce rebra l a t r o p h y , l e a r n i n g d i s t u r b a n c e s , some-
t imes o c c u r r i n g many years a f t e r the t r e a t m e n t , urge to look f o r 
another method o f CNS-prophylaxis o f b e t t e r o r at l eas t the same e f f i -
cacy. T ied to the r i g i d t r i a l p r o t o c o l o f the SNWLK the p o s s i b i l i t i e s 
to d e v i a t e from the method o f CNS-prophylaxis p r e s c r i b e d are l i m i t e d . 
In I* c h i l d r e n w i t h ALL the CNS-prophy 1 ax i s has been executed by h i g h -
2 
dose MTX i . v . i n f u s i o n s w i t h i . t . a d m i n i s t r a t i o n o f MTX ( I Z j mg/m ) 
2 
and Predn iso lon (125 mg/m ) h a l f an hour p r i o r to the d i s c o n t i n u a t i o n 
o f the i n f u s i o n . 
S ix hours a f t e r the d i s c o n t i n u a t i o n o f the i n f u s i o n a rescue w i t h 
l e u c o v o r i n , by way o f i . v . i n f u s i o n o f a dose equal to 5% o f the dose 
o f MTX, is g iven d u r i n g two hours . 
A f t e r the i n f u s i o n o f l eucovo r in 5 doses o f c i t r o v o r u m f a c t o r 
(15 mg o r a l l y ) have been admin i s te red every s i x hou rs . 
One day be fo re the i n f u s i o n o f MTX,sodi um b i ca rbona te (6 dd 1 g) is 
adm in i s t e red t o the p a t i e n t in o rde r to o b t a i n a u r i n a r y pH o f more 
than 7· The a d m i n i s t r a t i o n o f sod i urn b i ca rbona te con t inues u n t i l 2k 
hours a f t e r the l as t dose o f c i t r o v o r u m f a c t o r . 
Dur ing and a f t e r the i n f u s i o n blood is sampled f o r pharmacok ine t i c 
s t udy . 
112 
Before MTX ¡s injected into the spinal canal, CSF is sampled for 
detection of MTX, in order to get an impression of the concentration 
of MTX in the CSF after long-term ¡.v. infusion only. 
The purpose of this study is the examination of the concentration 
profile of MTX in plasma and the possible changes it causes in the 
concentration profile in subsequent infusions. The i.v. infusion may 
reach a therapeutic value in the CSF and could be used as a method of 
CNS-prophylaxis. This value is obtained by a "steady-state" concentra-
tion of MTX in the CSF of 5 x 1U- mol/1 during at least 18 hours. 
Because frequent sampling of CSF is usually impossible, the concentra-
tion of MTX, determined just before the i.t. injection of MTX at the 
time of discontinuation of the infusion, is considered to be a 
reflection of the "steady-state" concentration of MTX in the CSF 
during the i.v. infusion. 
The results of this study have been summarized in Table 27. 
All patients show some differences in the method of treatment. 
In patient 1, the 3 infusions have been given with intervals of 14 
days. Some peak concentrations are observed due to irregularities in 
the infusion rate. This can be seen more clearly in patient 2. In 
this patient however, the interval between the first and the second 
infusion was only 1 week. After the second infusion the boy developed 
a severe toxicity (fever, marrow depression, mucositis of the mouth 
and d i arrhoea) . 
In patient k the very high dose of MTX has not resulted in a "steady-
state" concentration in plasma, and the concentration in the CSF will 
be maintained for a period too short to result in a therapeutic value. 
The concentration of MTX in the CSF shows a gradual decrease, resulting 
in an increased ratio plasma/CSF. The same phenomenon can be observed 
with 7-OH-MTX. This can be explained by the increasing exsorption of 
MTX from the CSF, due to the ¡ntralumbar administration of MTX by the 
time of discontinuation of the i.v. infusion. One can even imagine 
that the quantity of MTX entering the CSF by the infusion will be 
exsorbed more rapidly too. In that case it may be concluded that the 
¡ntralumbar administration of MTX during the infusion of high-dose 
MTX with the purpose of augmenting the concentration of MTX in the 
И З 
CSF o b t a i n e d by the i n f u s i o n is c o n t r a - i n d i c a t e d . 
In c o n c l u s i o n we may say t h a t i t appears t h a t the use o f h igh-dose 
MTX i . v . i n f u s i o n s f o r CNS-prophy1 a x i s is f e a s i b l e . The u n f u s i o n 
p e r i o d should be at l e a s t 2k h o u r s . The i n t e r v a l between 2 subsequent 
i n f u s i o n s s h o u l d be in our o p i n i o n , at l e a s t 14 days, in o r d e r t o 
avo id t o x i c i t y ( p a t . 2 Table 2 7 ) . 
Table 27 High-dose MTX i n f u s i o n s in 4 c h i l d r e n w i t h ALL 
The c-itrovomm factor rescue (CF-rescue). 
Since reduced f o l a t e s compete e f f e c t i v e l y w i t h MTX f o r t r a n s p o r t i n t o 
mammalian c e l l s , p a r t i c u l a r l y in human marrow and g a s t r o i n t e s t i n a l 
c e l l s , CF may be a b l e t o b l o c k the M T X - i n f l u x i f the r a t i o o f e x t r a ­
c e l l u l a r CF t o MTX is h i g h . Moreover, the e n t r y o f CF f a c i l i t i e s the 
e f f l u x of MTX out o f c e l l s by a c o u n t e r t r a n s p o r t mechanism. Once i n ­
s i d e the c e l l , CF i s r a p i d l y m e t a b o l i z e d i n t o o t h e r f o l a t e s coenzymes 
(Nixon 1973). The net r e s u l t o f these events is the r e l e a s e o f MTX-
i n h i b i t i o n o f p u r i n e - and TMP-biosynthesi s , an increase in the poo 1-
s i z e o f reduced f o l a t e s and a decrease in f r e e o r excess MTX in the 
c e l l . This r e s u l t s in the recovery o f ONA-synthesi s. 
m 
S t u d i e s o f normal human marrow (Hryn iuk 1969, Chabner 1973) i n d i c a t e 
t h a t p r e - t r e a t i n g c e l l s w i t h h igh-dose MTX, and s u b s e q u e n t l y adding 
CF s t i l l in the presence o f MTX, a t e n f o l d excess o f CF is r e q u i r e d 
f o r e f f e c t i v e r e v e r s a l o f the DNA-synthesi s . The process o f recovery 
o f the DNA-synthesi s is c a l l e d " r e s c u e " . The d u r a t i o n o f the CF-
rescue should be s u f f i c i e n t to cover the l e n g t h o f t ime t h a t the 
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c o n c e n t r a t i o n o f MTX in b l o o d exceeds 10 mol/1 (Chabner 1973)· The 
longer the de lay b e f o r e b e g i n n i n g w i t h the CF-rescue a f t e r h igh-dose 
MTX a d m i n i s t r a t i o n , the less e f f e c t i v e the rescue may be. When the 
CF-admiη i s t r a t ion is delayed f o r more than 42-48 h o u r s , f o l l o w i n g the 
h igh-dose MTX, severe and i r r e v e r s i b l e t o x i c i t y may o c c u r (Mead 1963, 
B e r t i n o 1977)· The moment and method o f a d m i n i s t r a t i o n ( i . V . o r o r a l ­
l y ) o f reduced f o l a t e s ( l e u c o v o r i n , c i t r o v o r u m f a c t o r ) is sometimes 
c o n t r o v e r s i a l in the l i t e r a t u r e . E a r l y a d m i n i s t r a t i o n o f reduced f o ­
l a t e s may be i n e f f e c t i v e as a rescue. The h i g h c o n c e n t r a t i o n o f MTX 
w i l l p r e v e n t the c o m p e t i t i v e a c t i v i t y o f the reduced f o l a t e s , unless 
t h e c o n c e n t r a t i o n o f the reduced f o l a t e s is 10 t imes h i g h e r than the 
c o n c e n t r a t i o n o f MTX. Rescue at the moment o f d i s c o n t i n u a t i o n of the 
i n f u s i o n w i t h MTX r e q u i r e s an e x t r e m e l y h i g h dose o f l e u c o v o r i n and 
one may wonder whether a s h o r t de lay between the d i s c o n t i n u a t i o n 
of t h e MTX- infus ion and the i n i t i a t i o n o f the r e s c u e - t r e a t m e n t could 
be o f p r o f i t . Most o f the l i t e r a t u r e about r e s c u e - t r e a t m e n t s does 
not o f f e r a s i m p l e and p r a c t i c a l method o f rescue w i t h l e u c o v o r i n 
f o l l o w i n g an i n f u s i o n o f h igh-dose MTX. Sauer (I98O) o f f e r s a method 
o f c a l c u l a t i o n o f the dose o f l e u c o v o r i n a c c o r d i n g t o the c o n c e n t r a ­
t i o n o f MTX, determined at the moment o f d i s c o n t i n u i n g the i n f u s i o n 
w i t h MTX. Th is c a l c u l a t i o n however, is not in agreement w i t h the 
p h a r m a c o k i n e t i c parameters o f MTX and l e u c o v o r i n we have found. 
We s t u d i e d the c o n c e n t r a t i o n p r o f i l e o f 5 - m e t h y 1 - t e t r a h y d r o f o l a t e , 
t h e main and a c t i v e m e t a b o l i t e o f l e u c o v o r i n and c i t r o v o r u m f a c t o r , 
in plasma and u r i n e in a t w e l v e - y e a r s - o l d boy. Leucovor in has been 
a d m i n i s t e r e d by i . v . i n f u s i o n d u r i n g an i n f u s i o n p e r i o d o f 3 hours 
( F i g . 2 0 ) . 
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5 - M e t h y l - t e t r a h y d r o f o l a t e appears t o be e l i m i n a t e d a c c o r d i n g t o a 
one-compartment model. From t h i s model the p h a r m a c o k i n e t i c 
parameters can be c a l c u l a t e d : 
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F i g . 20 C o n c e n t r a t i o n p r o f i l e o f 5-Me-THFA in plasma in a p a t . d u r i n g 
and a f t e r i . v . i n f u s i o n o f 200 mg l e u c o v o r i n in 3 h r s . 
V = 5.13 1 ; t = 5.97 h; k e ] = 0.12 h " ' ; 
r e l a t i v e t o t a l body c l e a r a n c e = 0.053 1/h/kg; A.U.C. = 
336.2 χ 10-7 m o l . h / 1 . 
A c c o r d i n g t o these parameters we can c a l c u l a t e the dose o f l e u c o v o r i n 
r e q u i r e d f o r the rescue t r e a t m e n t a c c o r d i n g t o the c o n c e n t r a t i o n o f 
МТл at the moment the rescue has t o be s t a r t e d ( e q . 5 ) : 
Relat i ve 
cone total body 
Dose of leucovorin = 10 χ 'χ Mol. x 0.001
 x x
( ].e 
(mg/kg/h) M T X weight clearance 
•k ..t 
e 1 ν 
The ratio of the molecular weight of leucovorin and methotrexate is 
assumed to be 1. 
In practice the concentration of MTX determined at the moment of star­
ting the rescue treatment should be multiplied by 5.¿t χ 10 2 to obtain 
the dose of leucovorin (mg/kg/h). 
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Sauer (I98O) advises to infuse the calculated dose of leucovorin in 
15 minutes every 6 hours. A new calculation of the dose of leucovorin 
has to be made after four doses, again according to the concentration 
of MTX in the plasma at that moment. The rescue treatment can be stop-
-8 
ped when the concentration of MTX has become less than 5 x 1 0 mol/1. 
A small dose of CF (15 mg) produces a rather high concentration of its 
main and active metabolite, 5"iTiethy 1 -tet rahydrofol ate (5-Me-THF) . 
Although the concentration of CF in serum decreases to less than 
1.0 χ 10 mol/l in 't hours, the concentration of 5"Me-THF in plasma 
-k hours after the administration of CF- persists at more than 
1.0 χ 10 mol/1. This concentration is maintained during at least 6 
hours (Herbert 1962, Nahas I969). 
It is assumed that CF or 5"Me-THF passes the blood-CSF barrier only 
in an insignificant way( Nanas I9t>9). By treating children during the 
CNS-prophyIaxis with small doses of CF, a number of acute side-effects 
of MTX may be prevented wichout diminishing the required actions of 
MTX on leukemic cells in the subarachnoidal space (Goldin 1955, 1966). 
This procedure is cal led "CF-protection" (Hi I 1 1977). 
More knowledge of the competition of high concentrations of MTX with 
reduced folates is necessary to appreciate the efficacy of CF-rescue 
and protection procedures in the treatment schedules with MTX. 
The concentration profiles of MTX during and follouing various methods 
of i.v. infusion of 500 mg MTX and ooncomiLanl i.t. injection of MTX. 
Calculating the concentration profile of MTX during and following i.V. 
infusion of ^ 80 mg MTX (dose rate = 20 mg/h) together with an i.t. 
injection of 7 mg of MTX, at the moment of discontinuation of the in­
fusion, it appears that the minimum therapeutic concentration of MTX 
in the CSF is not achieved during the infusion and only for a very 
short time following the i.t. injection (Fig.21). The values of the k's 
are according to the values of Fig. 19 and ρ ι ijg 
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Fig. 21 Calculation of the concentration profile of MTX in plasma 
and CSF during and after i.v. infusion of '•SO mg MTX in 
2k hrs and i.t. injection of MTX (7 mg) at the moment of 
discontinuation of the infusion. 
Following the hematologic remission induction treatment with prednison, 
vincristin and asparaginase, Freeman (1977) and Мое (1978) administered 
three courses of i.v. infusions with MTX at three-weekly intervals. 
2 
MTX was administered by i.v. injection (170 mg/m ), as loading dose, 
2 ? 
followed by an i.v. infusion of 330 mg/m during Ik h. MTX (12 mg/m ) 
was also intrathecally injected at j " 2 h after the beginning with the 
MTX-infusion. A CF-rescue followed 2k h after the discontinuation of 
the infusion with MTX by a üingle i.v. dose of leucovorin (12 mg/m ) . 
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In accordance w i t h our c a l c u l a t i o n s (F ig .21 ) we were s c e p t i c a l about 
the e f f i c a c y o f t h i s method as CNS-prophy1axis. 
We had the o p p o r t u n i t y to study moa i f i cat ions o f the Freeman-protocol 
in a t e n - y e a r s - o l d boy w i t h ALL. This s tudy was d iscussed w i t h both 
the paren ts and the p a t i e n t be fo re the t rea tmen t was begun. Both pa-
ren ts and the boy were w i l l i n g t o g ive t h e i r f u l l c o - o p e r a t i o n . 
The th ree ¡ .v . i n f u s i o n s were admin i s te red as o u t l i n e d in Table 28. 
Infus ion 
1 
2 
3 
Day of 
treatment 
1 
21 
hi 
Bolus 
inject ion 
at time 0 
(mg) 
170 
170 
-
I ν infusion 
(2Ί h) 
(mg) 
330 
330 
50C 
Time of CF-rescue 
after ιntιt at ion 
ι ν infusion 
(h) 
1*8 
ii8 
hS 
Τ ime of ι t 
injection after 
ι π ιtι at ι on ι ν 
ιnfus ion ) (h) 
2 
2Ί 
2Ί 
) I t injection of MTX (12 mg) and Prednisolon (12; mg) 
Table 28 Administration-scheme of MTX in a pat. with ALL, used as 
CNS-prophy1axi s 
During and after the first infusion blood samples have been taken to 
detect MTX and its metabolites. CSF samples have been collected two 
hours after the beginning with the infusion, just before the i.t. in­
jection of MTX and Prednisolon, and at 2k, 30, AS and 60 hours after 
starting the first infusion. With the next two infusions, CSF samples 
have been collected only prior to the i.t. injection of MTX. One minu­
te after the i.t. injection of MTX in the first and the second course, 
a few drops of CSF were collected. 
Results. 
Cide-effeats owing to MTX in the patient 
A l r e a d y a f t e r the f i r s t course r a t h e r severe mucosa l e s i o n s in the 
mouth haven been o b s e r v e d . This t o x i c s i d e - e f f e c t o c c u r r e d a f t e r 
each i n f u s i o n , d e s p i t e the rescue w i t h c i t r o v o r u m f a c t o r ( i . v . ) 
Infusion 1 
Bolus inject on 1 7 0 m g l тс С 
К infusion 3 3 0 m g during 24 h 
Leucovorin 12 m g iv t i m ç 4 8 h 
11 infection 12 m g t ime 2 h 
Concentrat ion profi le Ol MTX m plasma 
dav 1 
Intubon 2 
Во us inject on iTOmc l me О 
Iv infusion 3 3 0 m g dur"ης 24 f 
Leucovorin 12n-tg iv l ime 4Θ h 
) t injeci ion I 2 m j t i m e 2 3 ! > n 
M T X 
- - 7 O H M T X 
16 2 Ί 32 4 0 4Θ 5 6 6 4 hours 
inluworSOOmgWTI | 
/\^^ 
/ " 
1 
i 
1 5 x 1 0 7 m o i M 
LV 
• 
Infusion Э 
No bolus n j e t t o n 
Iv nfus on SOOmg dLTing 24 h 
L e i x c v o r n ^ m g i v l i m e 4 П 
i t j n j e c t O n 1 2 m g urne 23 5 n 
M T X 
7 OH MTX 
1 
1 
ν 
\ \ 
ƒ MTX n C S F \ 
1 
¡ Ccncenlrat ion p rod i * ο ι MTX in plasma 
1 day 42 
i 
16 24 32 4 0 4Θ Hours 16 24 32 4 0 4Θ h o u r s 
F i g . 22 The c o n c e n t r a t i o n p r o f i l e s o f MTX and 7ΌΗ-ΜΤΧ in plasma 
d u r i n g 3 subsequent i . v . i n f u s i o n s o f MTX ( t o t a l dose = 
500 mg) and i . t . i n j e c t i o n o f MTX (12 mg) d u r i n g the i n f u s i o n s 
in a p a t . wi t h ALL. 
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On account of this observation it may be concluded that the rescue 
prescribed by Freeman is insufficient in our patient. 
Concentration profiles. 
The concentration profile of MTX and 7"0H-MTX in plasma of the three 
different courses ¡s illustrated by Fig.22. Although the i.v. bolus 
injection (infusion 1 and 2) of one third of the total dose of MTX 
results in a high concentration of MTX in plasma, the period of time 
of that concentration is short (2 h). The mean maximum concentration 
during the first infusion is 3 times less than the mean maximum con-
centration obtained by the 3rd course, without i.v. bolus injection 
of one-third of the total dose (5.h χ 10 mol/1 vs 1.7 x 10 mol/l). 
The mean maximum concentration of 7"0H-MTX however, is the same in the 
first 2 courses {2.h χ 10 mol/l vs 2.6 χ 10 mol/1)· The production 
of 7ΌΗ-ΜΤΧ in the first course however, is more rapid than in the 
third course. The duration οΓ a concentration of MTX over the level 
of 5 x 10 mol/1 is different in first and third course: 
the first course shows a duration of 30 hours, the third course of 39 
hours. The bolus injection of one-third of the dose does not improve 
the concentration level of MTX during the 2k hours infusion and can­
not be considered to be a "loading-dose." 
The concentration profile of MTX in the second course is remarkably 
different from the first and third course: the concentration profile 
rather appears to be an i.v. bolus injection. This unexpected concen­
tration profile cannot be explained at this stage of the study. 
The mean maximum concentration of 7"0H-MTX in the second course is 
about the same as in the first course (3.2 χ 10 mol/1) but the eli­
mination of 7"0H-MTX is slower than in the first course. 
The concentration profile of MTX in the CSF (Fig.23) shows that the 
contribution of the infusions to the concentration level in the CSF 
is very small and of no value indeed. The ratio of the mean concentra­
tion of MTX in plasma to CSF is 33 ag<ain. The minimum therapeutic 
concentration can in no way be reached in the CSF by these infusions. 
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о infusion 2(day21 ) 
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Fig. 23 Possible concentration profile of MTX in CSF during and after 
i.v. infusion (500 mg) and i.t. injection (12 mg) of MTX in 
a pat. with ALL. 
Following the intralumbar administration of MTX (12 mg) the concentra-
tion in the lumbar sac is very high (1.36 χ 10 mol/1). By this concen­
tration we can calculate the distribution volume in the CSF of the lum­
bar sac to be 19.^ ml. From this small reservoir, MTX is transported 
to the other locations of the subaracnoidal space and to the blood. 
In the lumbar sac the concentration of MTX reaches the minimum thera­
peutic concentration 48 hours after the injection. Assuming that only 
5% of the intratheca!ly injected MTX reaches the large cisterns of 
the subarachnoidal space (p. 76 ) , the quantity of onjected MTX could 
be just sufficient to maintain the minimum therapeutic concentration 
during 18 hours at this place. However, subsequent i.t. administrations 
of MTX result in an increasing exsorption of MTX from the CSF. 
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The i.t. injection of MTX at the time of initiation of the infusion 
with MTX according to the protocol of Freeman and Мое (Fig.23) demon­
strates that the concentration of MTX in the CSF remains more than 
5 x 1 0 пк>1/1 during ^8 hours. This cannot be explained by either the 
i.t. injection, or by the i.v. infusion only. Apparently the i.t. 
injection at the time of beginning the i.v. infusion results in a 
delayed elimination of MTX from the CSF, maybe because MTX in the CSF 
cannot be exsorbed against the higher concentration In plasma. We can­
not yet understand this phenomenon on pharmacokinetic grounds. 
The good results of Мое, obtained by this method of CNS-prophy1 axis, 
should be considered to be the result of both early i.t. administration 
of MTX during the hematologic induction treatment of children with ALL, 
and the adequate treatment of the sanctuaries by the subsequent infu­
sions with relative small doses of MTX. 
Calculation of the dose-rate of MTX 
The dose-rate of MTX in high-dose MTX infusions in order to obtain a 
desired concentration of MTX in the CSF depends on the ratio of the 
mean maximum concentration of MTX in plasma and in CSF, the total body 
clearance (ty') of MTX, the weight of the child and the infusion period. 
Theoretically the dose rate is also depending on the rate of elimina-
-k . t 
tion of MTX according to (1-е el" ), but this value approaches to 
1 when it approaches infinity (in practise, when t = 't χ t,). The dose­
rate of MTX in order to obtain the minimum therapeutic concentration 
of MTX in the CSF can be calculated according to eq.6: 
» ^ desired Plasma/ relative .. . 
Dose-rate __,. „ _ , , , Mol ι L\ 
——т.—TT— =conc. χ CSF χ total body χ . . (eq.6) 
g/kg/h . ' weight ч in CSF ratio clearance a 
The parameter "relative total body clearance" characterizes the clearing 
of a hypothetic plasma volume of a drug. It comprises not only the re­
nal excretion, but all other pathways of elimination and metabolism, 
and may be expressed by 
relative V » d o 5 e 1/h/kg) 
AUC χ body weight 
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In Table 29 the total body clearances, AUC and distribution volumes 
of 10 i.v. high-dose MTX infusions have been calculated 
Infusion 
1 
2 
3 
k 
5 
6 
7 
8 
9 
10 
mean 
Infus ior 
t ime 
(h) 
2Ί 
2^ 
21» 
6 
21i 
2Ί 
21) 
2i< 
2!. 
21* 
Body 
weight 
(kg) 
1(1 
1(2 
1(0.3 
21». 0 
69.9 
62.2 
69.2 
28.0 
28.0 
28.0 
Dose 
rate 
mg/kc 
/h " 
2.03 
1.98 
2.06 
6.95 
1.79 
2.01 
1.80 
0.7* 
ОЛЬ 
0.7k 
Area 
under 
the curve 
no).h/1 
(хЮ"*1) 
9.88 
10.13 
7.56 
3.63 
8.60 
7.76 
12.20 
0.87 
1.16 
1.63 
é.ìk 
Total body 
с 1 earance 
l/h 
4.35 
5.82 
6.06 
7.68 
8.51 
δ . Μ 
12.71 
9.ι<9 
6.75 
7.12 
D i s t r i b u í i o r 
vo 1 urne 
1 
6.02 
11.00 
9.1*8 
15.69 
13.61 
21.25 
8.57 
46.75 
1.1.36 
25.35 
19.91 
Relat ive 
t o ta l body 
clearance 
1/h/kg 
0.108 
0.104 
0.144 
0.253 
0.110 
0.153 
0.078 
O.454 
0.338 
n . j l i l 
O.198 
Table 29 Some pharmacokinetic parameters in high-dose MTX infusions 
in chi]dren 
By using the mean values of the parameters we can calculate the dose 
rate of MTX to obtain the minimum therapeutic concentration 
(5 x 10 rnol/l) in the CSF by high-dose infusion only to be 
2.3І mg/kg/h. 
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СопаЪивгоп 
Only by r e a c h i n g the minimum t h e r a p e u t i c c o n c e n t r a t i o n o f MTX 
(5 χ 10 mol/1) in the CSF d u r i n g a p e r i o d o f 18 h o u r s , an e f f i c a ­
c i o u s a n t i l e u k e m i c a c t i o n o f MTX can be e x p e c t e d . In o r d e r t o reach 
t h i s va lue by ¡ .v . i n f u s i o n . a dose- ra te of at l eas t 2 .31 mg/kg/h of 
MTX is r e q u i r e d . Concomitant i . t . i n j e c t i o n o f MTX w i l l r e s u l t in 
a very high c o n c e n t r a t i o n in the CSF f o l l o w i n g the f i r s t i . t . dose. 
However, by repea t i ng the i . t . a d m i n i s t r a t i o n in the subsequent 
i n f u s i o n s , the c o n c e n t r a t i o n o f MTX w i l l be less than a f t e r the f i r s t 
i n f u s i o n , due to an increase o f the e x s o r p t i o n of MTX. This is shown 
by the increase o f the r a t i o o f the mean maximum c o n c e n t r a t i o n o f MTX 
in plasma and CSF. This phenomenon makes i t d i f f i c u l t t o c a l c u l a t e 
e x a c t l y the dose o f MTX acco rd ing t o eq 6. We used the mean r a t i o o f 
plasma/CSF c o n c e n t r a t i o n of 10 i n f u s i o n s ( 5 1 . 3 , w i t h a range of 30 -81) . 
The increased e x s o r p t i o n o f MTX from the CSF reduces the value o f both 
i . v . and i . t . a d m i n i s t r a t i o n . The i . t . i n j e c t i o n o f MTX by the t ime 
o f d i s c o n t i n u a t i o n o f the i . v . i n f u s i o n in h igh-dose MTX a d m i n i s t r a -
t i o n s is cons idered to be c o n t r a i n d i c a t e d . 
The i . t . i n j e c t i o n o f MTX ¿-2 hours a f t e r the beg inn ing o f the i . v . 
i n f u s i o n accord ing to the method o f Freeman and Мое, should be s t u d i e d 
f u r t h e r p h a r m a c o k i n e t i c a l l y . 
The i . v . i n f u s i o n o f MTX d u r i n g 2h hours appears t o be an e f f i c a c i o u s 
method o f p r o p h y l a x i s , or t r e a t m e n t o f o v e r t CNS-leukemia. E s p e c i a l l y 
w i t h newly diagnosed c h i l d r e n w i t h ALL or in p a t i e n t s w i t h r e l a p s e , 
the h igh-dose MTX i . v . i n f u s i o n , f o l l o w e d by CF-rescue and w i t h p r o ­
t e c t i o n o f the renal f u n c t i o n by a 1 kal i. zat ion o f the u r i n e , may be 
c o n s i d e r e d a r a t h e r safe method o f t r e a t m e n t o f leukemic i n v a s i o n s 
( c l i n i c a l or s u b c l i n i c a l ) in the a r a c h n o i d . I t may p r e v e n t c o m p l i c a ­
t i o n s due t o lumbar p u n c t u r e s i n c h i l d r e n w i t h whom lumbar punctures 
mi ght be r i skf ui . 
The " s m a l l " i . v . doses (500 mg) a d m i n i s t e r e d in 2k h i n f u s i o n s (Free-
(Freeman 1977, Мое 1978) may be an e f f i c a c i o u s method o f t r e a t i n g 
prophy1 act i ca I l y some s a n c t u a r i e s ( l i v e r , s p l e e n , k i d n e y s , gonads, 
e y e s ) w i t n o u t tne o c c u r r e n c e o f s e r i o u s s i d e - e f f e c t s . But the d o s e - r a t e 
o f t h e i . v . i n f u s i o n o n l y is too smal l t o c o n s i d e r t h i s t r e a t m e n t 
as a method o f CNS-prophy1axis. 
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However, the concentration of MTX ¡η the CSF remains at a high level 
during a long period following an early i.t. injection of MTX 
(2 hours after the initiation of the i.v. infusion). 
The i.v. push of one-third of the total dose of MTX at the beginning 
of the i.v. infusion will not cause an increased concentration level 
of MTX in plasma during the infusion, and certainly not in the CSF. 
The elimination of the excess of MTX is too fast to consider this bolus 
injection to be of practical value. The profit of the high concentra­
tion during the first few hours of the infusion by this 'loading dose' 
is very small. The higher concentration level due to the continous 
infusion of the complete dose, without the loss of one-third by i.v. 
push, may contribute more to reach adequate concentrations of MTX 
in the sanctuaries. 
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SUMMARIZING CONCLUSIONS 
CNS-leukemia ¡s a l i f e - t h r e a t e n i n g c o n d i t i o n d u r i n g the course o f 
acute l ymphob las t i c leukemia in c h i l d r e n . To prevent the occur rence 
o f o v e r t CNS-leukemia, i . e . the occurrence o f leukemic c e l l s in the 
c e r e b r o s p i n a l f l u i d , a "prophy1 act i с" t r e a t m e n t is n e c e s s a r y . 
In f a c t , t h i s p r o p h y l a x i s is the t r e a t m e n t o f u n o b s e r v a b l e , sub­
c l i n i c a l , maybe not even e x i s t i n g , a t any r a t e , smal l i n v a s i o n s w i t h 
leukemic c e l l s in the a r a c h n o i d . Every c h i l d w i t h ALL must undergo 
t h i s t r e a t m e n t . By e x e c u t i n g t h i s " p r o p h y l a c t i c " t r e a t m e n t the i n c i ­
dence o f CNS-leukemia has decreased from 56% t o less than 10% in most 
i n v e s t i g a t i o n s . This a l s o means t h a t t h e r e is no doubt about t h e 
n e c e s s i t y o f the CNS-prophy1axis in c h i l d r e n w i t h ALL, but a l s o t h a t 
in at l e a s t 10% o f the p a t i e n t s a f a i l u r e o f t h i s t r e a t m e n t o c c u r s . 
N o t w i t h s t a n d i n g we have f o l l o w e d the usual i n t e r n a t i o n a l p r o t o ­
c o l s o f CNS-prophylaxis ( c r a n i a l i r r a d i a t i o n and i . t . a d m i n i s t r a t i o n 
o f MTX), we observed an i n c i d e n c e of 26% of o v e r t CNS-leukemia 
( f a i l u r e o f the CNS-prophy1axis) in our study o f 50 c h i l d r e n w i t h ALL. 
Moreover, the CNS-prophy1 a x i s was o f t e n accompanied by t o x i c s i d e -
e f f e c t s o f bone marrow and d i g e s t i v e t r a c t . 
The purpose o f t h i s s tudy has been to o b t a i n an e x p l a n a t i o n f o r 
f r e q u e n t f a i l u r e o f the CNS-prophy1axis and f o r the o c c u r r e n c e o f 
t o x i c s i d e - e f f e c t s . Because most o f the t o x i c s i d e - e f f e c t s c o u l d 
be due t o the i . t . a d m i n i s t r a t i o n o f MTX, we s t u d i e d t h i s drug 
pharmacokinet i c a l l y a f t e r the 5 subsequent i . t . i n j e c t i o n s d u r i n g 
the CNS-prophy1 a x i s . Moreover, i t may be p o s s i b l e t o propose a less 
t o x i c method o f CNS-prophy1 a x i s w i t h a s i m i l a r o r b e t t e r e f f i c a c y . 
The CNS-prophy1axis u s u a l l y c o n s i s t s o f two e l e m e n t s : r a d i o t h e r a p y 
and i . t . a d m i n i s t r a t i o n o f c y t o i t a t i c d r u g s : 
The f i r s t o n e , r a d i o t h e r a p y , is known t o be an e f f e c t i v e method o f 
d e s t r o y i n g leukemic c e l l s . In case o f o v e r t CNS-leukemia, i r r a d i a t i o n 
o f the t o t a l c e n t r a l nervous system is r e q u i r e d t o d e s t r o y the l e u k e ­
mic c e l l s . With the p r o p h y l a c t i c t r e a t m e n t o n l y the s k u l ' is i r r a d i a ­
t e d . The i r r a d i a t i o n o f the s k u l l causes s i d e - e f f e c t s . The best 
known s i d e - e f f e c t is the apathy-syndrome, which p r e v i o u s l y has always 
been c o n s i d e r e d t o be h a r m l e s s , but recent r e p o r t s show a r e l a t i o n ­
s h i p between the apathy-syndrome and l a t e sequelae o f the i r r a d i a t i o n , 
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even by relative small doses of 2400 Rad (in the Netherlands 2500 Rad). 
The late sequelae can be considered to be due to vascular damage in 
the brain. Smaller doses (1800 Rad) appear to be just as effective as 
the higher doses with about 8% failures of the CNS-prophy1 axis 
(Riehm 1977, Littman 1980, Nesbit I98I, Sather I98I). 
From these references may be concluded that, because of the facts 
mentioned above, a dose of I8OO Rad is sufficient in the prophylactic 
treatment of CNS-leukemia, and every dose of more than I8OO Rad should 
be considered to be contra-indicated. It must even be reconsidered 
whether cranial irradiation is still in its right place at all as 
a prophylactic treatment method in all cases of ALL. 
The other part of the CNS-prophylaxis consists of i.t. administration 
of methotrexate. Moreover in the Dutch treatment protocols the use 
of Prednisolon is advocated. The value of this drug until now is not 
certain. In our study, the animal-model suggests that Prednisolon 
influences the concentration of MTX in the CSF. It may be postulated 
that Prednisolon decreases the exsorption of MTX from the CSF into 
the blood. This is caused by a constriction of the blood vessels 
in the spinal canal following the administration of Prednisolon. 
The use of i.t. administration of MTX is based at first on the empi­
rical findings in patients with overt CNS-leukemia. Later on it has 
been confirmed by the results in patients without leukemic cells in 
the CSF. These findings have also led to the conclusion that MTX 
must be administered twice a week during the cranial irradiation. 
Our study however, demonstrates that the last three i.t. injections 
of MTX in the protocol of CNS-prophy1 axis used (two injections a 
week) cannot be effective, because the injected MTX is exsorbed from 
the CSF before it reaches the cranial subarachnoidal space. The con­
centration of MTX at the meninges of the brain will be smaller than 
the desired minimum therapeutic concentration of 5 χ 10 mol/1. 
The minimum therapeutic concentration of 5 x Ю mol/l is chosen 
arbitrarily in this study (Chapter V) and may be too small, but even 
this concentration cannot be obtained during a sufficiently long 
period after repeated intralumbar injections of MTX, owing to the 
increasing exsorption of MTX in the spinal canal. 
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The f a s t e x s o r p t i o n o f MTX from the CSF i n t o the b l o o d causes s i d e -
e f f e c t s t o the marrow and d i g e s t i v e t r a c t . An increase o f the e x s o r p ­
t i o n o f MTX from the CSF i n t o the plasma causes more s i d e - e f f e c t s 
f o l l o w i n g the t h i r d , f o u r t h and f i f t h i n j e c t i o n s . Extending the i n t e r 
va l o f two subsequent i . t . i n j e c t i o n s o f MTX might be a p o s s i b i l i t y 
t o reduce the t o x i c e f f e c t s , w i t h o u t d i m i n i s h i n g the t h e r a p e u t i c 
value o f MTX in the CSF. The long c e l l c y c l e o f leukemic c e l l s in 
the CSF (KUO 1975) p r o v i d e s enough t ime t o extend the i n t e r v a l of 
the two subsequent i n t r a t h e c a l i n j e c t i o n s . 
A c c o r d i n g t o the l i t e r a t u r e the use o f h igh-dose MTX f o l l o w e d by 
CF-rescue t o g e t h e r w i t h i . t . a d m i n i s t r a t i o n o f MTX might be as e f f e c ­
t i v e as c r a n i a l i r r a d i a t i o n t o g e t h e r w i t h i . t . a d m i n i s t r a t i o n o f 
MTX in p r e v e n t i n g o v e r t CNS-leukemiа. (Мое 1978, 1 9 8 l , Nesbi t I 9 8 I , 
Sather I 9 8 I ) . 
Our study shows t h a t the subsequent i . t . i n j e c t i o n s o f MTX d u r i n g 
the CNS-prophy1axis ( c r a n i a l i r r a d i a t i o n w i t h i . t . MTX) r e s u l t s in 
an increased e x s o r p t i o n o f MTX i n t o plasma. The c o m b i n a t i o n o f h i g h -
dose MTX i n f u s i o n s t o g e t h e r w i t h i . t . a d m i n i s t r a t i o n o f MTX a l s o 
r e s u l t s in an increased e x s o r p t i o n from the CSF i n t o plasma f o l l o w i n g 
repeated a d m i n i s t r a t i o n s . I t is f o r t h i s reason t h a t t h i s method is 
w i t h o u t p r o f i t . In such cases the f i r s t - c h o i c e t r e a t m e n t is the 
a d m i n i s t r a t i o n o f h igh-dose MTX i . v . i n f u s i o n s f o l l o w e d by CF-rescue 
o n l y . The c o m b i n a t i o n o f a r e l a t i v e l y small '-osed i . v . i n f u s i o n 
w i t h MTX (500 mg d u r i n g 24 h) and i . t . a d m i n i s t r a t i o n o f MTX at the 
b e g i n n i n g o f the i n f u s i o n (Freeman, Мое) appears t o r e s u l t in a 
remarkable p r o l o n g e d c o n c e n t r a t i o n o f MTX in the CSF. This observa­
t i o n s h o u l d be s t u d i e d f u r t h e r pharmacokinet i c a l l y . 
The CNS-prophy1axis in the t r e e t m e n t of ALL w i t h c h i l d r e n is u s u a l l y 
c a r r i e d out at the end o f the remi ss i o n - i n d u c t ion t r e a t m e n t . From 
Pinkel (1972) i t is learned t h a t the most i n t e n s i v e p a r t o f tne 
r e m i s s i o n i n d u c t i o n t r e a t m e n t is r e q u i r e d at the b e g i n n i n g of the 
' t o t a l t h e r a p y ' . At t h a t moment the load o f m a l i g n a n t c e l l s is at i t s 
maximum and moreover, the c o n d i t i o n o f the c h i l d is r e l a t i v e l y good. 
I t is s e l f - e v i d e n t t h a t the c e l l load o f leukemic c e l l s in the a r a c h ­
n o i d w i l l increase in the f i r s t days o r weeks o f ALL. 
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By t r e a t i n g the c e l l load in the a r a c h n o i d in the f i r s t days a f t e r 
the d i a g n o s i s o n l y smal l i n v a s i o n s have t o be t r e a t e d o r the i n v a s i o n 
of leukemic c e l l s in the a r a c h n o i d and the CSF w i l l be p r e v e n t e d . 
A t e c h n i c a l l y w e l l executed lumbar p u n c t u r e w i l l g i v e o n l y a smal l 
chance o f t r a n s p o r t a t i o n o f leukemic c e l l s from the t i s s u e s o f the 
lumbar r e g i o n i n t o the lumbar CSF. Moreover, the i . t . i n j e c t i o n o f 
MTX w i l l d e s t r o y g r a f t e d leukemic c e l l s i n the lumbar CSF. The e a r l y 
CMS-prophylaxis may be executed by i . t . i n j e c t i o n s o f MTX o n l y 
(once every one or two weeks d u r i n g the r e m i s s i o n i n d u c t i o n t r e a t m e n t ) 
or by i n t r o d u c i n g one o r more h igh-dose MTX i . v . i n f u s i o n s f o l l o w e d 
by CF-rescue. Such i n f u s i o n s can be c o n s i d e r e d t o be a method 
f o r t r e a t i n g o t h e r ' s a n c t u a r i e s ' (eyes, k i d n e y s , gonads) as w e l l . 
Concerning the t o x i c r e a c t i o n s , the t r a d i t i o n a l CNS-prophylaxis 
(2500 Rad c r a n i a l i r r a d i a t i o n and 5 subsequent i . t . i n j e c t i o n s o f 
MTX d u r i n g the i r r a d i a t i o n ) is o f t e n accompanied by i n c o n v e n i e n t 
s i d e - e f f e c t s . P r e v e n t i o n o f these s i d e - e f f e c t s is n e c e s s a r y , because 
the good c o n d i t i o n o f the c h i l d r e n at the end o f the r e m i s s i o n i n d u c ­
t i o n p e r i o d w i l l be reduced by these s i d e - e f f e c t s . This causes an 
unnecessary e x t e n s i o n o f the reconvalescence p e r i o d . 
By us ing a c i t r o v o r u m f a c t o r p r o t e c t i o n (p.1l6 ) the i n f l u e n c e o f the 
i n t r a t h e c a l l y i n j e c t e d MTX on marrow and d i g e s t i v e t r a c t may be 
reduced and may r e s u l t in a b e t t e r t o l e r a n c e . 
On the o t h e r hand we have showed t h a t the most e f f e c t i v e and less 
t o x i c doses o f i . t .MTX show a c o n c e n t r a t i o n p r o f i l e in plasma o f a 
slow e l i m i n a t i o n t y p e . This type is i n d i c a t e d by a c o n c e n t r a t i o n o f 
-8 MTX in plasma o f more than 't χ 1Q mol/1 18 hours a f t e r the i . t . 
- R i n j e c t i o n . A c o n c e n t r a t i o n o f MTX in plasma o f less than k χ 10 mol/1 
18 hours a f t e r the i . t . i n j e c t i o n r e f l e c t s an i n c r e a s e d e x s o r p t i o n 
r a t e and may cause an increased p r o b a b i l i t y o f more s i d e - e f f e c t s . 
We suppose t h a t smal l l e s i o n s in the v a s c u l a r w a l l s o f the b l o o d 
vessels in the s p i n a l canal caused by the a d m i n i s t r a t i o n o f MTX, are 
the cause o f t h i s i n c r e a s e d e x s o r p t i o n r a t e . 
Postponing the next i . t . i n j e c t i o n u n t i l the t o x i c r e a c t i o n s have 
disappeared and the e x s o r p t i o n r a t e has decreased a y a i n , may r e s u l t 
in a b e t t e r t o l e r a n c e o f the i . t . t r e a t m e n t s w i t h MTX. 
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Proposal for prophylactic· treatment of the CNS in ahilaren with ALL. 
Reducing the failures of CNS-prophy1 axis can only obtained by 
changing the current treatment protocol of the CNS-prophy1axis. 
According to the results of our investigations we suggest the follo­
wing protocols for the CNS-prophylaxis in children with ALL: 
General remarks on all children with ALL: 
1. The CNS-prophy1axis in children with ALL should be begun in the 
first week following the diagnosis, by a lumbar puncture. This 
puncture has to produce a representative sample of CSF in order 
to establish or to exclude the diagnosis "overt CNS-1eukemia". 
MTX and Prednisolon are administered intrathecally in both cases. 
2. The dose of MTX in i.t. administration should be estimated accor­
ding to Table 10. 
3. Following every i.t. injection of MTX the concentration of MTX 
has to be determined in plasma 18 hours after the i.t. injection. 
-8 h. Finding a concentration of MTX in plasma of more than h χ 10 mol/l 
18 h after i.t. injection, the elimination of MTX from the CSF 
into plasma is assumed to be according to the 'slow type'. 
A subsequent i.t. dose of MTX can be given. The interval between 
the two i.t. injections should be at least 1 week. 
-8 
5. Finding a concentration of MTX in plasma of less than k χ 10 mol/1 
18 h after i.t. injection, the elimination of MTX from the CSF into 
plasma is assumed to be according to the 'fast type'. 
The amount of MTX in the cranial subarachnoidal space will be 
insufficient for the therapeutic purposes. A following i.t. dose 
is useless and will probably cause systemic toxicity. 
The CNS-prophy1 axis should be continued by high-dose MTX infusions 
with an infusion period of 24 h. The dose rate of MTX should be at 
least 2.31 mg/kg/h. The infusion is followed by a rescue with 
reduced folates (Scheme 1 ) (see also p. II3). 
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Scheme I Schematic r e p r e s e n t a t i o n o f a p r o t o c o l f o r the use o f h i g h -
dose MTX i n f u s i o n s in c h i l d r e n w i t h ALL w i t h a f a s t type o f 
e l i m i n a t i o n f o l l o w i n g i . t . i n j e c t i o n o f MTX 
C h i l d r e n b e l o n g i n g t o the s t a n d a r d - r i s k p r o g n o s t i c group o f ALL 
may be t r e a t e d by a less i n t e n s i v e p r o t o c o l o f CNS-prophy1 a x i s as 
compared w i t h c h i l d r e n w i t h h i g h - r i s k ALL. We propose the f o l l o w i n g 
p r o t o c o l s : 
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A. C h i l d r e n w i t h s t a n d a r d - r i s k ALL, 
1. No r a d i o t h e r a p y should be g i v e n t o the CNS. 
2. A f t e r the d i a g n o s i s o f ALL, the CNS-prophylax is should be 
begun a c c o r d i n g t o the p r o p o s a l s in the genera l remarks. 
3. F o l l o w i n g the h e m a t o l o g i c r e m i s s i o n i n d u c t i o n t r e a t m e n t 
a n o t h e r t h r e e h igh-dose MTX i . v . i n f u s i o n s w i l l be g i v e n . 
The i n t e r v a l between two subsequent i n f u s i o n s has t o be 
2 weeks. 
In p r a c t i c e these c h i l d r e n w i l l u s u a l l y r e c e i v e 2-3 i . t . i n j e c t i o n s 
w i t h MTX and k h igh-dose MTX i . v . i n f u s i o n s f o l l o w e d by CF-rescue. 
CNS-PROPHYLAXIS IN CHILDREN WITH ALL 
HIGH-RISK ALL 
Intravenous infusion of high-dose MTX 
REMISSION INDUCTION TREATMENT 
ι ι ι I 
\ \ \ 
CRANIOSPINAL 
IRRADIATION 
cranium 1800 Rad 
spine 1200 Rad 
concentration of HTX in plasma 18 hours 
-8 
after i.t. injection < it χ 10 mol/l 
no further i.t. administration of MTX 
continue with high-dose MTX-infusions only 
Scheme I I Schematic r e p r e s e n t a t i o n o f the p r o t o c o l proposed f o r CNS-
p r o p h y l a x i s in c h i l d r e n w i t h h i g h - r i s k ALL 
B. C h i l d r e n w i t h h i g h - r i s k ALL, w i t h o u t leukemic c e l l s i n the 
CSF (Scheme I I ) . 
1 . A f t e r the d i a g n o s i s o f ALL, the CNS-prophylaxis should be begun 
a c c o r d i n g t o the p r o p o s a l s in the genera l remarks. 
2. In s p i t e o f the i . t . i n j e c t i o n s we propose t o g i v e 3 i . v . 
h igh-dose MTX i n f u s i o n s d u r i n g the r e m i s s i o n i n d u c t i o n 
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t r e a t m e n t p e r i o d . The i n t e r v a l between two subsequent 
i n f u s i o n s i s Tt days. 
3. F o l l o w i n g the hematologic r e m i s s i o n r a d i o t h e r a p y ( c r a n i o ­
s p i n a l i r r a d i a t i o n ) should be g i v e n . 
In p r a c t i c e these c h i l d r e n w i l l u s u a l l y r e c e i v e 2-3 i . t . i n j e c t i o n s 
w i t h MTX, t h r e e h igh-dose MTX i . v . i n f u s i o n s and o n l y a f t e r 
a c h i e v i n g the n e m a t o l o g i с remiss ion c r a n i o s p i n a l i r r a d i a t i o n . 
The d i f f e r e n c e s between the CNS-prohylax is p r o t o c o l s o f s t a n d a r d -
r i s k and h i g h - r i s k ALL a r e : 
1 . C r a n i o s p i n a l i r r a d i a t i o n in the h i g h - r i s k p r o t o c o l 
2. The o b l i g a t o r y high-dose MTX i . v . i n f u s i o n s in the h i g h - r i s k 
p r o t o c o l . 
When adapted t o new and o t h e r p h a r m a c o k i n e t i c and p h y s i o l o g i c 
knowledge in c h i l d r e n w i t h ALL, these t r e a t m e n t schemes w i l l 
i n c r e a s e the p r o b a b i l i t y o f b e t t e r c o n d i t i o n s in the c h i l d r e n 
d u r i n g and a f t e r the hematologic r e m i s s i o n i n d u c t i o n t r e a t m e n t . 
The e a r l y " p r o p h y l a c t i c " t r e a t m e n t o f the CNS i s more in keeping 
w i t h the p a t h o p h y s i o l o g i c p r o p e r t i e s of the i n v a s i o n o f leukemic 
c e l l s in the CNS w i t h c h i l d r e n s u f f e r i n g f rom ALL. The maximum load 
o f leukemic c e l l s can a l s o be found a t an e a r l y stage o f the d isease 
both in marrow and in the CNS. 
Reduct ion o f the l a t e sequelae o f the t r e a t m e n t by c h a n g i n g the 
methods o f use o f MTX and by d i m i n i s h i n g o r a b o l i s h i n g the c r a n i a l 
i r r a d i a t i o n in the p r o p h y l a c t i c t r e a t m e n t s c h e d u l e s , r e q u i r e s f u r t h e r 
and strenuous s t u d y . 
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Samenvatt i ng . 
Het doel van d i t p r o e f s c h r i f t is een v e r k l a r i n g te v inden voor de 
acute b i j v e r s c h i j n s e l e n d i e op t reden gedurende en en ige t i j d na de 
c e n t r a a l zenuwste lse l p rophy laxe (CZS-prophylaxe) b i j k inde ren met 
acute lymphoblasten leukemie (ALL) , aan de hand daarvan een methode 
van CZS-prophylaxe aan te geven d i e even e f f e c t i e f i s , maar minder 
b i j w e r k i n g e n v e r o o r z a a k t . 
In HOOFDSTUK I wordt de o n t w i k k e l i n g van de h u i d i g e , ook in Neder-
land g e b r u i k e l i j k e , CZS-prophy1 axe u i t eengeze t . Zowel r a d i o t h e r a p i e 
( s c h e d e l b e s t r a l i n g ) a l s ¡ n t r a t h e c a l e ( i . t . ) t o e d i e n i n g van metho-
t r e x a a t (MTX) worden h i e r b i j toegepas t . 
In HOOFDSTUK I I z i j n de chemische, biochemische en pharmacologisehe 
eigenschappen van MTX beschreven. Tevens wordt een o v e r z i c h t gegeven 
van de b e l a n g r i j k s t e b i j w e r k i n g e n van MTX. Deze worden in HOOFDSTUK 
I I I nader beschreven voorzover deze van belang z i j n b i j de CZS-
prophy l axe . 
HOOFDSTUK IV toon t het verband aan tussen hi-t t i j d s t i p van de CZS-
prophy laxe en de prognose van de ALL. Ind ien de remi ss i e - i n d u c t ie 
behandel ing langer duur t dan 50 dagen en men d ien tengevo lge l a a t s t a r t 
met de CZS-prophy1 axe, b l i j k t de prognose s l e c h t e r . 
De f r e q u e n t i e van de b i j w e r k i n g e n van de CZS-prophylaxe word t ge ïnven-
t a r i s e e r d b i j 50 k inderen met ALL. U i t het e l e c t r o e n c e p h a l o g r a f i s c h 
en echoencepha logra f i sch onderzoek kregen w i j de ind ruk dat deze 
w e i n i g be las tende onderzoeken een goed hulpmiddel z i j n b i j het op-
sporen van neu ro log i sche beschad ig ingen , h e t z i j door de ALL h e t z i j 
door de t h e r a p i e , d i t kan worden u i t g e b r e i d d .m.v . CT-scanning. 
Het 1 iquoronderzoek toont aan dat de 5 1umbaalpunct ies gedurende de 
CZS-prophy1 axe een cel r e a c t i e en een verhoging van het t o t a a l e i w i t 
in de l i q u o r veroorzaken , 
In HOOFDSTUK V wordt u i t de l i t e r a t u u r de minimaal t he rapeu t i sche 
c o n c e n t r a t i e van MTX a f g e l e i d , om in l i c h a a m s v l o e i s t o f f e n de lympho-
b l a s t e n i r r e v e r s i b e l in hun o n t w i k k e l i n g te remmen. Een c o n c e n t r a t i e 
van 5 x 1 0 m o l / l moet h i e r t o e langer dan 18 uur worden gehandhaafd. 
Aangezien de toename van de l i q u o r r u i m t e n i e t p a r a l l e l v e r l o o p t aan 
de groe i van net l i chaam, wordt een v o o r s t e l gedaan de dose r i ng van 
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MTX per m lichaamsoppervlak bij de intrathecale toediening te 
vervangen door een aan de leeftijd van het kind gefixeerde dosering 
van MTX, met een maximale dosering van 12 mg. Het optreden van over-
dosering zal hierdoor worden verminderd. 
In HOOFDSTUK VI wordt de verdeling van MTX in het CZS nagegaan voor 
zover dit in de literatuur bekend is. In aansluiting hierop worden in 
HOOFDSTUK Vil de belangrijkste algemene pharmacokinetische aspecten 
van de compartiment modellen besproken. 
HOOFDSTUK VIM geeft een beschrijving van ^h kinderen met ALL 
gedurende de CZS-prophy1 axe waarbij na intrathecale toediening van 
MTX pharmacokinetisch onderzoek werd verricht. De methoden van onder-
zoek en het verloop van MTX na i.t. toediening worden beschreven in 
HOOFDSTUK IX. Na i.t. toediening blijkt het concentratieverloop van 
MTX in plasma te veranderen bij opeenvolgende i.t. injecties. 
De aanvankelijk relatief trage eliminatie van MTX na de Ie i.t, dosis 
verandert in een snel eliminatietype bij latere doses. 
Dit snelle eliminatietype benadert het concentratieverloop van MTX 
na i.v. bolus injectie. In HOOFDSTUK X wordt aan de hand van een 
pharmacokinetisch onderzoek bij 14 kinderen met ALL aangetoond dat 
het verloop van de MTX-concentratie in het plasma, zoals beschreven 
is in hoofdstuk 9, voorkomt bij vrijwel alle kinderen gedurende de 
CZS-prophy1 axe. Deze verandering in eliminatie blijkt te berusten 
op een versneld transport van MTX uit de liquor naar het bloed 
(exsorptie). De groep patiënten moet echter als te klein worden be-
schouwd om statistische verschillen tussen de pharmacokinetische 
parameters van patiënten met en zonder bijwerkingen te kunnen aanto-
nen. Een belangrijke factor bij het ontstaan van toxische effecten 
van MTX is een langdurig (meer dan 12 uur durende) concentratie van 
MTX boven een bepaald niveau (1 χ 10 mol/l) in het plasma. 
In HOOFDSTUK XI wordt het concentratieverloop van MTX in de liquor 
beschreven aan de hand van MTX bepalingen in de liquor vlak voor 
het toedienen van de volgende dosis MTX. Ook nu blijkt weer dat de 
halfwaarde tijd van MTX in de liquor bij opeenvolgende injecties 
afneemt. Dit heeft tot gevolg dat slechts een klein gedeelte van de 
toegediende MTX gedurende een te korte tijd in de liquorruimte van 
de schedel terecht komt. Juist hier moet MTX de anti-leukemisehe 
werking ten toon spreiden. 
136 
Uit onze gegevens wordt berekend dat slechts de eerste i.t. injectie 
gedurende een voldoende lange tijd de minimaal therapeutische concen­
tratie kan handhaven in de 1iquorruimte van de schedel. Daalt de half­
waarde tijd van MTX in de liquor tot onder de 0.73 h, dan is de vol­
gende i.t. dosis zinloos. Deze halfwaarde tijd is uit de plasma-
concentratie af te leiden: Wanneer de plasmaconcentratie 18 uur na de 
-8 
i.t. injectie hoger is dan k χ 10 mol/l, dan wijst dit op een half­
waarde tijd in de liquor van meer dan 0.73 h, passend bij een trage 
exsorpt ie. 
Uit het diermodel (HOOFDSTUK XII) blijkt dat het concentratieverloop 
van MTX in plasma en liquor na i.t. toediening bij de geit niet 
niet zondermeer vergelijkbaar is met het verloop van de MTX-concentra-
ties bij kinderen. Een belangrijke bevinding uit dit onderzoek bij de 
geit is dat het toevoegen van Prednisolon bij de i.t. injectie van 
MTX een vermindering van de exsorptiesnelhe id van MTX uit de liquor 
veroorzaakt. 
Het pathologisch-anatomisch onderzoek bij de geiten na de simulatie 
van de CZS-prophylaxe laat zien dat na toediening van MTX hyaline 
veranderingen optreden in de wand van de bloedvaten, terwijl be­
straling eerder een verandering in de structuur van het myéline ver-
zaakt. De bevindingen uit bovenstaande hoofdstukken worden samengevat 
in HOOFDSTUK XIII waarbij een hypothese wordt opgesteld over de 
(patho)-fys¡ologische veranderingen die optreden bij herhaalde i.t. 
toediening van MTX. Aan de hand hiervan worden voorstellen gepostu-
leerd waarop de CZS-prophylaxe bij kinderen met ALL een meer effi-
ciënt verloop zou kunnen hebben, met een vermindering van het aantal 
bijwerkingen van deze behandeling. Aan een aantal bijwerkingen zal 
men echter niet kunnen ontkomen. 
Een van de methoden om een effectieve CZS-prophylaxe m.b.v. MTX te 
bereiken is het toepassen van high-dose MTX infusen gevolgd door 
een rescue met citrovorum factor (HOOFDSTUK XIV). Deze infusen moeten 
een duur hebben van 2k uur, terwijl de dosis van MTX tenminste 
2.31 mg/kg/uur moet bedragen om een minimaal therapeutische concen-
tratie in de liquor te bereiken. Bij een dergelijk infuus moet men 
afzien van i.t. toediening van MTX. 
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de neoplastische aandoeningen bij kinderen. 
Er werd o.a. onderzoek gedaan naar de cytochemisehe afwijkingen in 
leukocyten bij kinderen met acute leukemie. 
In ÌSl1* werd hij ingeschreven in het special is tenregister als kinder-
arts. Hij vestigde zich toen als kinderarts te Kampen. Sinds augustus 
1975 is hij verbonden als chef de clinique aan de kinderkliniek van 
het St.Radboudziekenhuis te Nijmegen. 
Door de samenwerking van de kinderkliniek met het laboratorium voor 
Klinische Pharmacie werd eind 1976 het onderzoek naar de pharmacokine-
tiek van methotrexaat bij kinderen begonnen. Hierdoor was het mogelijk 
onder leiding van Prof.Dr. E. D.A. M.Schret 1 en en Dr.E. van der Kleijn 
dit proefschrift te bewerken. 
STELLINGEN 
1. Schedel bestral ing als onderdeel van de centraal zenuwstelsel 
prophylaxe bij kinderen met een z.g. 'normal-risk' acute 
lymphoblasten leukemie, kan achterwege worden gelaten, mits 
reeds in de eerste dagen na het stellen van de diagnose een 
"prophy1 act i sehe" behandeling wordt begonnen door middel van 
cytostat i ca. 
dit proefschrift 
2. Het aantonen van leukemische cellen in de liquor cerebro 
spinalis door lumbaal punctie bij kinderen met acute lympho-
blasten leukemie, wijst op een vergevorderd stadium van CZS-
leukemie. 
3. Bij de behandeling van een centraal zenuwstelsel leukemie bij 
kinderen met acute lymphoblasten leukemie, verdient de intra-
ventri cul ai re toediening van cytostatica de voorkeur boven de 
intra-1umbale toediening. 
Bleyer W.A. e.a. Blood SU 83b (1378) 
h. Het te verwachten effect van een intra-1umbaal toegediende 
hoeveelheid methotrexaat kan worden beoordeeld aan de daarop-
volgende concentraties van het methotrexaat in het plasma. 
dit proefschrift 
5. Het berekenen van de dosis van een cytostaticum per eenheid 
van lichaamsoppervlakte, zoals dit gebruikelijk is in de be-
handelingschema's van patiënten met kanker, biedt geen voor-
deel boven de berekening per eenheid van lichaamsgewicht. 
Beiden zijn ontoereikend. 
dit proefschrift 
6 . P reopera t i eve behandel ing door middel van r a d i o t h e r a p i e e n / o f 
chemotherap ie , b i j k inderen met Wi lm's tumoren, zoals d i t door 
de SI0P wordt aanbevolen, is s l e c h t s z i n v o l b i j g ro te o f inope-
rabe l l i j k e n d e tumoren. 
Voûte P.A. β·α· Yearly Feport on the Wilm's Tumor 
trials & Studies STOP 1, 2, 5. 
Abstracts Xllltri Meeting of the Société Internationale 
d'Oncologie Pédiatrique. 
Sept. lb-19 (1980) Marseille 
7. Door de toename van het gebruik van cytostatica en door het 
steeds hoger doseren van deze stoffen, zowel in kankercentra 
als in algemene ziekenhuizen, ontstaan naast medische ook 
ethische problemen die nog onvoldoende onderzocht zijn. 
8. Verminderde lengtegroei bij kinderen na behandeling voor een 
tnedul loblastoom d.m.v. radiotherapie is vaak niet het gevolg 
van groeihormoondeficiëntie. 
Broadbent V.A. e.a. Cancer 48: 26 (1081) 
9. Tijdens en na de behandeling van kinderen met platina-
verbindingen is een regelmatig herhaald, uitgebreid gehoors-
onderzoek noodzakelijk. 
Green A.A. e.a. in Cisplatin Current Status and neu 
developments (Ed. A. W. Prestayko e.a.) Academic Press 
New York 1980 
10. De verzorgers van patiënten met kanker verdienen een even nauw-
keurige begeleiding en ondersteuning als de kankerpatiënt en 
zijn fami lie zei f. 
11. De aspecifieke Symptomatologie van stoornissen in de purine-
en pyrimi dinestofwisse1 ing rechtvaardigt een screenend onder-
zoek naar deze stoffen bij kinderen met onduidelijke neurolo-
¡jische, hematologisehe en/of immunologische aandoeningen. 
Van Gennip A.H. Thesis Utrecht (1981) 
12. Door de slechts geringe toxiciteit van adenosine-arabinosi de, 
is, bij het op klinische gronden vermoeden van een acute 
virale encephalitis bij kinderen, prompte toediening van dit 
virostaticum noodzakelijk. 
Geneesmiddelenbulletin lb: 49 (1981) 
13. Hoewel ophaaldiensten voor neonaten, zoals deze door de kinder-
artsen in Nederland zijn georganiseerd, een grote vooruitgang 
betekenen in de prognose voor de neonaat "at-risk", zou het 
transport in utero van de toekomstige neonaat niet alleen tijd-
en kostenbesparend zijn, maar ook de risico's voor de neonaat 
"at-risk" beperken. 
14. Een geslagen hond is beter af dan een battered child. 



